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Incidence, predictors, healthcare utilization, and 
cost associated with antipsychotic polypharmacy 
in the Texas Medicaid population 
 
 
Pooja Rajiv Desai, PhD 
The University of Texas at Austin, 2014 
 
Supervisor:  Kenneth A. Lawson 
 
Antipsychotic medications are effective in the treatment of psychotic disorders. 
Monotherapy (MT) with antipsychotics is consistently recommended as the treatment of 
choice by several guidelines yet antipsychotic polypharmacy (APP) is widespread in 
clinical practice. The objectives of this study were to evaluate the incidence of APP, 
identify predictors of APP, and compare adherence, health resource utilization, and costs 
between patients on MT and APP using prescription and medication claims from Texas 
Medicaid (2006 to 2011).   
Patients newly initiated on antipsychotics were followed for 12 months and 
categorized into the APP (exposure to two or more antipsychotics for a defined time 
interval) and MT (no evidence of APP during the study period) groups. This sample of 
patients was used to evaluate incidence and predictors of APP and compare medication 
adherence and persistence between the MT and APP groups using multiple, logistic, and 
Cox proportional hazards regressions. Patients in the MT and APP groups were then 
 viii 
matched based on their duration of exposure to antipsychotics and all-cause healthcare 
utilization and costs were compared using logistic and generalized linear models 
regression (negative binomial, Poisson, and gamma). Regression analyses for patients 
matched on duration of antipsychotic exposure accounted for the correlation between 
matched pairs. 
The incidence of APP was 5.4%. Several demographic, clinical, physician, and 
prior utilization characteristics were associated with APP. Medication adherence and 
persistence were better in the APP group. Length of hospital stay and medical, drug, and 
total costs were higher for the APP group. Sensitivity analyses were conducted for 
psychiatric-related costs and varied overlap and gap periods. The results for most of the 
sensitivity analyses were similar to the base case. 
Patients prescribed APP had higher medical, drug and total costs and also higher 
healthcare utilization i.e. increased drug costs were not offset by decreased medical costs. 
Long-term APP raises concern as state Medicaid agencies are allocating their limited 
resources to this expensive treatment which has very scarce data supporting its use. More 
effectiveness research on APP is needed to help provide prescription guidance to 
clinicians for patients who do not respond well to treatment with a single antipsychotic.  
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1.1.  Problem statement 
 Webster’s dictionary defines polypharmacy as the act of prescribing two or more drugs 
together to treat a single condition.1
 
Fulton and Allen describe polypharmacy as the use of 
medications which are not clinically indicated.2 Evidence-based medication (EBM) informs us 
about the clinical indications of medications based on safety and efficacy.3
 
Prescribing more 
medications than clinically warranted is considered a questionable practice due to safety 
concerns. However, it is important to remember that pharmacotherapy is a complex field 
encompassing more than EBM suggestions of safety and efficacy.    
Antipsychotic polypharmacy (APP) is the concomitant use of more than one 
antipsychotic medication. Clinical guidelines recommend monotherapy of antipsychotics as the 
preferred therapy.4
,5,6,7,8,9 Despite consistent monotherapy recommendations, the use of APP is 
widespread in clinical practice. The prevalence of APP varies depending on clinical settings. In 
                                               
1 Dictionary.com. Polypharmacy [online]. Available from URL: 
http://dictionary.reference.com/browse/polypharmacy. Accessed October 23, 2012. 
2 Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract 2005; 17 (4): 123-
32. 
3 Tranulis C, Skalli L, Lalonde P, et al. Benefits and risks of antipsychotic polypharmacy: an evidence-based review 
of the literature. Drug Saf 2008;31(1):7-20. 
4 The expert consensus guideline series. Treatment of schizophrenia. J Clin Psychiatry 1999; 60 suppl 11:3-80. 
5 National Institute for Clinical Excellence: Core interventions in the treatment and 
management of schizophrenia in adults in primary and secondary care. NICE Clinical Guideline 82; 2009. 
6Moore TA, Buchanan RW, Buckley PF, et al. The Texas medication algorithm project antipsychotic algorithm for 
schizophrenia: 2006 update. J Clin Psychiatry 2007;68(11):1751-62. 
7American Psychiatric Association: Practice guidelines for the treatment of patients with schizophrenia. In Am J 
Psychiatry Volume 161. 2nd ed. American Psychiatric Association; 2004:1-56. 
8Kreyenbuhl J, Buchanan RW, Dickerson FB, et al. The Schizophrenia Patient Outcomes Research Team (PORT): 
updated treatment recommendations 2009. Schizophr Bull 2010; 36(1):94-103.  
9 The International Psychopharmacology Algorithm Project. IPAP schizophrenia algorithm. 
Available at: www.ipap.org/schiz. Assessed October 9, 2012. 
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inpatient settings the prevalence ranges from 8%10 to as high as 68%11 while studies conducted 
in outpatient settings show prevalence rates from 4%12 to 26%.13 According to a meta-analysis 
conducted by Gallego et al., the pooled prevalence of APP in North America between 1970 and 
2009 was 16% (Interquartile range [IQR]=7.2%-24.4%). From 1980 to 2000, the prevalence of 
APP in North America increased by 34.0%, from 12.7% (IQR=4.5%–46%) to 17% (IQR=9.1%–
23.0%).14 Similar increases were noted in studies conducted using Medicaid databases. Clark et 
al.15 noted an increase of 18.6 percentage points from 5.7% in 1995 to 24.3% in 1999 and 
Ganguly et al.16 observed an increase of nine percentage points from 32.0% in 1998 to 41.0% in 
2000.  
Although the concomitant use of multiple antipsychotics is widespread, there is very 
limited evidence regarding the safety and efficacy of APP in controlled clinical trials. In fact, 
several potential hazards are associated with APP.17 It could lead to increased adverse effects, 
decreased benefits of an atypical antipsychotic if it is combined with a typical antipsychotic (e.g., 
increased risk of extrapyramidal side effects  along with the presence of metabolic side effects 
due to the atypical antipsychotics), and possible pharmacokinetic interactions. Studies have 
                                               
10 Dolder CR, McKinsey J. Antipsychotic polypharmacy among patients admitted to a geriatric psychiatry unit. J 
Psychiatr Pract 2011;17(5):368-74.   
11 Divac N, Jasović-Gasić M, Samardzić R, et al. Antipsychotic polypharmacy at the University Psychiatric 
Hospital in Serbia. Pharmacoepidemiol Drug Saf 2007;16(11):1250-1. 
12 Botts S, Hines H, Littrell R. Antipsychotic polypharmacy in the ambulatory care setting, 1993-2000. Psychiatr 
Serv 2003;54(8):1086. 
13 Procyshyn RM, Honer WG, Wu TK, et al. Persistent antipsychotic polypharmacy and excessive dosing in the 
community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin 
Psychiatry 2010;71(5):566-73. 
14 Gallego JA, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic 
review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 2012; 138(1):18-
28. 
15 Clark RE, Bartels SJ, Mellman TA, et al. Recent trends in antipsychotic combination therapy of schizophrenia 
and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 2002;28(1):75-84. 
16 Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends, and factors associated with antipsychotic 
polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004;65(10):1377-88.   
17 Tranulis C, Skalli L, Lalonde P, et al. Benefits and risks of antipsychotic polypharmacy: an evidence-based 
review of the literature. Drug Saf 2008;31(1):7-20. 
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shown that APP is associated with higher healthcare resource utilization and costs. A study 
conducted using an employer claims database found that the mean total medical cost for APP 
patients was about $7,000 more than for those on antipsychotic monotherapy (MT).18 The 
analysis controlled for patient characteristics and indicators of disease complexity. Gilmer et al. 
found that an increase of 9.3 percent points in APP over a five-year period was associated with 
an increase of almost two percent points in hospitalization rates.19 In addition, complex 
medication regimens, such as those associated with APP, could also lead to a reduction in 
medication adherence. 
 Few studies in the US  have used large databases, such as Medicaid, to estimate the 
prevalence of APP. Due to the debilitating nature of the diseases that antipsychotics are used to 
treat, it is possible that several antipsychotic users may be classified as disabled or have low 
incomes and hence, would be enrolled in state Medicaid programs. Most published studies are 
dated, with the most recent one by Constantine et al. examining the period from 2004-2006.20 
However, specific atypical antipsychotics, such as paliperdone (2007), iloperidone (2009), 
asenapine (2009), and lurasidone (2010) were approved more recently, i.e., after the most recent 
study that used a state Medicaid database to estimate the prevalence of APP was conducted. 
Therefore, research including these newer drugs is needed. In addition, no known study 
examining APP was conducted in Texas, a state with a higher than average prevalence of mental 
illness.21             
                                               
18 Loosbrock DL, Zhao Z, Johnstone BM, et al. Antipsychotic medication use patterns and associated costs of care 
for individuals with schizophrenia. J Ment Health Policy Econ 2003;6(2):67-75. 
19 Gilmer TP, Dolder CR, Folsom DP, et al. Antipsychotic polypharmacy trends among Medicaid beneficiaries with 
schizophrenia in San Diego County, 1999-2004. Psychiatr Serv 2007;58(7):1007-10. 
20 Constantine RJ, Andel R, Tandon R. Trends in adult antipsychotic polypharmacy: progress and challenges in 
Florida's Medicaid program. Community Ment Health J 2010;46(6):523-30. 
21 Welsh KJ, Patel CB, Fernando RC, et al. Prevalence of bipolar disorder and schizophrenia in Houston Outreach 
Medicine, Education, and Social Services (HOMES) clinic patients:  implications for student-managed clinics for 
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In view of the described gaps in the literature, this study aims to estimate the incidence, 



















                                                                                                                                                       





1.2. Significance  
Antipsychotics have revolutionized the treatment of psychiatric illnesses since their initial 
availability in the 1950s. With the introduction of atypical antipsychotics (also called second-
generation antipsychotics), the overall use of antipsychotic medications has increased 
tremendously. A statistical brief published by the Agency for Healthcare Research and Quality 
(AHRQ) using the Medical Expenditure Panel Survey (MEPS) showed that the total number of 
purchases of antipsychotics increased from 17.4 million in 1997 to 32.4 million in 2007, an 
increase of 86%.22  Expenditures for prescription antipsychotics in an outpatient setting increased 
almost 5-fold from $1.7 billion to $7.4 billion during the same period. Another study conducted 
by Alexander et al. using data from the IMS Health National Diagnostic and Therapeutic Index 
showed that the number of antipsychotic-related outpatient visits increased from 6.2 million in 
1995 to 16.7 million in 2006 and declined to 14.3 million in 2008.23 Data on those patient visits 
where typical or atypical antipsychotic use was reported were used in the analyses. They 
estimated that in 2008, $60 million and $9.9 billion were spent on typical (also called first-
generation antipsychotics) and atypical antipsychotics, respectively. The use of antipsychotics 
for Food and Drug Association (FDA)-approved indications increased from 4.4 million visits in 
1995 to 9 million visits in 2008. The estimated cost for off-label use of antipsychotics in 2008 
was $6 billion, of which $5.4 billion was for uses with uncertain evidence.  A prescribing shift 
occurred from typical antipsychotics in 1995 (84% of all antipsychotic visits) to atypical 
antipsychotics by 2008 (93% of all antipsychotic visits). The proportion of all typical 
                                               
22 Stagnitti, M. N. Trends in Antipsychotics Purchases and Expenses for the US Civilian Noninstitutionalized 
Population, 1997 and 2007. Statistical Brief #275. January 2010. Agency for Healthcare Research and Quality, 
Rockville, MD.                                                                                                                                                                
Available at: http://www.meps.ahrq.gov/mepsweb/data_files/publications/st275/stat275.pdf. Accessed April 3, 2014. 
23 Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the 
United States, 1995-2008. Pharmacoepidemiol Drug Saf 2011;20(2):177-84. 
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antipsychotics used for schizophrenia patients increased from 32% of typical treatment visits in 
1995 to 48% in 2008. Over the same period, atypical agents use increased for bipolar affective 
disorder (10% of all atypical treatment visits to 34%) and depression (12% to 18%) while their 
use for schizophrenia (56% to 23%) declined. 
It is likely that an increase in APP would have accompanied the increase in the use of 
antipsychotic medication. In addition to being associated with higher costs and questionable 
safety, some studies have shown that APP is associated with poorer patient outcomes.24
,25  
Research is needed to update the ‘real world’ prevalence of APP in the outpatient setting to 
provide healthcare professionals and policy makers with current information about the 
magnitude of the problem. Identification of patient-related predictors of APP would help 
healthcare providers recognize patients most likely to be prescribed APP. This insight would 
enable them to take preemptive steps to ensure that APP is used only when all other feasible 
treatment options have failed. Estimates of healthcare utilization and costs associated with APP 
will illustrate the enormous financial burden associated with APP. This will help policy makers 
in developing direction for state mental health agencies and other entities for addressing the 
challenges associated with APP.  
  
 
                                               
24 Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, et al. A double-blind controlled study of adjunctive 
treatment with risperidone in schizophrenic patients partially responsive to clozapine:efficacy and safety. J Clin 
Psychiatry 2005;66(1):63–72. 
25Honer WG, Thornton AE, Chen EY, et al. Clozapine alone versus clozapine and risperidone with refractory 
schizophrenia. N Engl J Med 2006;354(5):472–82. 
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2. LITERATURE REVIEW 
2.1. Antipsychotics and their uses 
2.1.1.  ANTIPSYCHOTIC MEDICATIONS 
Typical antipsychotics include chlorpromazine, fluphenazine, haloperidol, and 
perphenazine.26 They are associated with a number of neurological side effects including 
movement disorders, which are often irreversible, and orthostatic hypotension. Atypical 
antipsychotics, the newer class of drugs, include aripiprazole, clozapine, olanzapine, 
paliperidone, quetiapine, risperidone, and ziprasidone. They are generally associated with less 
severe side effects compared to typical antipsychotics; however, they have side effects associated 
with metabolic disorder such as diabetes, high cholesterol, and weight gain. They are more 
effective in treating negative symptoms and improving cognitive functioning. Table 1 provides a 
list of the generic and brand names of antipsychotics.   
Antipsychotics are approved by the FDA for use in patients with schizophrenia and 
bipolar disorder.27 Some antipsychotics are also prescribed for other diseases such as treatment 
resistant depression and others.28 However, antipsychotics are widely used for off-label 
indications (indications not approved by the FDA) to treat various psychiatric conditions. While 
it is legal for doctors to prescribe medications off-label, it is not legal for manufacturers to 
actively promote such use. A study conducted on off-label use of antipsychotics found that the 
                                               
26 Schizophrenia-Mayo Clinic Staff, Mayo Clinic. Available at: 
http://www.mayoclinic.com/health/schizophrenia/DS00196. Accessed October 15, 2010.  
27 Maglione M, Ruelaz Maher A, Hu J, Wang Z, Shanman R, Shekelle PG, Roth B, Hilton L, Suttorp MJ, Ewing 
BA, Motala A, Perry T. Off-Label use of atypical antipsychotics: An update. Comparative Effectiveness Review No. 
43. (Prepared by the Southern California Evidence-based Practice Center under Contract No. HHSA290-2007-
10062-1.) Rockville, MD: Agency for Healthcare Research and Quality. September 2011. Available at: 
www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed April 1, 2014. 
28 Christian R, Saavedra L, Gaynes BN, et al. Future Research Needs for First- and Second-Generation 
Antipsychotics for Children and Young Adults [Internet]. Rockville (MD): Agency for Healthcare Research and 
Quality (US); 2012 Feb. (Future Research Needs Papers, No. 13.) Appendix A, Tables of FDA-Approved 
Indications for First- and Second-Generation Antipsychotics. 
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most common indications included attention-deficit hyperactivity disorder (ADHD), anxiety, 
dementia in elderly patients, depression, eating disorders, insomnia, obsessive compulsive 
disorder, personality disorder, post-traumatic stress disorder (PTSD), substance use disorders, 
and Tourette’s syndrome. 
 
Table 1: Generic and brand names for antipsychotics 
Generic Name Brand name 
Typical antipsychotics 












Asenapine  Saphris 
Clozapine Clozaril, FazaClo 
Iloperidone Fanapt 
Lurasidone Latuda 
















2.1.2. SCHIZOPHRENIA AND ASSOCIATED DISORDERS 
Schizophrenia is a chronic debilitating disease characterized by perturbations of 
language, perception, thinking, social activity, affect, and volition.29 It generally begins in late 
adolescence with a gradual onset and the outcomes may progress from social withdrawal and 
perceptual distortions to chronic delusions and hallucinations. 
Patients may have positive symptoms, such as conceptual disorganization, delusions, or 
hallucinations or they may have negative symptoms such as loss of function, anhedonia, 
decreased emotional expression, impaired concentration, and diminished social engagement. For 
the diagnosis of schizophrenia to be confirmed, a patient must have at least two of these 
symptoms for one month and continuous symptoms for at least six months.  
The four main subtypes of schizophrenia are catatonic, paranoid, disorganized, and residual. The 
patient may have symptoms for more than one type.  
Catatonic schizophrenia: It is characterized by increase in motor activity, 
negativism, and imitation of speech and movement of others. 
Disorganized schizophrenia: There is disorganization of speech and behavior 
which is accompanied by silly behavior. 
Paranoid schizophrenia: Patients are preoccupied with a specific delusional 
system and do not show signs of disorganized schizophrenia. 
Residual schizophrenia: It is characterized by negative symptoms in the absence 
of delusions, hallucinations, and increased motor activity. 
 
 
                                               
29 Reus VI. Mental Disorders. In: , Kasper D, Braunwald E, Hauser SL, Longo DL, Jameson JL, Fauci AS, eds. 
Harrison’s Principles of Internal Medicine. 16th ed. New York: McGraw Hill; 2004. 
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In addition, there are two closely related disorders: 
Schizophreniform disorders: Patients have the symptoms of schizophrenia but not 
for the duration that is required to confirm a schizophrenia diagnosis.   
Schizoaffective disorders: Patients have the symptoms of schizophrenia and in 
addition have independent periods of mood disturbances.  
Antipsychotic medications are the cornerstone of treatment for schizophrenia, both for 
acute and maintenance treatment. They are effective in the treatment of hallucinations, delusions, 
and thought disorders. As noted previously, there are two types of antipsychotics: typical and 
atypical. Typical antipsychotics act by blocking the dopamine D2 receptors and atypical 
antipsychotics act on dopamine, serotonin, and other neurotransmitter systems.30 Some 
antipsychotics may act within a few hours or days of therapy initiation, but full effect usually 










                                               
30 Psychiatric Medicine. In: Kasper D, Braunwald E, Fauci AS, eds. Harrison’s Manual of Internal Medicine. 16th 
ed. New York: McGraw Hill; 2005:962-969. 
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2.1.3. BIPOLAR DISORDER 
Bipolar disorder is characterized by very quick mood swings between periods of very 
good or very irritable mood and depression.31 Bipolar disorder type I is characterized by at least 
one manic episode and periods of major depression. In bipolar disorder type II, people 
experience alternating periods of high energy and impulsiveness (called hypomania) and 
episodes of depression. Cyclothymia is a mild form of bipolar disorder where the patient 
alternates between hypomania and mild depression.  Bipolar disorder strikes in adolescence or 
early adulthood and occurs equally in males and females. The lifetime prevalence of bipolar I 
disorder in community samples ranges between 0.4%-1.6%, while that of bipolar II disorder is 
about 0.5%, and lifetime prevalence of cyclothymic disorder is 0.4%-1%.32  
Mood stabilizers are commonly used to treat bipolar disorder. Antipsychotics are also 
used for the condition. A systematic review conducted by Derry et al. found that antipsychotics 
are effective in the treatment of bipolar disorders.33 Literature suggests faster onset of 
haloperidol compared to lithium or atypical antipsychotics. Efficacy has also been demonstrated 
by atypical antipsychotics such as aripiprazole, clozapine, olanzapine, quetiapine, risperidone, 




                                               
31 US National Library of Medicine. Bipolar Disorder. Available at: 
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001924/. Accessed October 11, 2012.  
32 Mood Disorders. In: First MB ed. Diagnostic and Statistical Manual of Mental Disorders 4th ed. Washington 
(DC): American Psychiatric Association, 2000.   
33 Derry S, Moore RA. Atypical antipsychotics in bipolar disorder: systematic review of randomized trials. BMC 
Psychiatry 2007;7:40. 




2.2. Guidelines for use of antipsychotic medications 
Several practice guidelines have been developed on the use of antipsychotics for the 
treatment of schizophrenia. These include the Expert Consensus Guidelines on the treatment of 
schizophrenia, the National Institute of Health and Clinical Excellence (NICE) guidelines, the 
Texas Medication Algorithm Project (TMAP), the American Psychiatry Association (APA) 
guidelines, the Patient Outcomes Research Team (PORT), and the International 
Psychopharmacology Algorithm Project.   
According to the Expert Consensus Guidelines for the treatment of schizophrenia, 
patients with a first episode and predominantly positive or negative symptoms should be 
prescribed atypical antipsychotics.35 The guidelines also recommend atypical antipsychotics for 
those who have episodes despite good compliance with typical antipsychotics. For patients non-
compliant with oral medications, long-acting depot antipsychotics are recommended. For 
patients initiated on typical antipsychotics who experience inadequate response, the 
recommended treatment is switching to a newer atypical antipsychotic. If there is non-response 
with sequential trials to typical and newer atypical antipsychotics, the recommendation is raising 
the dose of the antipsychotic or switching to clozapine. The preferred methods of switching 
include cross-titration or overlap and taper; the preferred duration of switch is four to five weeks 
if the switch does not involve clozapine and seven to eight weeks if the switch does involve 
clozapine. Thus, polypharmacy with antipsychotics during switching is acceptable for up to eight 
weeks.  
                                               
35 The expert consensus guideline series. Treatment of schizophrenia. J Clin Psychiatry 1999; 60 suppl 11:3-80. 
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The NICE guidelines recommend that the choice of antipsychotic should be a combined 
decision of the patient and the physician.36 NICE recommends starting at the lower end of the 
licensed range and then titrating upwards. Trials of medications at optimum doses must be 
carried out at least for four to six weeks. Avoid loading doses of the antipsychotics. As required 
prescriptions to antipsychotics may be made but the physician must take into account their effect 
on the total dose, efficacy, side effects, and adherence. Clozapine must be offered to patients 
whose illness does not respond to sequential trials of at least two antipsychotics (one of which 
must be a non-clozapine second-generation antipsychotic). If there is no response even after 
prescribing clozapine, consider adding a second antipsychotic to augment treatment with 
clozapine. An adequate trial of an augmentation may be from eight to 10 weeks. The selected 
antipsychotic must not compound the side effects of clozapine. Antipsychotic polypharmacy is 
not recommended except for a short period of time while switching medications.  
According to the TMAP, atypicals are preferred as treatment for first-episode 
schizophrenia due to better tolerance.37
,38 In case of failure with one atypical antipsychotic, the 
algorithm recommends use of typical antipsychotics or other atypicals. Two failed trials of 
antipsychotics warrant the use of clozapine. The guideline recommends that long delays to 
initiation of clozapine should be avoided. Patients with persistent symptoms of suicide or 
violence or comorbid substance abuse disorder should be initiated on clozapine early. In case of 
partial response to clozapine, it should be combined with other atypical and typical 
antipsychotics. In case of clozapine refusal or non-response to polypharmacy with clozapine, the 
                                               
36 National Institute for Clinical Excellence: Core interventions in the treatment and 
management of schizophrenia in adults in primary and secondary care. NICE Clinical Guideline 82; 2009. 
37 Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for 
schizophrenia: 2003 update.  J Clin Psychiatry 2004; 65(4):500-8. 
38 Moore TA, Buchanan RW, Buckley PF, et al. The Texas medication algorithm project antipsychotic algorithm 
for schizophrenia: 2006 update. J Clin Psychiatry. 2007;68(11):1751-62.  
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use of monotherapy, probably a typical or atypical antipsychotic, before moving to non-
clozapine polypharmacy is recommended. Combinations of antipsychotics are attempted only 
when all monotherapy has failed.          
The APA guidelines recommend use of an atypical antipsychotic for first episode 
patients.39 Atypical antipsychotics are also recommended for patients with a history of 
extrapyramidal side effects, prolactin elevation, weight gain, hyperglycemia, or hyperlipidemia. 
For those with persistent suicidal ideation or persistent hostility or aggressive behavior, the 
guidelines recommend clozapine. Long-acting injectable antipsychotics are recommended for 
those with poor adherence to oral antipsychotics. 
The PORT recommends antipsychotics other than clozapine and olanzapine as first-line 
treatment for persons experiencing first-episode schizophrenia.40 Patients with multi-episode 
schizophrenia must be offered continuous antipsychotic treatment to maintain symptom relief 
and reduce risk of relapse. PORT guidelines recommend the use of long-acting injectable 
antipsychotics when that is the preferred route of administration (in case of non-adherence with 
oral drugs). Clozapine should be offered to patients who continue to experience clinically 
significant positive symptoms after two adequate trials of antipsychotic agents. People with 
symptoms of hostility and suicide should also be treated with clozapine.    
The International Psychopharmacology Algorithm Project recommends an initial trial of 
four to six weeks with an atypical antipsychotic (amisulpride, aripiprazole, quetiapine, 
risperidone, or ziprasidone) or if that is unavailable, with a typical antipsychotic.41 If the trial is 
                                               
39 Lehman AF, Lieberman JA, Dixon LB, et al. Practice guidelines for the treatment of patients with schizophrenia, 
second edition. Am J Psychiatry 2004;161:Suppl:1-56. 
40 Kreyenbuhl J, Buchanan RW, Dickerson FB, et al. The schizophrenia Patient Outcomes Research Team (PORT): 
updated treatment recommendations 2009. Schizophr Bull 2010; 36(1):94-103. 
41 The International Psychopharmacology Algorithm Project. IPAP schizophrenia algorithm. 
Available at: www.ipap.org/schiz. Accessed October 9, 2012. 
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inadequate or it fails, the dose is adjusted. An adequate trial is one which continues for at least 
four to six weeks with the patient receiving the therapeutic dose for at least four weeks. If 
psychoses persist even after dose adjustment, then a four to six week trial of a second atypical 
antipsychotic (if available or a typical antipsychotic is if the atypical is unavailable) is carried out 
before moving the patient to clozapine. The choice of the second medication depends on the first 
one and the reasons for treatment failure other than lack of efficacy (such as side effects). If 
psychoses persist or the patient suffers from tardive dyskinesia or tardive dystonia despite an 
adequate trial, the patient is put on a six-month trial of clozapine up to 900 mg/day. If the 
symptoms continue to persist, the clozapine is optimized or augmented with electroconvulsive 
therapy or adjuvant medication.       
All the guidelines recommend polypharmacy of antipsychotics only when all other 
monotherapy options have been unsuccessful. Also, apart from the Expert Consensus Guidelines 
for the treatment of schizophrenia, no other guidelines offer any guidance on the duration of 
polypharmacy. Table 2 provides a summary of the guidelines. 
16 
 



























Project,         
2005 
First episode SGA SGA, FGA SGA SGA SGA, FGA SGA 
Second choice SGA SGA, FGA SGA, FGA SGA, FGA, 
Clozapine 
SGA, FGA SGA 
Third choice Clozapine Clozapine Clozapine Clozapine Clozapine Clozapine 











Fifth choice - - SGA, FGA - - - 
Sixth choice - - Combinations - - - 
                                               
42 Moore TA, Covell NH, Essock SM, et al. Real-world antipsychotic treatment 
practices. Psychiatr Clin North Am 2007;30(3):401-16. 
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2.3. Antipsychotic prescribing trends  
The use of antipsychotic medications in the general population increased tremendously in 
the mid-1990s due to the introduction of atypical antipsychotics. One reason for this increase in 
utilization is that atypical antipsychotics are associated with fewer side effects than typical 
antipsychotics. Another possible reason for widespread antipsychotic use was FDA approval of 
several atypical antipsychotics for conditions other than schizophrenia and bipolar disorder.  
In a longitudinal analysis of national data to study antipsychotic prescribing in US 
nursing homes from 1996 to 2006, Castle et al. found that the use of antipsychotics increased 
from 16.4% in 1996 to 25.9% in 2006.43 The authors found that controlling for facility, staffing, 
and resident factors, for-profit facilities were more likely than non-profit facilities to increase 
antipsychotic use and organizations which were chain facilities were less likely to increase 
antipsychotic use compared to independent facilities.     
Several studies have been conducted using the National Ambulatory Medical Care 
Survey (NAMCS), a nationally representative ongoing survey of US office-based physicians, to 
determine antipsychotic usage trends. A study conducted by Daumit et al. used the NAMCS and 
the National Hospital Ambulatory Medical Care Survey from 1992 to 2000.44 The authors found 
that for patients between 18 to 69 years of age, antipsychotic medications were prescribed or 
continued in 5,032 visits (only unweighted frequencies were reported in the study) and 33% of 
the visits involved prescription or continuation of an atypical antipsychotic over the eight-year 
study period. The percentage of visits with an atypical medication prescribed increased 
dramatically during the study period.  
                                               
43 Castle NG, Hanlon JT, Handler SM. Results of a longitudinal analysis of national data to examine relationships 
between organizational market characteristics and changes in antipsychotic prescribing in US nursing homes from 
1996 to 2006. Am J Geriatr Pharmacother 2009;7(3):14-50. 
44 Daumit GL, Crum RM, Guallar E, et al. Outpatient prescriptions for atypical antipsychotics for African 
Americans, Hispanics, and whites in the United States. Arch Gen Psychiatry 2003;60(2):121-8. 
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Sankaranarayanan et al. used the NAMCS 1996-2002 files. Over the eight-year study 
period, there were 47.7 million visits involving a mental health disorder and the mention of an 
antipsychotic.45 There was an increase of 195% and 149% for atypical and combination 
antipsychotics, respectively, from 1996-1997 to 2002-2003 and a 71% decrease in the use of 
typical antipsychotics over the same period. Another study conducted by Aparasu et al. used 
1998-2002 NAMCS data and reported a nearly two-fold increase in the number of antipsychotic-
related visits from 4.6 million in 1998 to 8.6 million in 2002.46 The proportion of visits 
associated with atypical antipsychotics rose from 40% to 84% and the number of visits 
associated with typicals declined.  
NAMCS has also been used to study antipsychotic prescribing trends in children. Copper 
et al. analyzed data from 1995 to 2002 and found that there were 5,762,193 visits to healthcare 
providers where children were prescribed antipsychotics.47 Antipsychotic prescribing frequency 
increased from 8.6 per 1,000 children in 1995-1996 to 39.4 per 1,000 children in 2001-2002. 
More than half the antipsychotics were prescribed for behavioral indications or affective 
disorders, indications for which antipsychotic use in children has not been thoroughly studied.  
Comer and his colleagues used 1996-2007 NAMCS data to analyze the trends of 
outpatient visits with antipsychotic prescriptions in patients with anxiety disorder.48 Over the 12-
year study period, antipsychotic prescribing rose from 6.9% (1996-1999) to 14.5% (2004-2007) 
                                               
45 Sankaranarayanan J, Puumala SE. Antipsychotic use at adult ambulatory care visits by patients with mental 
health disorders in the United States, 1996-2003: national estimates and associated factors. Clin Ther 
2007;29(4):723-41. 
46 Aparasu RR, Bhatara V, Gupta S. U.S. national trends in the use of antipsychotics during office visits, 1998-
2002. Ann Clin Psychiatry 2005;17(3):147-52. 
47 Cooper WO, Arbogast PG, Ding H, et al. Trends in prescribing of antipsychotic medications for US children. 
Ambul Pediatr 2006;6(2):79-83. 
48 Comer JS, Mojtabai R, Olfson M. National trends in the antipsychotic treatment of psychiatric outpatients with 
anxiety disorders.  Am J Psychiatry 2011;168(10):1057-65. 
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among visits for anxiety disorders with no co-occurring diagnosis of an FDA-approved 
indication for antipsychotics and from 10.6% (1996-1999) to 21.3% (2004-2007) overall.  
Yang et al. used the Veterans Affairs (VA) database from Texas (1997-2002) to evaluate 
antipsychotic medication utilization trends. They found that between 1997 and 2002 
antipsychotic prescriptions changed from primarily typicals to primarily atypicals. Overall 
combination therapy increased slightly over time (4.3%), switching remained stable (14.1%), and 
monotherapy remained predominant (81.5%).49 Weintraub et al. found that overall antipsychotic 
medication use between 2002 and 2008 in VA patients with Parkinson disease (PD).50 However, 
while the number of prescriptions for risperidone and olanzapine decreased, prescriptions for 
quetiapine increased. In 2008, 50% of the patients with PD had an antipsychotic prescription 
and, for those treated with atypical antipsychotics, 66% used quetiapine. About 30% received 
high-potency antipsychotics (defined in this study as those antipsychotics associated with 
causing or worsening parkinsonism). 
The IMS Health National Disease and Therapeutic Index was used to study trends in the 
use of second-generation antipsychotics from 1998 to 2008.51 This study showed that the number 
of visits in which mood stabilizers and typical antipsychotics were prescribed declined and those 
in which atypical antipsychotics were prescribed increased by 42%. 
Among non-dual eligible Medicaid beneficiaries in Texas, the number of patients with 
prescriptions for antipsychotics increased from 52,292 (2.5% of all beneficiaries) to 128,437 
                                               
49 Yang M, Barner JC, Lawson KA, et al. Antipsychotic medication utilization trends among Texas veterans: 1997-
2002.  Ann Pharmacother 2008;42(9):1229-38. 
50 Weintraub D, Chen P, Ignacio RV, et al. Patterns and trends in antipsychotic prescribing for Parkinson disease 
psychosis. Arch Neurol 2011;68(7):899-904. 
51 Pillarella J, Higashi A, Alexander GC, et al. Trends in use of second-generation antipsychotics for treatment of 
bipolar disorder in the United States, 1998-2009. Psychiatr Serv 2012;63(1):83-6. 
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(3.8% of all beneficiaries) from 2001 to 2008.52 This highlights the tremendous increase in the 
prescribing of antipsychotic medications in the past decade. This increase in prescribing of 
antipsychotic medications may have been accompanied by a simultaneous increase in the co-
prescribing of multiple antipsychotics. The prevalence of antipsychotic polypharmacy will be 















                                               
52 Medicaid Analytic eXtract (MAX) Rx Table Listing. Available at: http://www.cms.gov/Research-Statistics-Data-
and-Systems/Computer-Data-and-Systems/MedicaidDataSourcesGenInfo/Medicaid-Analytic-eXtract-MAX-Rx-
Table-Listing.html. Accessed March 15, 2014.   
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2.4. Benefits and risks of antipsychotic polypharmacy 
Antipsychotic polypharmacy (APP) is the concurrent use of two or more antipsychotic 
medications. Although this practice is not supported by any established treatment guidelines, 
APP is prominent in routine clinical practice with rates varying from 4% to almost 65% 
depending on the setting, year, and methodology used to define and calculate APP.53
,54 The 
prevalence of APP will be discussed in more detail in the next section. This section describes the 
risks and benefits associated with APP and briefly discusses the published clinical evidence 
regarding the concurrent use of multiple antipsychotics. 
The pharmacologic justification to use  APP is to achieve better therapeutic activity by 
enhancing D2 (dopamine) receptor blockade or antagonism of several receptors beyond the D2 
and 5-HT2 (5-hydroxytryptamine) receptors based on the possibility  that the other receptors may 
be relevant in the pathogenesis of positive and negative symptoms. Positron emission studies 
have shown that 60% to 80% D2 occupancy is needed to achieve the optimal therapeutic 
response while avoiding extra-pyramidal symptoms (EPS).55
,56 Clozapine and quetiapine are too 
loosely bound to achieve D2 occupancy more than 70% when administered alone, but when 
given in combination with a high-affinity D2 blocker such as risperidone, the required D2 
blockade can be achieved while retaining the reduced risks of EPS.57
,58  A second antipsychotic 
                                               
53 Botts S, Hines H, Littrell R. Antipsychotic polypharmacy in the ambulatory care setting, 1993-2000. Psychiatr 
Serv 2003;54(8):1086. 
54 Gallego JA, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic 
review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 2012; 138(1):18-
28. 
55 Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. 
Implications for atypical antipsychotic action. J Psychiatry Neurosci 2000;25(2):161–6. 
56 Nordstrom AL, Farde L,Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic 
drug effects: A double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33(4):227–35. 
57 Freudenreich O, Goff  DC. Antipsychotic combination therapy in schizophrenia: a review of efficacy and risk of 
current combinations. Acta Psychiatr Scand 2002;106(5):323-30. 
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may also be added to reduce adverse effects of the first. For example, apripiprazole is sometimes 
added to reduce plasma prolactin levels which have been elevated by the use of a potent D2 
receptor blocker.59
,60 APP may also be used while switching from one antipsychotic to another 
where a second antipsychotic is initiated while the first drug dosage is tapered until 
discontinuation. Often times a patient’s symptoms appear to respond better when the 
antipsychotics are being co-administered which could lead to permanent polypharmacy.61
,62 It is 
important for the clinician to attempt discontinuation of  the initial medication and use 
symptomatic treatments for side effects which may arise during return to monotherapy before 
deciding to use long-term polypharmacy. APP may also be used to manage particularly 
challenging symptoms.  Efficacy towards aggressive behavior differs among atypical 
antipsychotics.63 Another common reason for concomitant antipsychotic use is the use of the 
second antipsychotic “as needed” (pro re nata (prn)). Although this is prescribed for short-term 
use, since the “prn” prescriptions are discretionary, a small proportion of these cases may 
translate into long-term polypharmacy.64      
                                                                                                                                                       
58 Kapur S, Zipursky RB, Remington G, et al. 5HT-2 and D2 receptor occupancy of olanzapine in schizophrenia: A 
PET  investigation. Am J Psychiatry 1998;155(7):921–8. 
59 Shim JC, Shim JG, Kelly DL, et al. Adjunctive therapy with a dopamine partial agonist, aripiprazole, for 
antipsychotic-induced hyperprolactinemia: a placebo controlled trial. Am J Psychiatry 2007; 164(9):1404-10.  
60 Hoffer ZS, Roth RL, Matthew M. Evidence for the partial dopamine receptor agonist aripiprazole as first-line 
treatment of psychosis in patient with iatrogenic or tumorigenic hyperprolactinemia. Psychosomatics 2009; 
50(4):317-24. 
61 Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: Comparing monotherapy with 
polypharmacy and augmentation. Curr Med Chem 2004;11(3):313–27. 
62 Stahl SM. Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret? J Clin Psychiatry 
1999;60(7):425–6. 
63 Eisen C, Shaner R, Unutzer J, et al. Datapoints: second-generation antipsychotic medication combinations for 
schizophrenia. Psychiatr Serv 2008;59(3):235. 
64 Langan J, Shajahan P. Antipsychotic polypharmacy: review of mechanisms, mortality and management. The 
Psychiatrist 2010; 34:58-62.  
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There are several problems associated with APP. These include a potential risk of poor 
adherence due to complex medication regimens,65 an increase in possible adverse effects due to 
drug interactions, and exposure of patients to high doses of  antipsychotic drugs.66
,67 Concurrent 
antipsychotic use is a major contributor toward high-dose prescribing, although the therapeutic 
value of this is uncertain as there is no convincing evidence that higher than the licensed doses of 
antipsychotics are more advantageous in the treatment of acute episodes or treatment-resistant 
schizophrenia.68 Combining typical and atypical antipsychotics increases the risk of adverse 
effects such as EPS and thus, the advantage of using an atypical may be lost.69 Paton et al. noted 
that the proportions of patients prescribed anti-Parkinsonian drugs (to combat EPS) were almost 
the same in patients on typical antipsychotics and those on a combination of typical and atypical 
antipsychotics. Use of APP may also be associated with increased risk of metabolic diseases70 
and mortality.71
,72 APP is also associated with a high financial burden. Details on the economic 
impact of APP are discussed in a later section.        
The clinical evidence on APP is limited to case studies and open-label studies with few 
randomized controlled trials. In a review, Patrick et al. (2005) searched PubMed from 1976 to 
                                               
65 Fenton WS, Blyler CR, Heinssen RK. Determinant of medication compliance in schizophrenia: empirical and 
clinical findings. Schizophr Bull 1997: 23(4):637-51. 
66 Paton C, Barnes TR, Cavanagh MR, et al. High-dose and combination antipsychotic prescribing in acute adult 
wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry. 2008;192(6):435-9. 
67 Taylor D, Atkinson J, Fischetti C, et al. A prospective 6-month analysis of the naturalistic use of aripiprazole: 
factors predicting favorable outcome. Acta Psychiatr Scand 2007; 116(6):461-6.   
68 Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004; 
24(2):192-208. 
69 Paton C, Lelliott P, Harrington M, et al. Patterns of antipsychotic and anticholinergic prescribing for hospital 
inpatients. J Psychopharmacol 2003;17(2):223-9.  
70 Correll CU, Fredrickson AM, Kane JM, et al. Does antipsychotic polypharmacy increase the risk of metabolic 
syndrome? Schizophr Res 2007;89(1-3):91-100. 
71 Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. 
Schizophr Res 2009;113(1):1-11.  
72 Baandrup L, Gasse C, Jensen VD, et al. Antipsychotic polypharmacy and risk of death from natural causes in 
patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry 2010;71(2):103-8.  
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2002 to identify case series, clinical trials and reports that compared monotherapy and APP.73 
They found 52 studies, of which four were double-blind studies, 13 were open-label clinical 
trials, and 35 were case reports; only one open-label study and two case studies examined 
outcomes associated with monotherapy versus combination therapy in the same set of patients. 
The most frequently used combinations were clozapine with risperidone. More than half the 
studies (28 out of 52) involved treatment with atypical antipsychotics. Three quarters of the 
double-blind studies and 69% of the open-label trials found combination therapy more effective 
than monotherapy at alleviating symptoms and 13 out of the 35 case studies also reported overall 
positive symptoms. Patrick et al. concluded that although APP is not evidence based, there is no 
evidence against its use and recommended further research.    
In the same year, Chan and Sweeting reviewed combinations of atypical antipsychotics 
other than clozapine and found four open-label studies, five case series, and 12 case reports 
which showed clinical effectiveness of combination therapy.74 There were no randomized 
controlled trials. There were seven cases where combination therapy with aripiprazole led to 
deterioration of symptoms. There were three cases which demonstrated that combinations were 
associated with adverse effects.  
More recently in 2008, Pandurangi and Dalkilic conducted a review and identified 75 
studies on the use of combinations of atypical antipsychotics (including clozapine).75 They 
identified the following combinations: clozapine + risperidone (26 reports, of which only four 
were randomized controlled trials—one showed symptom improvement in the combination 
                                               
73 Patrick V, Levin E, Schleifer S. Antipsychotic polypharmacy: Is there evidence for its use? J Psychiatr Pract 
2005;11(4):248–57. 
74 Chan J, Sweeting M. Combination therapy with non-clozapine atypical antipsychotic medication: A review of 
current evidence. J Psychopharmacol 2007;21(6):657–64. 
75 Pandurangi AK, Dalkilic A. Polypharmacy with second-generation antipsychotics: a review of evidence. J 
Psychiatr Pract 2008;14(6):345-67. 
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group, one showed no significant difference between the two groups, and two showed better 
symptom control in the monotherapy group), clozapine + sulpiride or amisulpride (five case 
studies, one double-blind placebo controlled trial (which showed improvement in the 
combination group), one single-blind randomized trial),  clozapine + olanzapine (two case 
reports), clozapine + quetiapine (one case study and one case report), clozapine + ziprasidone 
(one open-label non-randomized study, one case study and three case reports), and clozapine + 
aripiprazole (one open-label non-randomized study, four case reports, and four case studies). 
Numerous case reports on combinations of atypical antipsychotics were found but there were no 
blinded or controlled randomized trials. Two open-label randomized trials were found. Potkins et 
al.76 examined the combination of quetiapine and risperidone and Kotler et al.77 studied 
olanzapine plus sulpiride. Of the eight randomized trials found, three trials supported use of a 
second atypical antipsychotic and one found selective improvement in disorganized thinking, 
two found no significant benefit of the combination, one found limited benefit involving 
improved mood symptoms, and one was a pharmacokinetic study that found that risperidone did 
not affect serum quetiapine levels.78
,79,80,81,82,83,84 There is widespread use of combination 
                                               
76 Potkin SG, Thyrum PT, Alva G, et al. The safety and pharmacokinetics of quetiapine when co-administered with 
haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol 2002(2);22:121–30. 
77 Kotler M, Strous RD, Reznik I, et al. Sulpiride augmentation of olanzapine in the management of treatment-
resistant chronic schizophrenia: Evidence for improvement of mood symptomatology. Int Clin Psychopharmacol 
2004;19(1):23–6. 
78 Potkin SG, Thyrum PT, Alva G, et al. The safety and pharmacokinetics of quetiapine when co-administered with 
haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol 2002(2);22:121–30. 
79 Kotler M, Strous RD, Reznik I, et al. Sulpiride augmentation of olanzapine in the management of treatment-
resistant chronic schizophrenia: Evidence for improvement of mood symptomatology. Int Clin Psychopharmacol 
2004;19(1):23–6.  
80 Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially 
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therapy, but due to the duration and cost issues associated with undertaking large efficacy trials, 
it may be reasonable to focus on specific combinations; for example, those which are most 
frequently used. 
Several meta-analyses have been conducted on antipsychotic combinations. Paton et al. 
included four trials and concluded that a long clinical trial of clozapine with atypical 
antipsychotics should be conducted.85 Taylor and Smith86 found marginal benefit of combination 
therapy (compared to placebo) based on 10 trials and Correll et al.87 also reported a small effect 
in favor of combination therapy. Barbui et al.88 evaluated 21 research articles and found weak 
evidence and modest to absent effect. A Cochrane review89 of trials of clozapine with other 
antipsychotics did not find any evidence to modify existing recommendations.  
A recent review of literature conducted by Lochmann van Bennekom et al. demonstrated 
that theories behind APP had only modest clinical and pre-clinical evidence.90 Studies supporting 
the neurobiological effects of APP were lacking and the efficacy literature is limited to modest 
beneficial clinical evidence.   
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The widespread use of antipsychotic polypharmacy is probably due to insufficient effects 
of monotherapy. It is important to conduct RCTs, naturalistic studies and head-to-head 


















                                               




2.5. Prevalence of antipsychotic polypharmacy 
Several guidelines, including the APA guidelines,92 the schizophrenia PORT treatment 
recommendations,93
,94 the TMAP schizophrenia algorithms,95 the NICE guidelines,96  the Expert 
Consensus Guidelines for treatment of patients with schizophrenia,97 and the International 
Psychopharmacology Algorithm Project98 recognize antipsychotics as the cornerstone therapy 
for treatment of patients with schizophrenia, and have consistently recommended monotherapy 
as the treatment of choice.  
Although none of the expert guidelines advocate polypharmacy of antipsychotics, the 
TMAP algorithm states that for some individual patients, a combination of antipsychotics might 
be optimal but there is no way to predict who might benefit and there are numerous possible 
antipsychotic combinations.99 Thus, the algorithm does not recommend trials of combinations 
until clozapine has failed and it also guides the physician to be alert to improvement in patient 
status during the temporary medication overlap period while switching from one antipsychotic to 
another and consider return to the combination if none of the monotherapies are as effective as 
the combination. The Expert Consensus guidelines offer guidance on the duration of concomitant 
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use of two antipsychotics at no longer than 8 weeks (60 days) while switching from one 
antipsychotic to another using the overlap and tapering or cross-titration method of switching.100  
Only the Expert Consensus guidelines provide an operational definition for long-term 
antipsychotic polypharmacy. Different studies have used different definitions of polypharmacy 
and, thus, the prevalence of APP widely varies. The rates of APP also vary tremendously across 
different treatment settings.  
Monotherapy is preferred as it is possible to document a patient’s response to each 
medication, reduce the complexity of the treatment regimen, reduce the risk of adverse events, 
and make it easier to manage future symptoms.101 In the case of polypharmacy, there is increased 
likelihood of pharmacokinetic and pharmacodynamic interactions and the ‘atypical’ nature of the 
antipsychotic is lost if it is combined with a typical antipsychotic.              
Despite consistent recommendations for monotherapy, the use of combinations of 
antipsychotics is widespread. This is likely due to the introduction of several new atypical 
antipsychotics in the past two decades that have augmented the arsenal of typical antipsychotics 
that were already available.   
A study by Leslie et al. estimated the prevalence of APP in a Veterans Affairs (VA) 
population with schizophrenia between June and September 1999 at 6.8%.102 Another study used 
the National Psychosis Registry of the VA and examined long-term APP in patients with 
schizophrenia and schizoaffective disorder between 1999 and 2001.103 The authors estimated that 
9.5% of the patients had long-term APP, defined as receipt of two or more antipsychotics 
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concomitantly for at least 90 consecutive days during the study period. Weissman evaluated the 
extent of APP in the New York Metropolitan region VA among schizophrenia patients between 
2000 and 2001 and noted an increase in APP from 15% to 17%.104  
Ganguly et al. examined Medicaid-eligible schizophrenia patients from the states of 
California and Georgia between 1998 and 2000.105 They found that 23% (Georgia: 18.1%, 
California: 29.3%) of the patients received long-term APP, defined as concomitant use of two or 
more antipsychotics for at least 61 days without a break period of 31 days or more. Non-
clozapine polypharmacy was more prevalent than clozapine polypharmacy (19.4% vs. 2.5%). 
Within the non-clozapine polypharmacy group, atypical + typical was the most prevalent 
combination (15.7%), followed by atypical + atypical (3.9%), and finally typical + typical 
(2.8%). Gilmer and his colleagues used California Medicaid data from 1999 to 2004 to study 
trends in the prevalence of APP in patients with schizophrenia.106 The monthly rate of second-
generation APP increased from 3.3% in 1999 to 13.7% in 2004 and the rate of combination of 
first- and second-generation antipsychotics decreased from 10.8% in 1999 to 8.3% in 2004. The 
proportion of patients receiving APP for 12 months increased from 5.1% in 1999 to 14.4% in 
2004.  
Another study examined the prevalence of APP among fee-for-service (FFS) Medicaid 
beneficiaries in five states (California, Nebraska, Oregon, Utah and Wyoming) from 1998 to 
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2003.107 Polypharmacy was defined as the initiation of multiple antipsychotics or at least 60 
consecutive days of concomitant antipsychotic medication overlapping the index medication.  
The overall prevalence of APP was 6.4% (3,534 patients). The highest rates of APP were 
observed in patients with a schizophrenia diagnosis, those having ten or more unique mental 
health diagnoses, those with clozapine as the index drug, and those with a recent mental health-
related hospitalization.  
More recently, Constantine et al. studied the trends of APP in the FFS population of 
Florida’s Medicaid program between 2002 and 2006.108 APP was defined as use of two or more 
antipsychotics for 60 consecutive days with no gap exceeding 15 days. The overall prevalence of 
APP was 21%. The prevalence showed an increasing trend until 2004 and a decreasing trend 
thereafter. The authors carried out a similar study of children (ages six to 12 years) and 
adolescents (ages 13 to 17 years) in the Florida Medicaid program over the same time period 
using the same definition for APP.109 Seven percent of the children and 8% of the adolescents 
had APP and the mean length of the polypharmacy episode was 170 and 186 days for children 
and adolescents, respectively. Times to initiation of polypharmacy were 506 and 385 days for 
children and adolescents, respectively. Kogut et al. used Rhode Island Medicaid FFS claims to 
estimate the extent of APP in 2003. They found that 10.1% of the patients had at least two 
prescription fills for two different antipsychotic medications during the 90 days prior to the most 
recent prescription fill. Of the patients eligible for the study, eight percent used two atypical 
antipsychotics and 2.1% used one typical and one atypical antipsychotic. The highest rates of 
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polypharmacy were observed in males and in patients between 18 and 64 years of age.110 Clark 
and his colleagues used prescription claims from New Hampshire Medicaid beneficiaries with 
schizophrenia or schizoaffective disorder between 1995 and 1999 and found that the proportion 
of patients treated with atypical antipsychotics grew from 43% in 1995 to 90% in 1999. 
Concurrent use of two or more antipsychotic medications increased from 5.7% in 1995 to 24.3% 
in 1999.111     
Botts et al. used the National Ambulatory Medical Care Survey (NAMCS) 1993-2000, a 
multistage probability survey of visits to office-based physicians in the US, to estimate APP in 
ambulatory care.112 Antipsychotics were reported in one percent of the visits and of these, four 
percent of the visits reported prescription of two antipsychotics. The APP rate increased over 
each two-year period. A study by Barbui et al. looked at the extent of polypharmacy among 
schizophrenia patients in four European countries (Croydon (UK), Verona (Italy), Amsterdam 
(Netherlands), and Leipzig (Germany)) and found that among the 375 patients, 13% persistently 
received polypharmacy.113 APP was defined as use of two or more antipsychotics at baseline and 
follow-up of the study. A study conducted in British Columbia, Canada between October 2005 
and October 2006 to determine the proportion of community mental health outpatients treated 
with persistent APP (two antipsychotics for at least 90 days) estimated the overall prevalence of 
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APP at 25.7%.114 The prevalence of persistent APP was highest for patients with schizoaffective 
disorder (33.7%), followed by schizophrenia (31.7%), psychosis not otherwise specified 
(20.0%), bipolar disorder (16.9%), and major depression (14.3%).  
Several studies have also been conducted in inpatient settings to estimate the extent of 
APP. Jaffe et al. estimated the rate of APP among inpatients in a large state hospital in New York 
in 1999.115 Co-prescribing (intentional co-prescribing of two antipsychotics for at least 28 days) 
occurred in 37.3% of the patients and 4.6% were treated with three or more antipsychotics. The 
mean length of a polypharmacy episode was 97 days. Another study conducted on inpatients in a 
hospital in Spain found that for the patients admitted in March 2011, the prevalence of APP was 
47.1%. Twenty-four percent of the patients on APP were elderly people.116 Quetiapine was the 
most highly prescribed drug (56.8%) in combinations. A study conducted over a 60-day 
surveillance period (between December 2000 to February 2001) among patients at the William 
R. Sharpe, Jr. Hospital found that of the 201 patients placed on scheduled antipsychotics, 85 
(41%) were prescribed more than one antipsychotic concomitantly.117 In a study conducted using 
inpatients admitted into the University Psychiatric Hospital in Serbia between 2002 and 2005, 
APP was observed in 67.7% of the hospitalizations. APP with two drugs was seen in 63.3% and 
that with three drugs was seen in 4.1% of the hospitalizations. APP was defined as concomitant 
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use of more than one antipsychotic for at least 28 days.118 McCue et al. reviewed medical records 
of patients discharged from the Woodhull Medical and Mental Health Center between 1995 and 
2000 and found that none of the patients were discharged on treatment with more than one 
antipsychotic in 1995, while 15.9% of the patients were in 2000.119 Dolder et al. conducted a 
retrospective analysis of patients admitted to a geriatric facility in North Carolina between 2006 
and 2010 and found that nearly 13% of the patients had APP at the time of admission and this 
was reduced to eight percent at the time of discharge.120 Quetiapine was the drug which was 
most commonly involved with antipsychotic polypharmacy. An audit carried out at the Birch 
Hill Hospital, Lancashire found the prevalence of APP at 17.4%.121                                
Faries et al. used data from the U.S. Schizophrenia Care and Assessment Program (US-
SCAP), a non-randomized, naturalistic, three-year prospective multi-center study conducted 
between July 1997 and September 2003.122 Patients were enrolled from California, Colorado, 
Connecticut, Florida, Maryland, and North Carolina and were from different health care systems. 
On a daily basis, APP was defined as use of more than one antipsychotic medication. Substantial 
APP was defined as use of two or more antipsychotics concomitantly for at least 60 but less than 
300 days and predominant APP was defined as use of two or more antipsychotics concomitantly 
for 300 or more days out of the year. Monotherapy, substantial monotherapy, and predominant 
monotherapy had similar definitions. During a one-year follow-up period, only a third of the 
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patients were on predominant monotherapy. Almost 58% of the patients had at least one 
prolonged period of polypharmacy for 60 days or more. Patients averaged 195.5 days on 
monotherapy, 155.7 days on polypharmacy, and 13.9 days without antipsychotic therapy. 
Another one-year naturalistic study conducted in Japan between 2003 and 2004 by Ye et al. 
reported that of the 1,850 patients eligible for the study, 56.8% had APP (defined as concomitant 
use of two or more antipsychotics for at least 60 days) at some point during the one-year study 
period.123    
Aggarwal et al. examined  the concomitant use of oral antipsychotics in patients treated 
with long-acting intramuscular (LAI) antipsychotics for schizophrenia and schizoaffective 
disorder from the Connecticut Mental Health Center between July 1, 2009 and June 30, 2010.124 
Concomitancy was defined as simultaneous oral and LAI antipsychotic use at any time during 
the study period. Of the 124 patients on LAIs, 46% were prescribed a concomitant oral 
antipsychotic. This is contrary to the notion that LAIs are used as monotherapy in ‘real-world’ 
settings. Such concomitancy may represent a common practice of APP and should be 
investigated further.    
Tungaraza et al. conducted a study that looked at the use of multiple antipsychotic 
medications in people living in the community under the community mental health team 
(CMHT) in the urban and rural parts of North East Wales between 2006 and 2007.125 
Psychotropic polypharmacy was widespread in this population with 67.3% taking more than one 
psychotropic drug. Of the 211 individuals examined, 82.5% were on a single antipsychotic, and 
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17.5% were on two antipsychotics. In a two-phase national survey conducted between 2002 and 
2003 in Italy to investigate characteristics of patients admitted to acute inpatient facilities, the 
extent of antipsychotic polypharmacy was found to be 32.6%.126     
Despite recommendations of antipsychotic monotherapy by several expert guidelines, 
APP is widely practiced in various clinical settings. A meta-analysis of studies estimating the 
prevalence of APP between 1970 and 2009 found that the median prevalence of APP was 
19.6%.127 Another meta-analysis estimated the prevalence of APP among antipsychotic treated 
youth at 9.6 ±7.2% (5.9 ± 4.5% in child studies, 12.0 ± 7.9% in adolescent studies).128   
Generally, the concurrent use of more than one antipsychotic varied over a very wide 
range, from as low as 4% to as high as almost 65%, depending on the population studied, the 
year when the study was conducted, the study method, definition of APP, the type of treatment 
site, and the duration of the study period.   
Table 3 contains a summary of the studies that evaluated the prevalence of APP. 
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Table 3: Summary of studies that evaluated the prevalence of antipsychotic polypharmacy 
Author Year Prevalence Population Definition of APP 
US: Administrative data bases 
Leslie et al. (2001) 1999 6.8% Veterans Affairs Patients prescribed more 
than one antipsychotic 
during a one-week 
window 
Clark et al. (2002) 1995-1999 5.7-24.3% New Hampshire Medicaid 
beneficiaries  
Using combination of 
antipsychotics for over 
nine months 
Weissman (2002) 2000-2001 15-17% New York metropolitan 
region Veterans Affairs 
Co-prescription of two or 
more antipsychotics for at 
least two months  
Botts et al. (2003) 1993-2000 4% NAMCS At least two 
antipsychotics prescribed 
at the office-based 
physician visit 
Ganguly et al. (2004) 1998-2000 23% California and Georgia 
Medicaid beneficiaries 
Concomitant use of two or 
more antipsychotics for at 
least 61 days without a 
break period of 31 days or 
more  
Faries et al. (2005) July, 1997 and 
September, 2003 
58% Three-year prospective 
multi-center study with 
patients from California, 
Colorado, Connecticut, 
Florida, Maryland, and 
North Carolina and 
different healthcare 
systems 
Use of two or more 
antipsychotics 
concomitantly for at least 
60 but less than 300 days 
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Table 3: Summary of studies that evaluated the prevalence of antipsychotic polypharmacy  (continued) 
Author Year Prevalence Population Definition of APP 
Kogut et al. (2005) 2003 10.1% Fee-for-service Rhode 
Island Medicaid 
beneficiaries 
At least two dispensings 
of two different 
antipsychotics during the 
90 days prior to the most 
recent dispensing 
Kreyenbuhl et al. 
(2006) 
1999-2000 9.5% Veterans Affairs Receipt of two or more 
antipsychotics 
concomitantly for at least 
90 consecutive days  





Morrato et al. (2007) 1998-2003 6.4% California, Oregon, Utah, 
Nebraska, and Wyoming 
Medicaid beneficiaries  
Initiation of multiple 
antipsychotics or at least 
60 consecutive days of 
concomitant antipsychotic 
medication overlapping 
the index medication     
Constantine et al. 
(2010) 
2002-2006 21% Fee-for-service Florida 
Medicaid beneficiaries 
Use of two or more 
antipsychotics for greater 
than 60 consecutive days 
with no gap exceeding 15 
days  
Constantine et al. 
(2010)  




children and adolescents  
Use of two or more 
antipsychotics for greater 
than 60 consecutive days 






Table 3: Summary of studies that evaluated the prevalence of antipsychotic polypharmacy (continued) 
Author Year Prevalence Population Definition of APP 
Aggarwal et al. (2012) July 1, 2009 and June 
30, 2010 
46% (oral + long 
acting antipsychotic) 
Connecticut Mental 
Health Center   
Simultaneous oral and 
long acting injectable 
antipsychotic use at any 
time during study period 
Tungaraza et al. (2010) 2006 and 2007 17.5% Community-dwellers 
under the community 
mental health team 
(CMHT) in the urban and 
rural North East Wales 
Use of two antipsychotics  
Ye et al. (2012) 2003-2004 56.8% One-year naturalistic 
study conducted in Japan 
Concomitant use of two or 
more antipsychotics for at 
least 60 days  
US Hospitals 
Jaffe et al. (2003) 1999 37.3% Large state hospital in 
New York 
Intentional co-prescribing 
of two antipsychotics for 
at least 28 days  
McCue et al. (2003) 1995-2000 0% in 1995, 15.9% in 
2000 
Woodhul Medical and 
Mental Health Center, 
New York, US 
Receiving two or more 
antipsychotics at 
discharge 
Schumacher et al. 
(2003)  
December 2000 to 
February 2001 
41% William R. Sharpe, Jr. 
Hospital in West Virginia, 
US 
Receipt of two or more 
scheduled antipsychotics 
concomitantly  
Dolder et al. (2011) 2006-2010 13% at the time of 
admission, 8% at the 
time of discharge 
Geriatric facility in North 
Carolina 
Patients using multiple 
antipsychotics at 
admission and discharge 
Barbui et al. (2006)  13% UK, Italy, Netherlands, 
Germany 
Use of two or more 
antipsychotics at baseline 




Table 3: Summary of studies that evaluated the prevalence of antipsychotic polypharmacy (continued) 
Author Year Prevalence Population Definition of APP 
International hospitals 
Divac et al. (2007) 2002-2005 63.3% University Psychiatric 
Hospital in Serbia 
Concomitant use of more 
than one antipsychotic for 
at least 28 days 
Procyshyn et al. (2010) October 2005-October 
2006 
25.7% British Columbia, Canada Use of two antipsychotics 
for at least 90 days  
Ranceva et al. (2010) January-May 2008 17.4% Birch Hill Hospital, 
Lancashire  
Patients receiving more 
than one antipsychotic  
Santone et al. (2011) 2002 and 2003 32.6% Two-phase national 
survey conducted in Italy 
At least two 
antipsychotics 
simultaneously prescribed 
during index admission 
Lopez de Torre et al. 
(2012) 
March 2011 47.1% Inpatients in a Spanish 
hospital 
Use of two antipsychotics 
for one week 
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2.6. Predictors of antipsychotic polypharmacy 
It is important to identify characteristics of patients most likely to be prescribed APP so 
that this high-risk population can be monitored and their outcomes can be regularly evaluated. 
Several studies have attempted to identify this high-risk group of patients.  
A study conducted using Medicaid-eligible enrollees from Georgia and California 
between 1998 and 2000 used a stepwise logistic regression procedure to determine if 
demographics, diagnostic-related comorbidities, drug classes, antipsychotics agent, and prior 
healthcare utilization were related to long-term APP.129 Being eligible for California Medicaid, 
male gender, and belonging to the aid category (aged, blind, or disabled) were associated with 
increased likelihood of APP. Weight loss or malnutrition, diagnosis of epilepsy, other psychoses, 
and other mental disorders also predicted long-term concomitant use of multiple antipsychotics.  
Exposure to medication for cancer, Parkinson’s disease, and respiratory disorders were 
associated with increased likelihood of APP. Diagnosis for acquired immunodeficiency 
syndrome (AIDS), alcohol abuse, personality disorders, and use of drugs for cardiac conditions 
were associated with lower likelihood of APP. Psychiatric-related inpatient and outpatient  visits 
in the 6-month period prior to the index claim, regular use of antipsychotics, and index dates in 
the fourth quarter were also positively associated with APP.  
Morrato et al. used Medicaid data from five states (California, Nebraska, Oregon, Utah, 
and Wyoming) and reported the prevalence of APP at about six percent.130 They found that the 
strongest predictor for antipsychotic polypharmacy was a schizophrenia diagnosis, with 
concomitant antipsychotic use being three times as likely in patients with such a diagnosis 
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compared to those without any mental health diagnosis. In fact, the likelihood of polypharmacy 
increases with each additional diagnosis of a mental illness. Patients with mental health-related 
hospitalizations were more likely to have APP. Patients initiated on typical antipsychotics were 
more likely to have APP compared to those initiated on olanzapine and risperidone. With regards 
to demographic characteristics, males (compared to females), patients between 18 and 24 years 
of age (compared to those between 25 and 34 years of age), and Asians (compared to whites) 
were more likely to have APP.    
Kreyenbuhl et al. examined the predictors of long-term APP among Veterans Affairs 
(VA) patients with schizophrenia or schizoaffective disorder in 2000.131 The multivariate 
analyses carried out to identify the predictors of APP showed that younger, unmarried patients, 
those with a military service-related disability, and those with a schizophrenia diagnosis 
(compared to schizoaffective disorder) were more likely to be on multiple antipsychotics. 
African American patients were less likely to be on polypharmacy compared to whites. Patients 
with a depression or substance abuse diagnosis and those who had a higher co-morbidity burden 
as measured by the Charlson Comorbidity Index (CCI) were less likely to receive polypharmacy. 
Those who had a psychiatric hospitalization in the prior year or several outpatient mental health-
related visits were also more likely to receive APP.     
Biancosono et al. examined physicians’ reasons for prescribing multiple antipsychotics 
by conducting a study on psychiatric patients discharged from an inpatient facility and receiving 
antipsychotic therapy during a six-year recruitment period from 1998 to 2003 in Italy.132 They 
found that the factors which predicted APP were the Brief Psychiatric Rating Scale (BPRS) for 
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positive symptoms, BPRS for manic/hostility, being employed, and presence of APP on 
admission. Antipsychotic polypharmacy at admission was the strongest predictor of 
polypharmacy at discharge. Another study conducted in Italy by Santone et al. reported that APP 
was associated with a schizophrenia diagnosis, poor insight into the patient’s illness, and use of 
anti-Parkinsonism drugs.133  
A study examining APP among children in the fee-for-service component of Florida 
Medicaid between 2002 and 2007 found that adolescents (13-17 years) were more likely to 
receive polypharmacy compared to children (six to 12 years).134 Patients whose ethnicity was 
classified as ‘other’ were more likely to receive concomitant multiple antipsychotics compared to 
whites. Patients with a diagnosis of psychotic disorders were more likely to receive 
polypharmacy (compared to bipolar I disorder) and those with a diagnosis of major depressive 
disorder, other bipolar/mood disorder, ADHD, behavioral disorder, and anxiety/adjustment 
disorder were less likely to receive APP (compared to bipolar I disorder).  
In a prospective, observational study conducted on Japanese patients with schizophrenia 
between 2003 and 2004, stepwise logistic regression was used to identify predictors of 
antipsychotic monotherapy as compared to polypharmacy.135 The authors noted that older age, 
shorter duration of schizophrenia, outpatient status, presence of comorbid medical conditions, 
lower body mass index, no prior anticholinergic use, no prior mood stabilizer use, and switching 
from a previous antipsychotic were all associated with increased odds of antipsychotic 
monotherapy. Another study conducted in China found that younger age, number of 
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hospitalizations, site of study (Hong Kong vs. Beijing), and use of depot antipsychotics were all 
significantly associated with APP.136        
Dolder et al. conducted a retrospective analysis to study the patterns of use of 
antipsychotics among patients in a geriatric psychiatry unit in North Carolina between 2006 and 
2010.137 Patients with severe mental illness or dementia plus a mental illness were more likely to 
receive polypharmacy compared to those with dementia alone. Also those residing in a facility 
were more likely to receive multiple antipsychotics compared to those living at home. 
Gallego et al. conducted a meta-analysis of all the studies that estimated the prevalence of 
APP.138 They carried out a meta-regression to identify predictors of polypharmacy and found that 
inpatient status, typical antipsychotic use, and a schizophrenia diagnosis independently predicted 
APP.  
 Based on a review of existing literature, Correll et al. found that APP was associated with 
patients, illness and treatment factors which pointed towards greater disease severity and 
chronicity. However, there were certain provider characteristics at play which suggested that 
some of the APP may be unfounded.139   
Table 4 contains a list of potential factors associated with APP. This table has been 
adapted from an article published by Ganguly et al.140   
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Table 4: Potential factors associated with antipsychotic polypharmacy (Adapted from 134) 
Diagnostic-related comorbidities Demographics 
Congestive heart failure Age 
Myocardial infarction Gender 
Cardiac arrhythmias Race 
Valvular disease  Eligibility categories 
Peripheral vascular disease Aid category (aged, blind, disabled) 
Hypertension Drug class 
Hemiplegia/paraplegia 4 cardiac drug classes 
(antiarrhythmic + inotropic +  vasopressor, 
ACE inhibitors, antianginal agents, loop 
diuretics) 
Epilepsy  Parkinson’s disease drugs 
Other neurologic disorders Peripheral vascular disorder drugs 
Chronic pulmonary disease  Hypertension drugs 
Asthma 3 respiratory drug classes 
(adrenergic bronchodilators + asthma 
vasopressors + combinations, methylxanthines, 
inhalers + leukotrienes + combinations) 
Tuberculosis  Insulins  
Diabetes, uncomplicated Oral hypoglycemic 
Diabetes, complicated Cancer drugs 
Thyroid disorder 3 Epilepsy drug classes 
(hydantoin + succinimide + oxazolidinedione, 
barbiturates +  certain benzodiazepines, 
miscellaneous anticonvulsants [valproic acid 
and derivatives, carbamazepine and 
derivatives, gabapentin, lamotrigine, tiagabine, 
topiramate, levetiracetam]) 
Renal failure and chronic disease  Glaucoma drugs 
Liver disease  Gout drugs 
Peptic ulcer disease  Hyperlipidemia, hypercholesterolemia drugs 
Acquired immunodeficiency syndrome  Thyroid disorder drugs 
Metastatic solid tumor Menopause drugs (hormone replacement 
therapy) 
Any malignancy Allergy drugs 
Rheumatoid arthritis/collagen vascular disease Anxiety drugs 
Coagulopathy Pain (terminal) drugs, narcotics, analgesics 
Obesity  Depression drugs 
Weight loss/malnutrition  Dementia/Alzheimer’s drugs 






Table 4: Potential factors associated with antipsychotic polypharmacy (Adapted from 134) 
(continued) 
Diagnostic-related comorbidities Drug class 
Anemia Rheumatologic drugs/Crohn’s disease 
drugs/ulcerative colitis drugs 
Sickle cell anemia Migraine drugs 
Drug abuse ESRD/transplant drugs 
Alcohol abuse Mean number of drugs classes per patient 
Bipolar and manic depressive illness Antipsychotic agents: Atypicals, typicals 
Other psychoses/mixed psychoses Mood stabilizers: Lithium 
Other mental disorders Prior healthcare utilization 
Personality disorders Mental health cost in prior period 
Depression or schizoaffective disorder Number of psychiatric outpatient visits, 
physician specialty  
Cerebrovascular disease Psychiatric inpatient episode, latest  inpatient 
days, cumulative inpatient days  
Alzheimer’s disease  Date variables 
Non-Alzheimer’s dementia Quarter in which episode started 
Non-head trauma  Year in which episode started 
Head trauma     
Drug overdose  
Ophthalmologic disease  
Anxiety states  




















2.7. Adherence to antipsychotics  
Medication adherence is extremely important in psychiatry, especially for chronic 
conditions. Non-adherence rates of 40% to 60% have been reported for antipsychotics, 18% to 
56% for mood stabilizers, and 30% to 97% (median 63%) for antidepressants.141
,142,143 These 
poor adherence rates, in part, explain the difference between the efficacy seen during clinical 
trials and effectiveness seen during routine clinical practice.144  
Several studies have shown poor adherence to antipsychotic medications. In a three-year 
prospective, naturalistic study conducted among patients with schizophrenia between 1997 and 
2003, adherence was measured using medication possession ratio (MPR) and persistence was 
measured as time to all-cause medication discontinuation (first medication gap of more than 30 
days). Only 59% of the patients were deemed adherent (MPR>0.8). A greater proportion of 
atypical antipsychotic users were adherent (59.4%) compared to the typical antipsychotic users 
(34.5%). Persistence was significantly shorter for the typical antipsychotics group (173.9 days) 
compared to the atypical antipsychotics group (260.7 days).145  
Mullins et al. conducted a study in adult Maryland Medicaid patients with schizophrenia 
and measured discontinuation of antipsychotic agents using refill patterns. At one-year follow-
up, 90.4% of the patients had discontinued their antipsychotic medications. The discontinuation 
rates did not differ significantly for patients on aripiprazole, olanzapine, risperidone, or 
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ziprasidone but were significantly higher for those on quetiapine.146 Another retrospective 
database study was conducted on Quebec Drug Plan beneficiaries who were initiated on 
antipsychotics between 2000 and 2007. Patients initiated on quetiapine had a high risk of 
discontinuation compared to olanzapine initiators.  Risperidone, clozapine, and polytherapy users 
had a lower risk of discontinuation compared to olanzapine users. Those who discontinued were 
not likely to return to treatment and those who did return to treatment had a high likelihood of 
discontinuing again.147   
Some studies have been conducted to compare adherence to antipsychotics and time to 
discontinuation of medication in patients on monotherapy and those on APP. Between December 
2004 and March 2008, 15 sites in the National Institute of Mental Health’s Schizophrenia Trials 
Network and five sites in Connecticut’s public mental health system recruited adult patients who 
had a diagnosis of schizophrenia or schizoaffective disorder and were using two 
antipsychotics.148 Patients were randomly assigned to stay on polypharmacy or switch to 
monotherapy. Kaplan Meier and Cox proportional hazards analyses were carried out to 
determine time to discontinuation of therapy. The primary outcome was all-cause medication 
discontinuation. Of the 114 patients studied, 56 remained on polypharmacy and 58 switched to 
monotherapy. By month six, 86% of those on polypharmacy were still taking their assigned 
medication while 69% of those on monotherapy were still taking their assigned medication. 
However, two-thirds of the patients were successful in switching to monotherapy. They had no 
difference in symptom control compared to the polypharmacy group and the switch to 
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monotherapy resulted in weight loss. In the polypharmacy group, discontinuing one of the two 
antipsychotics lead to treatment discontinuation of all medications more quickly than when both 
medications were continued. In fact, another study by Hori et al. showed that if schizophrenia 
patients on APP switched to MT, it lead to improvements in attention, daily living and work 
skills.149  
In a retrospective cohort study conducted in Medicaid enrollees from California, 
Nebraska, Oregon, Utah, and Wyoming between 1998 and 2003, the authors compared 
medication adherence (measured using MPR) and persistence to antipsychotic medications 
between the polypharmacy and monotherapy groups.150 Each group was further divided into two 
categories based on whether the patients had concomitant psychotropic therapy or not. The 
polypharmacy group had higher adherence (0.82 for the no concomitant psychotropic therapy 
group, 0.83 for the concomitant psychotropic therapy group) compared to the monotherapy 
group (0.75 for both with and without psychotropic therapy groups). The persistence was also 
higher in the polypharmacy groups compared to the monotherapy groups (251, 283, 214, and 273 
days for the polypharmacy groups with and without psychotropic therapy and monotherapy 
groups with and without psychotropic therapy, respectively).          
A study by Katona et al. used data collected from the Hungarian National Health 
Insurance Fund's database to assess the time to all-cause medication discontinuation in patients 
on antipsychotic monotherapy either staying on monotherapy or switching to polypharmacy (two 
or more antipsychotics).151 All-cause discontinuation showed superiority for the monotherapy 
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group for most second generation antipsychotics (both oral and depot). For first generation 
antipsychotics, there was no difference between the monotherapy and polypharmacy group for 
the orals while the polypharmacy group showed superiority for the depot antipsychotics. For 
discontinuation due to mortality and hospitalizations, an advantage was noted in the 
polypharmacy group.  
Although adherence to antipsychotic therapy is  poor, it was observed that those on more 
than one antipsychotic had better adherence than those on a single antipsychotic medication. It 
has been well established that multiple antipsychotics lead to an increased likelihood of adverse 
events and drug interactions and are also associated with significantly higher costs than 
monotherapy.152 Combining an atypical antipsychotic with a typical antipsychotic makes it lose 
its ‘atypical’ nature and the patient is as likely to suffer from extrapyramidal symptoms including 
tardive dyskinesia as those on typical antipsychotics.153 Studies have demonstrated that patients 
are more likely to be adherent to simple medication regimens rather than complex 
regimens.154
,155 Despite these factors, studies comparing monotherapy and polypharmacy of 
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2.8. Factors affecting adherence to antipsychotics 
Regular use of antipsychotic medications is the cornerstone of treatment for psychotic 
disorders as it helps prevent relapse of the disease. Several studies have been conducted to 
identify predictors of non-adherence among antipsychotic users. The literature on factors 
predicting non-adherence is vast; this literature review is focused on studies that were considered 
to be relevant to the current study.  
Valenstein et al. reported that in a cohort of VA patients with schizophrenia or 
schizoaffective disorder between October 1998 and September 1999, about 40% of the patients 
receiving one antipsychotic and 38% receiving two antipsychotics had an MPR < 0.8, indicating 
poor adherence.156 The patient factors predicting poor adherence included African American 
ethnicity and young age. Those with poor adherence were less likely to have ever received high 
antipsychotic doses. Patients on atypical antipsychotics were more likely to be poorly adherent 
than those on typical antipsychotics (41.5% vs. 37.8%).     
Another study conducted by Valenstein et al. used data from VA patients with 
schizophrenia between 2000 and 2003.157 The authors examined whether the patients had 
consistently good adherence (MPR≥0.8 in all four years), consistently poor adherence (MPR<0.8 
in all four years), or inconsistent adherence. The authors found that 36% to 37% of the patients 
had poor adherence in each year. About 18% were consistently poorly adherent and 43% were 
inconsistently adherent. Patients who were younger, non-white, had a substance abuse diagnosis, 
had a psychiatric-related hospitalization, or predominantly used typical antipsychotics were more 
likely to have consistently poor adherence.     
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Sajatovic et al. used VA data from 2003 and evaluated  adherence to antipsychotic 
medications among patients with bipolar disorder.158 They found that about 45% of  patients 
received antipsychotic medications for bipolar disorder and these patients were more likely to be 
younger and have comorbid substance abuse or post-traumatic stress disorder compared to those 
not receiving antipsychotics. A little less than half the patients (48.1%) were partially adherent 
(0.5 < MPR <0.8) (21.2%) or non-adherent (MPR≤ 0.5) (26.9%) and 51.9% were adherent 
(MPR≥0.8). The mean MPR was 0.76 and the median duration of treatment was 240 days. 
Factors associated with non-adherence included younger age, minority ethnicity, comorbid 
substance abuse disorder, and homelessness.       
Between 2004 and 2006 Kreyenbuhl et al. evaluated the time to discontinuation among 
VA patients with schizophrenia.159 The median time to discontinuation differed by antipsychotic 
and ranged from a minimum of 95 days for haloperidol to a maximum of 164 days for 
chlorpromazine. Eighty-four percent of the patients discontinued their index antipsychotic during 
the follow-up period. The factors associated with greater risk of discontinuation included 
younger age, non-white ethnicity, homelessness, comorbid substance abuse disorder, prior (three 
months before index antipsychotic drug was started) hospitalization, and use of another 
antipsychotic at the time of discontinuation of the index medication (switching).    
A study was conducted using community-dwelling Medicaid beneficiaries from Florida 
with schizophrenia between 1999 and 2000.160 The patients were divided into four categories 
depending on their adherence: maximal adherence (75-100%), moderate adherence (50-74.9%), 
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limited adherence (25-49.9%), and negligible adherence (0-24.9%); the proportions of patients in 
each class were 64%, 12.4%, 18.8%, and 4.9%, respectively. Logistic regression analysis was 
carried out to identify factors predicting adherence. Being male, older or middle aged, white, and 
without co-occurring substance abuse was associated with high adherence rates.   
Another study conducted using Florida Medicaid beneficiaries with schizophrenia 
between 2004 and 2005 found that the mean adherence (measured as MPR) and medication 
persistence were 0.79 and 94.1%, respectively.161 Persistence was defined as the number of days 
between the first and last antipsychotic prescription divided by the number of days remaining in 
the follow-up period after the first antipsychotic prescription was filled. The proportions of 
patients with an MPR between 0.8 and 1, 0.5 to less than 0.8, and less than 0.5 were 66%, 20%, 
and 14%, respectively. The predictors of poor adherence included new initiation of treatment, 
younger age, substance abuse disorder, use of a mood stabilizer, antidepressant, anxiolytic, or 
anticholinergic, and use of long-acting first-generation antipsychotics.   
It has been consistently seen across several studies using administrative claims data that 
certain factors such as younger age, ethnic minorities, psychiatric-related comorbidities, inpatient 
hospitalizations, and concurrent use of other psychotropic medications are associated with poor 
adherence to antipsychotic medications. It is important to identify patients poorly adherent to 
antipsychotics and monitor them carefully as poor adherence is associated with more 
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2.9. Healthcare utilization in antipsychotic users 
This section contains an overview of healthcare utilization in antipsychotic users. There 
is very limited literature that specifically compares the healthcare utilization in people on 
antipsychotic monotherapy and polypharmacy.  Therefore, studies that have examined healthcare 
utilization in antipsychotic users are briefly discussed. 
APP has been associated with increased rates of hospitalizations. Gilmer et al. found that 
among San Diego county Medicaid beneficiaries with schizophrenia, the proportion of patients 
using APP for 12 months increased from 3.3% in 1999 to 13.7% in 2004, and the proportion of 
those using APP who were hospitalized increased from 7.2% to 9.0% during the same period.162  
Sajatovic et al. examined gender differences in clinical characteristics and hospital resource 
utilization among older people with schizophrenia or schizoaffective disorder in an acute care 
state hospital between January and December 1998. There were no gender differences with 
respect to length of stay, type and amount of prescribed antipsychotics, and use of seclusion 
facilities in the hospital. This was based on observation of 66 individuals.163 Katona et al. used 
the data from the Hungarian National Health Insurance Fund's database and found that 
medication discontinuation due to a hospitalization or death was lesser in patients with 
antipsychotic polypharmacy (using two antipsychotics) as compared to those with 
monotherapy.164     
Adult patients with schizophrenia from California Medicaid (1998-2001) were used to 
compare the resource utilization between patients who continued on their index medication, 
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switched medications, and abandoned medications. The use of psychiatric and non-psychiatric 
emergency services was higher for the switchers as compared to the continuers. The same trend 
was observed for inpatient hospitalizations, non-psychiatric physician visits or outpatient 
hospital visits, and use of other outpatient psychiatric or non-psychiatric services. Healthcare 
resource utilization was seen to be higher for switchers compared to the continuers.165        
Al-Zakwani et al. examined pharmacy and medical reimbursement data from a 
southeastern US health plan to compare the healthcare utilization between atypical and typical 
antipsychotic users. After adjusting for baseline characteristics, time of therapy, and medication 
adherence (measured as MPR), the patients using atypical antipsychotics experienced fewer 
inpatient hopitalizations, emergency department visits, and physician office visits compared to 
the typical antipsychotic users.166  
Chen et al. compared utilization patterns in schizophrenia patients with and without 
exposure to mood stabilizers using Georgia Medicaid enrollees between 1999 and 2001. The 
groups were matched using propensity scores controlling for demographic factors, comorbidities, 
prior utilization, and prescriber specialty. Patients on both antipsychotics and mood stabilizers 
were on therapy for a longer period of time and incurred higher drug costs compared to those on 
antipsychotics only, but there was no significant difference in total healthcare expenditures, 
hospitalizations, emergency department visits, and nursing home visits between the two 
groups.167    
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Iasevoli et al. conducted a study among psychotic inpatients in an Italian hospital.168 
Patients were categorized into the two (or more) and one antipsychotic groups. After four weeks 
of treatment it was observed that both groups significantly improved in global psychopathology, 
but the improvement was better in the MT vs. the APP group. This study assessed clinical 
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2.10. Cost of antipsychotic polypharmacy 
Potentially appropriate uses of APP include using it in acute care settings where 
immediate response is required or while switching from one antipsychotic to another. A more 
controversial use is the long-term maintenance of a patient on more than one antipsychotic due to 
partial or non-response to monotherapy. In theory, all antipsychotics are able to control positive 
symptoms of psychosis by blocking D2 dopamine receptors.169 Atypical antipsychotics do this by 
completely blocking the D2 receptors in the limbic area, which controls the psychosis, while 
incompletely blocking the D2 receptors in the extrapyramidal area, which prevents the motor side 
effects.170 The extrapyramidal receptors can be completely blocked by giving a typical 
antipsychotic in addition to the atypical or by increasing the dosage of the atypical antipsychotic. 
Since it is not possible to block more than 100% of the D2 receptors that control psychosis, 
further addition of drugs might block the wrong D2 receptors (those causing  extrapyramidal side 
effects) giving the same clinical effect as a typical antipsychotic but costing almost 20 times as 
much as typical monotherapy.171  
Loosbrock et al. examined the medication use patterns for the calendar year 1997 using 
the IMS Health LifeLink employer claims database which contains information from indemnity 
and Preferred Provider Organizations for almost 1.6 million employees, dependents, and 
retirees.172 Patients with schizophrenia were identified using ICD-9 codes. Patients were 
classified into one of the following five categories: (1) no treatment—patients taking no 
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antipsychotics; (2) monotherapy—patients taking a single antipsychotic; (3) switch—patients 
who discontinued their prescribed antipsychotic and got a prescription for another one; (4) 
augment—continued with initially prescribed antipsychotic and had at least one additional 
antipsychotic medication; and (5) concomitant use—patients who were on concomitant use of 
more than one antipsychotic at the start of the observation period. The mean cost per patient was 
$11,042. Of the total cost, 63% was attributable to institutional costs which included inpatient, 
outpatient, and other institutional costs, and 23% was attributable to outpatient medication costs. 
Atypical antipsychotics represented eight percent of the total costs or a third of the outpatient 
medication costs. After controlling for all other factors, compared to monotherapy, all other 
groups were associated with higher total costs (total costs included medication costs and 
institutional costs). Mean total costs were $4,244 higher in the augmented group compared to the 
monotherapy group when all other factors were controlled for. Those in the concomitant use 
group had $7,109 higher mean total costs compared to the monotherapy group. 
Zhu and colleagues used data from the US Schizophrenia Care Assessment Program (US-
SCAP) a large, nonrandomized, naturalistic, three-year prospective, multi-site study conducted 
between July 1997 and September 2003.173 Participants were enrolled from diverse healthcare 
systems in six states: California, Colorado, Connecticut, Florida, Maryland, and North Carolina. 
Patients with schizophrenia initiating on olanzapine, risperidone, and quetiapine were included in 
the study. The total cost differed by the medication and was highest for quetiapine, followed by 
risperidone and then olanzapine. The one-year post period cost for other antipsychotics was also 
higher in the group that initiated on quetiapine ($3,439) compared to risperidone ($1,936) and 
olanzapine ($1,530). Thus, the total cost for all antipsychotics was the highest for quetiapine 
                                               
173 Zhu B, Ascher-Svanum H, Faries DE, et al. Cost of antipsychotic polypharmacy in the treatment of 
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initiators, followed by ripseridone and olanzapine. The mean cost of a concomitant atypical 
(typical) antipsychotic was $7.44 ($1.26) per day for quetiapine initiators, $3.15 ($1.15) for 
risperidone initiators, and $2.02 ($1.79) for olanzapine initiators. Thus, the practice of APP adds 
substantial cost to the antipsychotic medication and may even double the cost of the medication. 
Stahl et al. analyzed California Medicaid data between May 1, 1999 and August 31, 2000 
to assess the antipsychotic usage patterns among patients initiating on risperidone, olanzapine, or 
quetiapine.174 The patient population was divided into three categories: (1) patients who received 
only one second-generation antipsychotic (SGA) in the 16-month study period; (2) those who 
received more than one SGA for not more than 59 days out of any 75-day period concomitantly; 
and (3) those who received more than one of the three drugs simultaneously for at least 60 days 
out any 75-day period. The total number of patients receiving one of the three SGAs for 60 days 
out of any 75-day period during the study period was 116,114. The total expenditure for Medi-
Cal beneficiaries receiving an SGA was $309,644,640. Those in the first group (N=91,969) 
accounted for $219,123,216 (70.8%), those in the second group (N=19,350) accounted for 
$54,380,659 (17.6%), and the third group (N=4,795) accounted for $36,134,508 (11.7%). The 
mean costs per patient for groups one, two, and three were $2,382, $2,810, and $7,536, 
respectively. Thus, the cost per patient on polypharmacy was more than 3 times that for a patient 
on monotherapy.            
Valuck et al. conducted a retrospective cohort study of Medicaid-eligible antipsychotic 
users from five western state Medicaid programs—California, Nebraska, Oregon, Utah, and 
Wyoming—between 1998 and 2003.175 Patients were classified as receiving polypharmacy or 
                                               
174 Stahl SM, Grady MM. High-cost use of second-generation antipsychotics under California's Medicaid program. 
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175 Valuck RJ, Morrato EH, Dodd S, et al. How expensive is antipsychotic polypharmacy? Experience from five 
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not based on the pattern of antipsychotic medication prescriptions in the year following the index 
antipsychotic drug claim. Polypharmacy was defined as more than one antipsychotic for at least 
60 days during the 365-day period following the index antipsychotic drug claim. The 
monotherapy group included patients who did not have any APP during the one-year study 
period. The final cohort included 55,383 patients with APP. Over the five-year study period, the 
median drug expenditure increased and the non-drug expenditure decreased. Patients who 
initiated on typical antipsychotics had higher non-drug costs compared to drug costs while the 
trend was reversed for those initiating on atypical antipsychotics. The difference in adjusted drug 
costs between monotherapy and polypharmacy differed by state;  polypharmacy cost $2,079 
more in California, $1,991 more in Oregon and $1,716 more in Utah. When patients had APP 
and concomitant non-antipsychotic psychotropic therapy, the adjusted differences compared to 
monotherapy were $3,486, $7,058, $2,801 for California, Oregon, and Utah, respectively. The 
differences in the non-drug costs were much smaller for both comparisons. The sample size of 
the number of enrollees from Nebraska and Wyoming was too small to be included in this 
analysis. For those on polypharmacy, drug costs represented 70% to 80% of the costs while for 
those on monotherapy, drug costs represented about 58% of the costs. APP was associated with a 
2-fold increase in the likelihood of being a high-cost patient (top 20% of the adjusted total 
healthcare costs). The likelihood of being in the high-cost group increased with an increase in the 
number of mental health comorbidities and better adherence. This was consistent for all states 
used in the analysis of high costs (California, Oregon, and Utah). For patients in California 
(which had the largest sample size), individuals were more likely to be in the high-cost group if 
they had diabetes, dyslipidemia, hypertension, APP alone or in combination with other 
psychotropic medications.    
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Trends in the use of antipsychotic medications between 1999 and 2004 in California 
Medicaid beneficiaries with schizophrenia were analyzed by Gilmer et al. 176 They divided the 
patients into four groups for each month that the patient was enrolled in Medi-Cal: first-
generation antipsychotic (FGA) medication only, SGA medication only, a FGA and a SGA, and 
multiple SGA medications. There were 15,962 unique Medi-Cal beneficiaries with schizophrenia 
who had prescription fills for antipsychotics between 1999 and 2004. For the full sample, the 
annual antipsychotic medication cost per patient increased from $4,148 in 1999 to $5,231 in 
2004, which was a 27% increase. The per patient cost of FGA monotherapy decreased from $117 
in 1999 to $53 in 2004, that of SGA monotherapy increased from $2,982 to $3,269, the cost of 
the FGA and SGA combination group decreased only slightly from $670 in 1999 to $567 in 
2004, but an increase of $983 was seen in the SGA polypharmacy group with the costs 
increasing from $359 to $1,342.            
More recently, Bandup et al. conducted a study using data from adult schizophrenia 
patients in two psychiatric referral centers in Denmark on January 1, 2008 and January 1, 
2009.177 The study population consisted of 736 patients. The total healthcare costs for the 
polypharmacy group was higher than that for the monotherapy group. This difference was 
attributed to consumption of psychiatric services including inpatient and outpatient services. The 
polypharmacy patients had an excess of seven to nine inpatient days and six to nine outpatient 
contacts compared with the monotherapy group. The average cost for an individual in the 
polypharmacy group was 25% and 17% higher than monotherapy before and after adjusting for 
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the covariates, respectively. This corresponded to a cost difference of €5,357 in 2007 and €2,330 
in 2008.   
A program was developed in Florida to identify prescribers with unusual 
psychotherapeutic prescription patterns and track their utilization and costs in Florida 
Medicaid.178 Patients prescribed two or three antipsychotics for 60 days or two antipsychotics for 
90 days or more were categorized as having ‘unusual’ antipsychotic prescription patterns. It was 
seen that a disproportionately small number of prescribers were responsible for a large share of 
the unusual prescribing and the associated costs. The top 13 prescribers accounted for 13 percent 
of the total cost spent on antipsychotics by the Florida Medicaid program and 9.3 percent of the 
total cost for all drugs    
Several studies have highlighted the high costs associated with APP. Continuing such 
high-cost prescribing without documented benefit might cause payors to  restrict access to 
atypical antipsychotics due to the perception of squandering away precious resources. This 
would be a regrettable step in psychotherapeutics.179 There is rising concern regarding the 
increasing costs of SGAs among state Medicaid program administrators and pharmaceutical 
insurance plan benefit managers. If polypharmacy prescribing patterns are left unchanged, it 
could lead to administrative efforts to cut costs and dictate prescribing practices. The rising costs 
of SGAs have also raised the threat that these useful resources might be restricted as Pharmacy 
and Therapeutics committees may make decisions to remove some of these agents from 
formularies based only on costs.180 Restricting expensive practices like polypharmacy only to 
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patients who fail all monotherapy treatments, including clozapine use, might be a means of 






















2.11. Factors affecting costs of antipsychotics 
A report by the Agency for Healthcare Research and Quality (AHRQ) on utilization and 
expenditure trends of antipsychotics calculated using the Medical Expenditure Panel Survey 
(MEPS), a nationally representative survey of community-dwelling US residents, showed that 
the expenditure on antipsychotics increased three-fold from $1.7 billion in 1997 to $7.4 billion in 
2007.181 The average annual expenditure on antipsychotics increased from $765 to $1,905 when 
comparing 1997 to 2007. The average expenditure per prescription for an antipsychotic increased 
from $96 to $228 when comparing 1997 to 2007.  
The previous section described several studies that demonstrated that antipsychotic 
polypharmacy is an important predictor of high medical and pharmacy-related costs. In this 
section, other demographic and clinical factors which are associated with high costs are 
discussed. There is a vast literature on the predictors of high costs among users of antipsychotics; 
therefore, only studies that are relevant to the current study will be discussed.  
Data from the Medicaid Managed Behavioral Health Care and Vulnerable Populations 
Project was used to estimate expenditures on antipsychotics using patients from Florida, Oregon, 
and Pennsylvania during 1997 and1998.182 Patient interviews and administrative claims were 
used to estimate the expenditures. Medical and services costs in the six months after initial 
assessment for the typical, atypical, and combination antipsychotic groups were $3,463, $6,528, 
and $6,590, respectively. Multivariate analyses showed that even after controlling for 
demographic and clinical factors, the medication group was still a significant predictor of high 
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costs. African Americans had lower costs than Caucasians, and factors associated with higher 
costs included presence of a psychosis diagnosis, inpatient or outpatient use prior to interview, 
and medication class (particularly use of atypical antipsychotics and use of combination of 
typical and atypical antipsychotics).  
A study conducted by Rascati et al. using Texas Medicaid data from January 1997 to 
August 1998 compared the costs of schizophrenia patients initiated on risperidone or 
olanzapine.183 The annual mean per patient schizophrenia-related unadjusted cost was $4,892 
and the total unadjusted healthcare cost was $7,101. Multivariate analyses were conducted using 
a two-stage instrumental variables model. Use of an atypical antipsychotic medication, number 
of antipsychotic medications used, prior hospitalizations, presence of co-morbidities, age, sex, 
region of residence, previous costs, and the number of treatment days were all significantly 
associated with the total schizophrenia-related expenditure.  The number of antipsychotic 
medications used, prior hospitalizations, and number of treatment days were associated with 
higher costs, while the presence of nonorganic mental illnesses was associated with lower total 
costs. Age was found to be negatively associated with costs, and females had lower expenditures 
compared to males. Patients in either group who discontinued therapy had lower schizophrenia-
related total costs. There was no significant difference in the total schizophrenia-related costs 
between patients initiated on olanzapine and risperidone. However, olanzapine users had 
significantly lower medical costs compared to risperidone users.     
Gilmer et al. conducted a study to evaluate the effect of adherence on costs using 
Medicaid-eligible patients with schizophrenia from San Diego County.184 Patients were 
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classified into four categories depending on their cumulative MPR: non-adherent (0.00–0.49), 
partially adherent (0.50–0.79), adherent (0.80–1.10), and excess medication fillers (>1.10). 
Patients who were adherent had significantly lower pharmacy and medical costs as compared to 
those who were partially adherent, non-adherent, and excess fillers. Thus, adherence is an 
important predictor of high costs among schizophrenia patients and improving adherence has the 
potential to improve health of such patients without a very large increase in cost.  
Marcus et al. found that gaps in the use of antipsychotic medication were associated with 
the cost of schizophrenia.185 The investigators used California Medicaid data and made 
adjustments to provide a national estimate of $106 million higher total inpatient costs due to gaps 
in antipsychotic medication adherence. Svarstad et al. used claims data for severely mentally ill 
patients in Wisconsin and reached a similar conclusion that irregular medication use increases 
hospitalizations, which in turn, translates to high costs for schizophrenia.186   
It is important to identify factors associated with high costs as this might help policy 
makers design interventions to target the high-risk population and curb the rising costs. Research 
has shown that demographic characteristics such as age, gender, race/ethnicity, and region of 
residence and clinical factors such as co-morbid diseases, prior inpatient and outpatient visits, 
and poor adherence are associated with high costs.  
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2.12. Interventions to reduce antipsychotic polypharmacy 
Several interventions are being carried out to limit APP. Some of them have been 
successful, but studies have shown that availability and dissemination of treatment algorithms 
alone is not very effective in changing prescriber behavior.187
,188,189,190  
A study was carried out in the Institute of Mental Health (the only state mental health 
institute) in Singapore which compared the extent of APP and second-generation antipsychotic 
doses (among other things) in patients admitted into an early psychosis intervention program 
(EPIP) to their matched controls between 2001 and 2004.191 The EPIP program emphasized use 
of a single antipsychotic and short-term use of benzodiazepines for disturbed behavior early 
during treatment rather than increasing antipsychotic dosage. There were regular audits to check 
compliance with guidelines. The EPIP group had lower levels of APP and more use of second-
generation antipsychotics at baseline (prescribed > one antipsychotic- EPIP: 4.6%, control group: 
22.7%) and at the third month (prescribed > one antipsychotic- EPIP: 5.6%, control group: 
23.1%).  
A performance improvement initiative carried out in a state psychiatric hospital between 
November 2001 and August 2002 reduced the rates of APP by 10%.192 Baseline prescribing 
patterns from May 2001 were summarized for each psychiatrist. In the coming months, case 
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discussions, talks and seminars on psychopharmacology were carried out but a review of the 
psychiatrists’ prescribing patterns in November 2001 showed no change with respect to APP. 
Therefore, the chief psychiatrist met individually with each psychiatrist to compare their 
performance with anonymous peers and also asked them to reduce APP by 10% over the 
following six months. The rate of APP fell from 42% in November 2001 to 31% at follow-up in 
August 2002.    
Hazra et al. carried out a study at the Center for Addiction and Mental Health in Canada 
in 2006 and 2008.193 The antipsychotic prescription claims for all patients were collected and 
when the pharmacist detected instances of APP, he/she contacted the physician using a scripted 
telephone call and advised them about an ongoing prospective study aimed at examining the 
safety of reduction of APP. The research team also met with clinicians and inpatient and 
ambulatory staff of the schizophrenia program during weekly team meetings and gave them 
information on the risks, benefits, and existing evidence on APP. Concomitant use of two 
antipsychotics decreased  from 10.3% in 2006 to 6.6% in 2008 and simultaneous use of three 
antipsychotics decreased from 5.3% to 0%. 
Goren et al. conducted a study in a regional academic health center to determine the rate 
of antipsychotic polytherapy at the time of patient discharge.194 The study was conducted during 
three periods: a three-month baseline period (August 2006 to October 2006); in July 2007, after 
delivery of 4 educational seminars to psychiatrists from November 2006 to June 2007; and in 
June 2008, following the provision of monthly prescriber-specific audit feedback from August 
2007 to June 2008. Lectures on best-practice were also given to the nurses to prepare them for 
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the change. The proportion of patients prescribed two antipsychotics decreased from 33.9% at 
baseline to 21.8% after the educational seminars and 12.2% after the audit. The changes in the 
proportion prescribed three antipsychotics during the same intervals were 5.9% to 2.5% to 0%.       
A three-phase intervention was carried out in the New York Office of Mental Health 
(NYOMH) network of psychiatric hospitals.195 Phase one consisted of implementation of The 
Psychiatric Services and Clinical Knowledge Enhancement System (PSYCKES), a web-based 
support system to help in decision making and quality improvement, and a prior approval 
process to prescribe a patient more than two antipsychotics. In phase two, the hospital leaders 
received information from the office of the medical director identifying patients on APP. In 
phase 3, PSYCKES continued but prior-approval was discontinued. In phase one, APP fell from 
16.9 to 9.7 inpatients per 1,000; in phase two, it decreased to 3.9 inpatients per 1,000. In phase 
three, the prevalence remained low at 3.1 inpatients per 1,000. On 36-month long-term follow-
up, the rate of polypharmacy increased to 9.2 inpatients per 1,000, but remained below those at 
baseline level (16.9 per 1,000).   
The Developing Evidence-Based Implementation Trial (DEBIT) was carried out in 
psychiatric wards in southwest England in 19 adult psychiatry units.196 The intervention 
consisted of the following: an educational visit to the psychiatrists by a trained clinical 
pharmacist, and educational workbook and reminders on the medical charts of patients with 
APP. At the five-month follow-up, APP decreased modestly from 47.8% to 40.4%. After 
controlling for all other confounders, the odds of receiving APP were lower in the intervention 
group compared to the control group (Odds ratio: 0.43, 95% CI=0.21-0.90, p=0.028).  
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A controlled quasi-experimental study was performed in two municipalities in Denmark 
which were balanced at baseline with respect to the prevalence of APP, socioeconomic status of 
patients, and functional level of patients.197 The intervention was directed towards the psychiatric 
healthcare providers and consisted of the following: one day of educational lectures, six three-
hour long educational outreach visits, and electronic reminders while prescribing APP. The APP 
at baseline in the intervention and control groups was 68.5% (N=159) and 68.7% (N=241), 
respectively and that at one-year follow-up for the intervention and control groups was 71.8% 
(N=155) and 60.6% (N=234), respectively. The difference between the two groups at one-year 
follow-up was not statistically significant. Thus, the educational intervention failed to curb 
concurrent co-prescribing of antipsychotics.    
Another study conducted by Paton et al. to evaluate the impact of “as needed” dosing in 
psychiatric wards in UK found that a quality improvement program consisting of an audit of 
prescribing patterns, delivery of a quality improvement intervention, and re-audit after a year 
found only a small change in the prescribing patterns. The prevalence of high-dose 
antipsychotics at baseline and re-audit was 36% and 34%, respectively and that of APP was 43% 
and 39%, respectively.198  
Thus, several studies have shown that active monitoring of psychiatrists such as 
notifications by phone calls and letters can decrease APP.199
,200 Passive educational information 
                                               
197Baandrup L, Allerup P, Lublin H, et al. Evaluation of a multifaceted intervention to limit excessive antipsychotic 
co-prescribing in schizophrenia out-patients. Acta Psychiatr Scand 2010;122(5):367-74. 
198 Paton C, Barnes TR, Cavanagh MR, et al. High-dose and combination antipsychotic prescribing in acute adult 
wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry 2008;192(6):435-9.  
199 Fleischhacker WW, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. 
Int J Neuropsychopharmacol 2012;2:1-11. 
200 Tani H, Uchida H, Suzuki T, et al. Interventions to reduce antipsychotic polypharmacy: a systematic review. 
Schizophr Res 2013;143(1):215-20. 
71 
 
account for small decreases in concomitant co-prescribing of antipsychotics, and existence and 






















2.13. Need for studies on antipsychotic polypharmacy in Texas 
Several studies have been conducted to evaluate the prevalence of APP in different 
settings. These have been discussed in a previous section. Antipsychotic users generally suffer 
from psychoses. Given the chronic and debilitating nature of such mental illnesses, these patients 
are often classified as low-income or disabled and hence may be eligible for Medicaid. Only a 
few studies have been conducted using Medicaid data at a state level; they include California, 
Georgia,201 Utah, Wyoming, Nebraska, Oregon,202 and Florida.203
,204 We did not find any study 
that retrospectively evaluated the extent of APP using Texas Medicaid data.  
It is especially important to carry out such research for the state of Texas as it has a 
higher than average prevalence of patients with mental illnesses. For example, according to the 
state advocacy report of the National Alliance on Mental Illnesses, of the approximately 24.3 
million residents of Texas, 1,121,000 (4.6%) live with serious mental illness (3.43% adults and 
1.19% children).205      
A recent study by Welsh et al. conducted in the Houston Outreach Medicine, Education, 
and Social Services (HOMES) Clinic, a free clinic managed by students from The University of 
Texas Medical School at Houston, Baylor College of Medicine, The University of Texas School 
of Public Health at Houston, and the University of Houston School of Pharmacy, found that of 
the 286 patients visiting the clinic, 8.7% had a diagnosis of schizophrenia and 15.7% had a 
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diagnosis of bipolar disorder.206 These numbers are much higher than the national averages for 
the prevalence of the diseases.  
The use of antipsychotic medications in the Texas Medicaid program has increased 
tremendously in the past decade from 52,292 (2.5% of all beneficiaries) in 2001 to 128,437 
(3.8% of all beneficiaries) in 2008.207 Over the same time period, Texas Medicaid spending on 
antipsychotic medications increased from $55.8 million to $246.7 million. From 2001 to 2008, 
antipsychotics have consistently topped the list of the top 10 drug classes for pharmacy benefit 
use for non-dual-eligible Texas Medicaid beneficiaries in terms of total Medicaid prescription-
drug spending.  
Table 5 provides the total Texas Medicaid prescription expenditures on antipsychotics, 
number of prescriptions for antipsychotics, and proportion of all the non-dual-eligible 
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Table 5: Medicaid spending, number of users, and percentage of users for antipsychotic 







spending (USD) for 
non-dual eligible 
beneficiaries  
Number of users As a percentage of 
all beneficiaries 
2001  55,788,714  52,292  2.5 
2002  72,942,401  62,888  2.6 
2003  116,173,901  92,128  3.1 
2004  139,876,506  104,533  3.3 
2005  159,260,426  109,467  3.4 
2006  181,836,804  115,735  3.5 
2007  213,333,877  123,402  3.7 
2008  246,690,092  128,437  3.8 
Source: Medicaid Analytic eXtract (MAX) Rx Table Listing. Available at: 
http://www.cms.gov/Research-Statistics-Data-and-Systems/Computer-Data-and-
Systems/MedicaidDataSourcesGenInfo/Medicaid-Analytic-eXtract-MAX-Rx-Table-
Listing.html. Accessed March 15, 2013 
 
The high prevalence of mental health conditions in Texas coupled with the extremely 
high spending on antipsychotics by the state Medicaid program supports the conduct of a study 
evaluating the prevalence and outcomes of APP in this state. This is especially important in the 
light of the very limited evidence that supports co-prescription of multiple antipsychotic 













2.14. Rationale for the study 
The practice of APP is widespread with prevalence estimates ranging between 4% and 
65% depending on the definition of APP used in the study, the settings, and the year of the study. 
Some studies have shown that APP is associated with high costs but there is a paucity of 
literature on healthcare resource utilization and adherence to medication in patients prescribed 
APP. The widespread use of APP occurs despite the very limited evidence supporting the use of 
this practice. In fact, simultaneous use of multiple antipsychotics could lead to drug interactions, 
undesirable side effects, loss of the advantage of using an atypical antipsychotic when it is used 
in combination with a typical antipsychotic, and high costs.  
Texas has a higher than average prevalence of mental illnesses such as schizophrenia and 
bipolar disorder. Yet, the literature search did not reveal any study examining the prevalence and 
outcomes associated with APP in Texas. It is important to carry out such studies as the state 
Medicaid program spends a significant amount of money each year on antipsychotics. In fact, 
from 2001 to 2008, antipsychotics have topped the list of drug classes in terms of Texas 








2.14.1.   RATIONALE FOR OBJECTIVES 1-3 
Studies have estimated the prevalence and trends of APP using Medicaid data from 
California, Georgia,208 Utah, Wyoming, Nebraska, Oregon,209 and Florida.210
,211  However, 
despite the high prevalence of mental illnesses in Texas and the significant amount of money 
spent each year by Texas Medicaid on antipsychotics, there is no study examining the prevalence 
of APP in the Texas Medicaid program. 
Objectives 1 and 2 are to:  
1. Estimate the incidence of APP and classify patients into the monotherapy (MT) and APP 
groups; 
 Patients on monotherapy will be classified into one of the following subgroups: 
i. typical, 
ii. atypical, and 
iii. clozapine. 
 Patients on APP will be classified into one of the following subgroups: 
i. typical + typical,  
ii. atypical + atypical,  
iii. typical + atypical,  
iv. clozapine + typical, and  
v. clozapine + atypical. 
                                               
208 Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends, and factors associated with antipsychotic 
polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004;65(10):1377-88. 
209 Morrato EH, Dodd S, Oderda G, et al. Prevalence, utilization patterns, and predictors of antipsychotic 
polypharmacy: experience in a multistate Medicaid population, 1998-2003. Clin Ther 2007;29(1):183-95. 
210 Constantine RJ, Andel R, Tandon R. Trends in adult antipsychotic polypharmacy: progress and challenges in 
Florida's Medicaid program. Community Ment Health J 2010;46(6):523-30. 
211 Constantine RJ, Boaz T, Tandon R.  Antipsychotic polypharmacy in the treatment of children and adolescents in 
the fee-for-service component of a large state Medicaid program. Clin Ther 2010;32(5):949-59.  
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2. Describe and compare the demographic, clinical, physician, and prior utilization 






















2.14.2.   RATIONALE FOR OBJECTIVE 3 
Several studies have shown that demographic characteristics, presence of schizophrenia 
diagnoses, number of mental health-related comorbidities, use of typical antipsychotics, use of 
anticholinergic drugs, and prior psychiatric-related healthcare services utilization are associated 
with APP.212
,213,214 Ganguly et al. also found non-mental health-related drug use, non-mental 
health comorbidities, and year of initiation of drug therapy to be associated with APP.215  Patel et 
al. reported that physician specialty affected prescription of antipsychotics among youths in the 
Texas Medicaid program.216 They found that prescriptions written by psychiatrists accounted for 
80% of the antipsychotic prescriptions; the proportion of youths receiving such prescriptions 
from primary care physicians remained constant between 1996 and 2001. 
Objective 3 is to:  
3. To determine demographic, clinical, physician, and prior-utilization characteristics 
associated with increased likelihood of APP. 
 The hypotheses related to objective 3 are: 
H3.1: Younger patients are more likely to be on APP compared to older patients after 
controlling for other demographic, clinical, physician, and prior utilization 
characteristics. 
                                               
212 Morrato EH, Dodd S, Oderda G, et al. Prevalence, utilization patterns, and predictors of antipsychotic 
polypharmacy: experience in a multistate Medicaid population, 1998-2003. Clin Ther 2007;29(1):183-95.  
213 Kreyenbuhl JA, Valenstein M, McCarthy JF, et al. Long-term antipsychotic polypharmacy in the VA health 
system: patient characteristics and treatment patterns. Psychiatr Serv 2007;58(4):489-95. 
214 Ye W, Ascher-Svanum H, Flynn JA, et al. Predictors of antipsychotic monotherapy with olanzapine during a 1-
year naturalistic study of schizophrenia patients in Japan. Clinicoecon Outcomes Res 2012;4:13-9. 
215 Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends, and factors associated with antipsychotic 
polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004;65(10):1377-88.  
216 Patel NC, Crismon ML, Hoagwood K, et al. Physician specialty associated with antipsychotic prescribing for 
youths in the Texas Medicaid program. Med Care 2006;44(1):87-90. 
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H3.2: Male patients are more likely to be on APP compared to female patients after 
controlling for other demographic, clinical, physician, and prior utilization 
characteristics. 
H3.3: Caucasian patients are more likely to be on APP compared to the other 
ethnicities after controlling for other demographic, clinical, physician, and prior 
utilization characteristics. 
H3.4: Patients with an index antipsychotic claim in 2010 are more likely to be on APP 
compared to those with an index claim in other years after controlling for other 
demographic, clinical, physician, and prior utilization characteristics.  
H3.5: Patients with a schizophrenia/schizoaffective disorder diagnosis are more likely 
to be on APP compared to those with other mental health diagnoses after 
controlling for other demographic, clinical, physician, and prior utilization 
characteristics. 
H3.6: Patients without a substance abuse diagnosis are more likely to be on APP 
compared to those with such a diagnosis after controlling for other demographic, 
clinical, physician, and prior utilization characteristics. 
H3.7: The likelihood of APP increases with each additional comorbidity experienced 
by patients after controlling for other demographic, clinical, physician, and prior 
utilization characteristics.  
H3.8: Patients with a lower pre-index period CCI score are more likely to be on APP 
compared to those with a higher score after controlling for other demographic, 
clinical, physician, and prior utilization characteristics. 
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H3.9: Patients with a lower pre-index period CDS score are more likely to be on APP 
compared to those with a higher score after controlling for other demographic, 
clinical, physician, and prior utilization characteristics. 
H3.10: Patients initiated on typical antipsychotics are more likely to be on APP 
compared to those initiated on atypical antipsychotics after controlling for other 
demographic, clinical, physician, and prior utilization characteristics. 
H3.11: Patients initiated on oral antipsychotics are more likely to be on APP compared 
to those initiated on intramuscular antipsychotics after controlling for other 
demographic, clinical, physician, and prior utilization characteristics. 
H3.12: Patients with non-antipsychotic psychotropic drug use in addition to 
antipsychotic use are more likely to be on APP compared to those without it after 
controlling for other demographic, clinical, physician, and prior utilization 
characteristics.  
H3.13: Patients with anticholinergic drug use in addition to antipsychotic use are more 
likely to be on APP compared to those without it after controlling for other 
demographic, clinical, physician, and prior utilization characteristics. 
H3.14: Physician specialty is not associated with the likelihood of being on APP after 
controlling for other demographic, clinical, physician, and prior utilization 
characteristics. 
H3.15: Patients with multiple physicians prescribing antipsychotics are more likely to 
be on APP compared to those with a single physician prescribing 
antipsychotics after controlling for other demographic, clinical, physician, and 
prior utilization characteristics. 
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H3.16:  Patients whose prescribers are from rural areas are more likely to be prescribed 
APP compared to those whose physicians are from urban areas after controlling 
for other demographic, clinical, physician, and prior utilization characteristics. 
H3.17: Patients with a greater number of prior mental health-related hospitalizations 
are more likely to be on APP compared to those with fewer prior mental health-
related hospitalizations after controlling for other demographic, clinical, 
physician, and prior utilization characteristics. 
H3.18: Patients with a greater number of prior mental health-related 
outpatient/emergency department visits are more likely to be on APP compared 
to those with fewer prior mental health-related outpatient/emergency 
department visits after controlling for other demographic, clinical, physician, 











2.14.3.   RATIONALE FOR OBJECTIVE 4 
In general, non-adherence rates for psychotropic medications are quite high. Non-
adherence rates of 40% to 60% have been reported for antipsychotics, 18% to 56% for mood 
stabilizers, and 30% to 97% (median 63%) for antidepressants.217
,218,219 There is limited literature 
that compares adherence rates in the APP and MT populations. A few studies have shown that 
patients on APP had higher adherence compared to those on MT.220
,221  
Objective 4 is to:  
4. Compare adherence (measured as proportion of days covered [PDC]) and persistence 
between the MT and APP groups after controlling for age, sex, race/ethnicity, year of 
initiation of index antipsychotic, mental health diagnosis, substance abuse diagnosis, 
number of mental health comorbidities, pre-index CCI, pre-index CDS, index 
antipsychotic drug, mode of administration of index antipsychotic, use of psychotropic 
therapy, use of anticholinergic medications, clinical specialty of prescribing physician, 
number of physicians prescribing antipsychotics, urban/rural status for prescribing 
physician, number of mental health-related inpatient hospitalizations in the pre-index 
period, and number of mental health-related outpatient and emergency department visits 
in the pre-index period.  
 
                                               
217 Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry 2002; 63(5): 
384–90. 
218 Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in 
schizophrenia. Am J Psychiatry 2002; 159(10):1653–64. 
219 Pampallona S, Bollini P, Tibaldi G, Kupelnick B, Munnizza C. Patient adherence in the treatment of depression. 
Br J Psychiatry 2002; 180:104–9. 
220 Essock SM, Schooler NR, Stroup TS, et al. Effectiveness of switching from antipsychotic polypharmacy to 
monotherapy. Am J Psychiatry 2011;168(7):702-8.  
221 Morrato EH, Dodd S, Oderda G, et al. Prevalence, utilization patterns, and predictors of antipsychotic 




The hypothesis related to objective 9 is: 
H4.1: The adjusted adherence (PDC) is lower for the APP group compared to the 
MT group after controlling for covariates. 
H4.2: The odds of being adherent are lower for the APP group compared to the MT 
group after controlling for covariates.  
H4.3: The adjusted persistence is lower for the APP group compared to the MT group 













2.14.4.   RATIONALE FOR OBJECTIVES 5-7   
There is very limited literature222 that compares the health resource utilization between 
patients on MT and APP; however, since costs vary between these two groups, we expect their 
healthcare utilization to vary as well. 
Objectives 5 through 7 are to:  
5. Compare the likelihood of   a post-index all-cause inpatient hospitalization between the 
MT and APP groups after controlling for age, sex, race/ethnicity, year of initiation of 
index antipsychotic, mental health diagnosis, substance abuse diagnosis, number of 
mental health comorbidities, pre-index CCI, pre-index CDS, index antipsychotic drug, 
mode of administration of index antipsychotic, use of psychotropic therapy, use of 
anticholinergic medications, clinical specialty of prescribing physician, number of 
physicians prescribing antipsychotics, urban/rural status for prescribing physician, 
number of mental health-related inpatient hospitalizations in the pre-index period, and 
number of mental health-related outpatient and emergency department visits in the pre-
index period.   
The hypothesis related to objective 5 is: 
H5.1: The likelihood of an all-cause inpatient hospitalization in the post-index period 





                                               
222 Gilmer TP, Dolder CR, Folsom DP, et al. Antipsychotic polypharmacy trends among Medicaid beneficiaries 
with schizophrenia in San Diego County, 1999-2004. Psychiatr Serv 2007;58(7):1007-10. 
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6. Compare the all-cause length of stay in an inpatient facility during the post-index period 
between the MT and APP groups after controlling for age, sex, race/ethnicity, year of 
initiation of index antipsychotic, mental health diagnosis, substance abuse diagnosis, 
number of mental health comorbidities, pre-index CCI, pre-index CDS index 
antipsychotic drug, mode of administration of index antipsychotic, use of psychotropic 
therapy, use of anticholinergic medications, clinical specialty of prescribing physician, 
number of physicians prescribing antipsychotics, urban/rural status for prescribing 
physician, number of mental health-related inpatient hospitalizations in the pre-index 
period, and number of mental health-related outpatient and emergency department visits 
in the pre-index period. 
The hypothesis related to objective 6 is: 
H6.1: The adjusted all-cause length of stay in an inpatient facility during the post-
index period is higher for the APP group compared to the MT group after 












7. Compare the number of all-cause post-index outpatient visits between the MT and APP 
groups after controlling for age, sex, race/ethnicity, year of initiation of index 
antipsychotic, mental health diagnosis, substance abuse diagnosis, number of mental 
health comorbidities, pre-index CCI, pre-index CDS, index antipsychotic drug, mode of 
administration of index antipsychotic, use of psychotropic therapy, use of anticholinergic 
medications, clinical specialty of prescribing physician, number of physicians  
prescribing antipsychotics, urban/rural status for prescribing physician, number of mental 
health-related inpatient hospitalizations in the pre-index period, and number of mental 
health-related outpatient and emergency department visits in the pre-index period.   
The hypothesis related to objective 7 is: 
H7.1: The adjusted number of all-cause outpatient/emergency department visits is 











2.14.5. RATIONALE FOR OBJECTIVE 8 
Loosbrock et al.223 noted that patients with APP spent an average of $7,109 more than 
those in the MT group while Stahl et al.224 noted a 3-fold increase in costs for patients 
concomitantly using multiple antipsychotics. APP is associated with a 2-fold increase in the 
likelihood of being in the high-cost group (i.e., patients in the top 20% of total healthcare 
costs).225 Gilmer et al. noted a per-patient increase of close to $1,000 in patients switching from 
MT to APP during the five-year study period.226 Thus, several studies have reported high costs in 
patients being prescribed APP.     
Objective 8 was to: 
8. Compare all-cause pharmacy, medical and total healthcare costs between the MT and 
APP groups after controlling for  age, sex, race/ethnicity, year of initiation of index 
antipsychotic, mental health diagnosis, substance abuse diagnosis, number of mental 
health comorbidities, pre-index CCI, pre-index CDS, index antipsychotic drug, mode of 
administration of index antipsychotic, use of psychotropic therapy, use of anticholinergic 
medications, clinical specialty of prescribing physician, number of physicians prescribing 
antipsychotics, urban/rural status for prescribing physician, number of mental health-
related inpatient hospitalizations in the pre-index period, and number of mental health-
related outpatient and emergency department visits in the pre-index period.  
 The hypotheses related to objective 8 are: 
                                               
223 Loosbrock DL, Zhao Z, Johnstone BM, et al. Antipsychotic medication use patterns and associated costs of care 
for individuals with schizophrenia. J Ment Health Policy Econ 2003;6(2):67-75. 
224 Stahl SM, Grady MM. High-cost use of second-generation antipsychotics under California's Medicaid program. 
Psychiatr Serv 2006;57(1):127-9. 
225 Valuck RJ, Morrato EH, Dodd S, et al. How expensive is antipsychotic polypharmacy? Experience from five 
US state Medicaid programs. Curr Med Res Opin 2007;23(10):2567-76. 
226 Gilmer TP, Dolder CR, Folsom DP, et al. Antipsychotic polypharmacy trends among Medicaid beneficiaries 




H8.1: The adjusted all-cause medical costs are higher for the APP group compared to 
the MT group after controlling for the covariates. 
H8.2: The adjusted all-cause drug costs are higher for the APP group compared to 
the MT group after controlling for the covariates. 
H8.3: The adjusted all-cause total costs are higher for the APP group compared to 




















3.1. Chapter outline 
Prescription and medical claims data from Texas Medicaid were utilized to meet the 
objectives and test the hypotheses presented in the previous chapter. This chapter describes the 
data source, study population, sample selection, study design, study variables, and statistical 
procedures used to meet the study objectives. The sensitivity analyses that were conducted to 
account for uncertainty in the estimates are described. A priori sample size calculations are also 
described.   
 
3.2. Institutional Review Board (IRB) approval 
The study was approved by the Institutional Review Board (IRB) of The University of 
Texas at Austin (IRB protocol number: 2012-11-0021). A waiver of informed consent was 
obtained because the research contains no more than minimal risk to the subjects, the waiver 
does not affect the rights and welfare of the subjects, and the research cannot reasonably be 
conducted without the waiver. In accordance with the IRB requirements, only de-identified data 









3.3. Data source 
The study was a retrospective database analysis using Texas Medicaid prescription and 
medical claims data. Medicaid was established in Texas in 1967 and is administered by the 
Texas Health and Human Services Commission (HHSC). It is jointly funded by the state and 
federal governments.227 In December 2011, 3.7 million (out of 25.9 million) Texans relied on 
Medicaid for health insurance or long-term services. It provides medical coverage for low-
income families, non-disabled children, individuals with disabilities, elderly people, pregnant 
women, and caretakers of dependent children. Medicaid is an entitlement program—the 
government cannot limit the number of people enrolled in it and Medicaid must pay for services 
covered under the program. In 2011, women and children accounted for a large proportion of the 
Medicaid population. About 55% of the beneficiaries were female and 77% were under 21 years 
of age. Although white non-disabled children comprise almost 66% of the Texas Medicaid 
population, they only account for 33% of the spending on direct healthcare services. Elderly, 
blind, or disabled people represent 25% of the Texas Medicaid population but are responsible for 




                                               
227 Texas Medicaid in Perspective. In: Texas Medicaid and CHIP in Perspective, 9th ed. Texas Health and Human 
Services Commission, 2012. Available at: 
http://www.hhsc.state.tx.us/medicaid/reports/PB9/1_PB_9th_ed_Introduction.pdf. Accessed on February 14, 2013. 
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3.4. Study population and sample selection 
3.4.1. Data collection 
Texas Medicaid data from January 1, 2006 to December 31, 2011 were extracted for the 
study. Subjects were identified based on having a claim for an oral or injectable antipsychotic 
between July 1, 2006 and December 31, 2010. The index date is the date of first antipsychotic 
prescription claim. Table 6 provides a list of the antipsychotic medications that were included in 
this study. Subjects in the APP group have an additional index date—the date of initiation of 
APP. This index date also fell between July 1, 2006 and December 31, 2010. For objectives 1 to 
4, patient medical and prescription claims were analyzed over an 18-month study period: six 
months pre-index and 12 months post-index. For objectives 5 to 8, medical and prescription 
claims were analyzed over a minimum 18-month period: six months pre-index and at least 12 
months post-index (more explanation regarding the timeline for each group is provided in section 
3.4.4). 
Figure 1 provides an illustration of the data extraction and subject identification periods 














Usual dosage range 
(mg/day) 
Maximum dose  
(mg/day) 
Typical antipsychotics 
Chlorpromazine 100-800 2,000 
Fluphenazine 2-20 40 
Haloperidol 2-20 100 
Loxapine 10-80 250 
Molindone 10-100 225 
Perphenazine 10-64 64 
Pimozide231 Initiate at 1-2 10 
Thioridazine 100-800 800 
Thiothixene 4-40 60 
Trifluoperazine 5-40 80 
Atypical antipsychotics 
Aripiprazole 15-30 30 
Asenapine  10-20 20 
Clozapine 50-500 900 
Iloperidone 2-24 24 
Lurasidone232 40 80 
Olanzapine 10-20 20 
Paliperidone
a
 3-9 12 
Quetiapine 250-500 800 
Risperidone
b
 2-8 16 
Ziprasidone 40-160 200 
a 
For long-acting injectable, the dosage range = 39-234 mg/day and manufacturer-recommended 
maximum = 234 mg/day 
b 
For long-acting injectable (Risperdal Consta), the dosage range = 2-50 mg every 2 weeks and 
manufacturer-recommended maximum = 50 mg/day 
 
 
                                               
228 US Food and Drug Administration. Atypical Antipsychotic Drugs Information. Available at: 
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm094303.htm. 
Accessed on October 15, 2012.  
229 US Food and Drug Administration. Information on Conventional Antipsychotics. Available at: 
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107211.htm. 
Accessed on October 15, 2012.  
230 Crismon L., Argo T.R., Buckley P.F. (2011). Chapter 76. Schizophrenia. In R.L. Talbert, J.T. DiPiro, G.R. 
Matzke, L.M. Posey, B.G. Wells, G.C. Yee (Eds), Pharmacotherapy: A Pathophysiologic Approach, 8th edition. 
Retrieved December 3, 2012 from http://www.accesspharmacy.com/content.aspx?aID=7987911. 
231 Lexi Comp. Pimozide. Available at: 
http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7494#f_dosages. Accessed December 3, 2012. 
232 Lexi Comp. Lurasidone. Available at: http://online.lexi.com/lco/action/doc/retrieve/docid/250/3543687#dosage. 
Accessed December 3, 2012. 
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Figure 1: Data extraction and subject identification periods 
 








One or more episodes of APP (at least 60 days of prescription of two or more antipsychotics 
without a gap in polypharmacy of more than 31 days) could occur for the APP group during the 
365-day study period  




























Figure 2: Data extraction and subject identification periods (continued) 
Objectives 5-8 
Antipsychotic Polypharmacy (APP) group 







Monotherapy (MT) group 









APP- Antipsychotic polypharmacy 
a
 Index date for antipsychotic is the day of the first prescription for an antipsychotic in patients 
who did not have any antipsychotic in the prior 6 months 
b 
Index date for APP is defined as the start of at least 60 days of prescription of two or more 
antipsychotics with no gap in polypharmacy for greater than 31 days and  no gap in therapy for 
more than 31 days  
c
 Pseudo index date for MT is the date X days after start of MT   
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3.4.2. Inclusion criteria 
The claims data from 2006 to 2008 included only those patients enrolled in the FFS 
component of the Texas Medicaid program. Data from 2009 to 2011 included enrollees from 
both the FFS and managed care components of Texas Medicaid.  
Patients meeting the following eligibility criteria were included in the study:  
(1)  between 18-63 years of age at the index date;  
(2)  newly initiated on any of the antipsychotics listed in Table 6 (i.e., no 
antipsychotics in the 6 months preceding the index date for the antipsychotic); and  
(3) continuously enrolled in Medicaid 180 days before the index date and 














3.4.3. Definition of antipsychotic polypharmacy and monotherapy 
Patients were classified as receiving APP if they received concomitant treatment with 
more than one antipsychotic medication for at least 60 days without a gap of more than 31     
days.233 A gap was defined as a period when the patient has only one or no antipsychotic 
medication.  
Patients were considered to be on monotherapy (MT) if there is no evidence of APP (as 
defined above) during the study period after the index antipsychotic claim. This allows inclusion 
of patients who may have had more than one antipsychotic drug for less than 60 days in the MT 
group. The cut-off point of 60 days was chosen because some guidelines recognize short-term 
polypharmacy (less than 60 days) as acceptable treatment for patients while switching from one 
antipsychotic medication to another.234 Figure 3 provides a depiction of how the patients will be 









                                               
233 Morrato EH, Dodd S, Oderda G, et al. Prevalence, utilization patterns, and predictors of antipsychotic 
polypharmacy: experience in a multistate Medicaid population, 1998-2003. Clin Ther 2007;29(1):183-95.  






















 The definitions provided in the figure were those used for objectives 1-4. For objectives 5-8 the 
following definitions were used: 
APP: Exposure to 2 or more antipsychotics for at least 60 days with no gap in polypharmacy for 
more than 31 days and no gap in therapy for more than 31 days 
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3.4.4. Patient selection 
Objectives 1-4: 
Objectives 1-4 involved evaluating the incidence of APP, comparing the characteristics 
of MT and APP patients, identifying predictors of APP and comparing the adherence and 
persistence in the MT and APP groups. Newly initiated antipsychotic users with at least two 
prescription claims for any of the study antipsychotic medications (listed in Table 6) were 
followed for 365-days after the index antipsychotic claim. The pre-period for these patients was 
defined as the 6-month period before the index date for the antipsychotic medication. The 
patients were checked for continuous Medicaid enrollment 180 days before and 365 days after 
the index antipsychotic claim. APP was defined as exposure to two or more antipsychotics for at 
least 60 days with no gap in polypharmacy for greater than 31 days. MT was defined as no 
exposure to APP in the one-year period after the index antipsychotic claim.   
Objectives 5-8: 
Patients having continuous therapy with antipsychotics during the study period without a 
gap in therapy of 31 days were included in these analyses. Hence, APP was defined as exposure 
to two or more antipsychotics for at least 60 days with no gap in polypharmacy for greater than 
31 days and no gap in any therapy for more than 31 days and MT was defined as no evidence of 
APP after the index antipsychotic claim and no gap in therapy for more than 31 days. This might 
decrease the external validity compared to a scenario in which patients with gaps in therapy of 
greater than 31 days are included (Objectives 1-4). However, it will improve internal validity and 
will enable us to investigate the association between APP and the observed outcomes.   
In order to ensure that patients in the APP and MT groups have had comparable exposure 
to antipsychotic medications, each patient in the APP group was matched to a patient in the MT 
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group with an almost equal time period (within a ±30 day range) of exposure to antipsychotics. 
For example, consider a patient in the APP group who was on monotherapy for three months 
before switching to APP. Once he switches to APP, he will be followed for one year (365 days). 
Thus, this patient will be matched to a patient in the MT group who was on MT between 14 to 16 
months (3 months + 12 month follow-up = 15 months ± 30 days range = 14 to 16 months). This 
would ensure that the patients have had exposure to antipsychotics for comparable lengths of 
time. The outcomes for both patients will be assessed in the last 12 months (i.e., Index date for 
APP+ 365 days period for the APP group; Pseudo index date for MT+ 365 days for the MT 
group). This ensures that outcomes are compared in the two groups after comparable periods of 
exposure to antipsychotics. The patients were matched based only on duration of exposure to 
antipsychotics; all other variables were controlled for in the regression analyses. This was done 
to ensure that we obtain a sufficiently large sample size for each analysis.  
The pre-period for each group will be defined as follows (refer to  
Figure 1): 
APP group: Pre-period=Index APP-180 
MT group: Pre-period=Index MT+X-180=Pseudo index date for MT-180 
For the APP group, the pre-period could be a period of no antipsychotic therapy, antipsychotic 
monotherapy, or a combination of the two, depending on the number of days the patient was on 
monotherapy prior to switching to APP. For the MT group, the pre-period could also be no 
antipsychotic therapy, antipsychotic monotherapy, or a combination of the two, depending on the 
pseudo index date for MT. 
Patients were checked for continuous Medicaid enrollment during the pre- and post-index 
periods.   
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3.5. Study design 
This study was a retrospective database analysis using Texas Medicaid medical and 
prescription claims data from 2006 to 2011. Incidence of APP, characteristics of patients in the 
MT and APP groups, and predictors of APP were determined. Furthermore, patients were 
classified into the APP and MT groups, and outcomes such as medication adherence and 
persistence, healthcare utilization, and costs were compared between the two groups. This 


















3.6. Study variables 
This section provides the operational definitions for the variables that were used in the study. 
3.6.1. Demographic characteristics 
Age, sex, and race/ethnicity were identified for each patient. Age was defined at the time 
of the index prescription. 
3.6.2. Clinical characteristics   
The year of initiation of the index antipsychotic was identified. The presence of a medical 
claim with a primary or secondary diagnosis represented by an International Classification of 
Disease, 9
th
 revision (ICD-9) code for a mental illness was used as an indicator for the presence 
of mental illness during the study period. The presence of an ICD-9 code of 295.XX was used to 
identify schizophrenia or schizoaffective disorder and ICD-9 codes of 296.4X-296.7X were used 
to identify bipolar disorder. Depression was identified with ICD-9 codes of 296.2X, 296.3X, 
300.4X and 311.  The presence of other mental illnesses were identified using ICD-9 codes 
between 290 and 319 excluding the ones previously mentioned. Patients were assigned the 
diagnosis that appeared most frequently in their claims. If two diagnoses appeared with equal 
frequency, the patient was classified as having ‘multiple diagnoses.’ Current substance abuse 
was identified using ICD-9 codes 303, 304, and 305. The presence of at least two prescription 
claims for antidepressants, anti-anxiety medications, and antimanic medications was used as an 
indicator for non-antipsychotic psychotropic therapy use during the study period.235 Using a 
method similar to Paulose-Ram et al., American Hospital Formulary Service (AHFS) codes were 
                                               
235 Morrato EH, Dodd S, Oderda G, et al. Prevalence, utilization patterns, and predictors of antipsychotic 
polypharmacy: experience in a multistate Medicaid population, 1998-2003. Clin Ther 2007;29(1):183-95. 
102 
 
used to identify psychotropic medications.236 The following categories were identified: (1) 
antidepressants (AHFS Drug Code: 28:16:04), (2) anxiolytics/sedatives/hypnotics (ASH) 
(28:24), and (3) antimanics (28:28). The presence of at least two prescription claims for 
trihexyphenidyl, biperiden, benztropine, promethazine, procyclidine, amantadine, piroheptine, or 
mazaticol was used as an indicator for the use of anticholinergic medications during the study 
period.237  
The number of unique mental health-related comorbidities was calculated for each patient 
during the 365-day study period. In order to assess the comorbidity burden in patients, the CCI 
was used. It was initially developed by Charlson and her colleagues by examining medical 
records of patients admitted in a New York hospital to derive a weighted comorbidity index.238 It 
has been widely used for risk adjustment in administrative databases and has also been used in 
studies of antipsychotic use.239
,240,241 The CCI for the pre-index period was calculated. In addition, 
the Chronic Disease Score (CDS) during the pre-index period was calculated. The CDS is a 
measure of disease severity that was suggested by Von Korff and others.242 It uses pharmacy 
claims data to determine the number of selected prescription medications used by the patient.  
                                               
236 Paulose-Ram R, Safran MA, Jonas BS, et al. Trends in psychotropic medication use among U.S. adults. 
Pharmacoepidemiol Drug Saf 2007;16(5):560-70. 
237 Xiang YT, Dickerson F, Kreyenbuhl J, et al. Common use of anticholinergic medications in older patients with 
schizophrenia: findings of the Research on Asian Psychotropic Prescription Pattern (REAP) study, 2001-2009. Int J 
Geriatr Psychiatry 2012. doi: 10.1002/gps.3827. [Epub ahead of print]. 
238 Charlson ME, Pompei P, Ales KL, et al. A New Method of Classifying Prognostic Comorbidity in Longitudinal 
Studies: Development and Validation. J Chronic Dis 1987;40(5):373-83. 
239 D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with 
administrative data bases. J Clin Epidemiol 1996;49(12):1429-33. 
240 Needham DM, Scales DC, Laupacis A, et al. A systematic review of the Charlson comorbidity index using 
Canadian administrative databases: a perspective on risk adjustment in critical care research. J Crit Care 
2005;20(1):12-9. 
241 Bera R, Offord S, Zubek D, et al. Impact on healthcare resource usage and costs among Medicaid-insured 
schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics. J Med Econ 2013. 
[Epub ahead of print]. 
242 Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin 
Epidemiol 1992; 45(2):197–203.  
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3.6.3. Physician characteristics   
Previous research has shown that physician specialty affects the prescription of 
antipsychotics. For this study, the clinical specialty of the physician was classified as psychiatry, 
family practice, other, and data unavailable. The number of physicians prescribing antipsychotics 
to each patient were also identified. The geographic location of the prescriber (urban/rural) was 
also identified. This was done using the county of residence of the patient as a proxy.  
3.6.4. Prior utilization 
The number of mental health-related inpatient hospitalizations and outpatient/emergency 
department visits in the six months prior to the index date were evaluated to determine pre-index 
utilization of health resources. This dataset did not allow for the classification of outpatient visits 
as physician visit, outpatient hospital visit, or emergency department visit.  The designation of 
“outpatient” visit encompasses all of these places of service.   
Table 7 contains a list of all variables and their operational definitions. These variables were used 












Table 7: Variable list  
Variable Operational definition 
Demographic characteristics 
Sex Dichotomized as:  
Males and  
Females 




Categorized into:  
Caucasians,  
African Americans,  
Hispanics, and  
Others 
Clinical characteristics 




2009, and  
2010 
Mental health diagnosis Categorized as: 
Schizophrenia/schizoaffective disorders (ICD-9 
code 295.XX); 
Bipolar disorders (ICD-9 codes 296.4X-296.7X);  
Depression (ICD-9 codes 296.2X, 296.3X, 
300.4X, and 311);  
Other mental health diagnoses (ICD-9 codes 
between 290 and 319 excluding the ones 
mentioned above);  
No mental health diagnoses; and 
Multiple  (more than one of the above diagnoses) 
Current substance abuse Dichotomized as  
Yes:  in the presence of  ICD-9 codes 303-305; or  
No 
Number of unique mental health diagnoses Count variable (presence of a medical claim for 
ICD-9 codes 290-319 [inclusive]) 
CCI-pre index Continuous variable indicating the Charlson 
comorbidity score for the 180-day pre-index 
period before the APP index date for APP group 







Table 7: Variable list (continued) 
Variable Operational definition 
CDS-pre index Continuous variable indicating the Chronic 
Disease Score the 180-day pre-index period before 
the APP index date for APP group and pseudo 
index date for MT group  
Index antipsychotic drug
a









Oral, or   
Intramuscular 
Use of psychotropic therapy during study 
period 
Categorized as:  
Yes in the presence of at least 2 prescription 
claims for  antidepressants, ASH, or antimanic 
drugs, or  
No 
Use of anticholinergic medications during 
study period 
Dichotomized as  
Yes: in the presence of at least two prescription 











Clinical specialty of prescribing physician Categorized as: 
Psychiatry, 
Family practice,  
Neurology,  
Other, or  
Data unavailable 
Number of physicians prescribing 
antipsychotics 
Count variable denoting number of physicians  
prescribing antipsychotics to each patient 







Table 7: Variable list (continued) 
Variable Operational definition 
Prior utilization 
Number of mental health-related inpatient 
hospitalizations in six-month pre-index period 
(six months before index date for 
antipsychotic) 
Count variable—Includes all hospitalizations 
associated with an ICD-9 code of 290-319 
(inclusive) 
Number of mental health-related outpatient/ 
emergency department visits in six-month pre-
index period  
(six months before index date for 
antipsychotic)  
Count variable—Includes all outpatient/emergency 
department visits associated with an ICD-9 code of 
290-319 (inclusive)  
ICD-9—International Classification of Disease, 9
th
 revision  
AHFS—American Hospital Formulary Service 
ASH—anxiolytics/sedative/hypnotics 
CCI—Charlson Comorbidity Index 
CDS—Chronic Disease Score 
a














3.6.5. Study outcomes 
The primary outcome of the study is the incidence of APP. Based on the definitions 
provided previously, patients were classified into the MT and APP cohorts; the characteristics of 
the cohorts were described and the predictors of APP were evaluated. Medication adherence 
(calculated as the proportion of days covered [PDC]) and persistence to antipsychotic medication 
was calculated and compared between the MT and APP groups. Patients in the MT and APP 
cohorts with no gap in polypharmacy for greater than 31 days and no gap in therapy of greater 
than 31 days were followed over a 365-day post-index (MT group: 365 days after pseudo index 
date; APP group: 365 days after APP start date) study period and the following outcomes were 
examined: likelihood of a post-index all-cause inpatient hospitalization, all-cause length of stay 
in inpatient facilities, number of post-index all-cause outpatient/emergency department visits, all-
cause medical costs, all-cause drug costs, all-cause total costs (drug + medical). All costs were 
converted to 2011 US dollars using medical consumer price indices.243  









                                               




Table 8: Outcomes assessed in the study  
Variable Operational definition 
Presence of APP
a
 Dichotomized as: 
Yes (exposure to 2 or more antipsychotics for at least 60 days with 
no gap in polypharmacy of more than 31 days);  or 




Proportion of days during the 365-day post-index period that: 
The patient had at least two antipsychotics (for APP group)
c
;  
The patient had at least one antipsychotic** (for MT group)  
Medication 
persistence  
Count variable—number of days on an antipsychotic prior to 
discontinuation (defined as a gap in therapy of greater than 31 days) 






Yes (presence of post-index all-cause inpatient hospitalization); 
No (absence of post-index all-cause inpatient hospitalization) 
Length of stay
b
 Count variable—post-index all-cause length of stay (in days) in an 
inpatient setting 




Count variable—post-index all-cause outpatient visits 
Medical costs
b
 Continuous variable—post-index all-cause medical costs (in USD) 
Drug costs
b
 Continuous variable—post-index all-cause drug costs (in USD) 
Total costs
b
 Continuous variable—post-index all-cause drug costs + medical 
costs (in USD)  
PDC-proportion of days covered 
a
 The definition provided is the one used for objectives 1-4 
For objectives 5-8 the APP and MT definitions were as follows: 
Presence of APP—Dichotomized as: 
Yes (exposure to 2 or more antipsychotics for at least 60 days with no gap in polypharmacy for 
more than 31 days and no gap in any therapy for more than 31 days); or 
No (exposure to no more than 1 antipsychotic during the study period after the index 
antipsychotic claim and no gap in therapy for more than 31 days) 
b
 The outcome in the APP group  after the index date for APP was examined 
c
 The adherence for the APP group was calculated in two ways. The first one is provided in the 
table (Scenario 1). The definition for Scenario 2 was: 
The patient had at least one antipsychotic for both MT and APP groups 
**Patient in the MT group may have more than one antipsychotic for certain periods but not long 





3.7. Statistical procedure 
The statistical procedures and tests that were conducted to meet each study objective are 
described below. 
3.7.1. Objectives 1-4 
3.7.1.1. Incidence of APP, characteristics of MT and APP groups and predictors of APP 
Objective 1: 
Categorizing patients into the APP and MT groups 
The Expert Consensus Guidelines on the care of patients with schizophrenia state that 
APP is acceptable for patients for up to 8 weeks while switching from one antipsychotic to 
another.244 For this the first four objectives of this study, APP was defined as concomitant use of 
two or more antipsychotics for at least 60 days without a gap in polypharmacy for more than 31 
days. MT was defined as exposure to no more than one antipsychotic in the one year period after 
the index antipsychotic claim. Patients were classified into the APP and MT groups. 
The number and proportion of patients on APP were evaluated.  The patients were then 
classified into one of the following categories: 
 Clozapine + atypical 
 Clozapine + typical  
 Typical + typical 
 Atypical + atypical 
 Atypical + typical 
                                               




The classification into groups was based on the medications used at the index of the longest APP 
episode if more than one episode was present.  
The mean and median number of days between start of antipsychotic therapy and start of 
polypharmacy and the mean and median number of days on polypharmacy during the 365-day 
study period have been reported in the Results. The mean and median number of APP episodes 
was also reported.  
The patients on monotherapy were classified into one of the following categories based 



















Characteristics of patients on APP and MT 
Descriptive statistics have been provided for demographic, clinical, physician, and 
utilization characteristics of patients on APP and MT. Frequencies and percentages have been 
provided for categorical variables and means (or medians) and standard deviations (interquartile 
ranges) for the continuous variables.    
Differences between the APP and MT groups with respect to gender, race/ethnicity, year 
of initiation of antipsychotic, type of mental health diagnosis, presence of substance abuse, type 
of index antipsychotic, mode of administration of index antipsychotic, use of psychotropic 
medications, use of anticholinergic medications, clinical specialty of the prescribing physician 
and geographic location of prescriber were tested using chi-square tests. Independent sample t-
tests were used to test the difference in age and Mann Whitney U tests were used to test the 
difference in number of physicians prescribing antipsychotics, number of mental health 
diagnoses, pre-index CCI, pre-index CDS, and number of mental health-related inpatient and 












Predictors of antipsychotic polypharmacy  
A logistic regression model was used to identify predictors of APP. Logistic regression is 
used when the dependent variable is dichotomous in nature (i.e., presence or absence of APP). 
The independent variables can be categorical or continuous. The odds of having APP were 
evaluated for each listed factor.  
The dependent variable was presence of APP dichotomized as yes or no. The independent 
variables included sex, age, race/ethnicity, year of initiation of index antipsychotic, mental health 
diagnosis, current substance abuse, number of mental health diagnoses,  pre-index CCI, pre-
index CDS, index antipsychotic drug, mode of administration of index antipsychotic, use of 
psychotropic therapy during the study period, use of anticholinergic medications during the study 
period, clinical specialty of prescribing physician, number of physicians prescribing 
antipsychotics, geographic location of prescriber, and number of mental health-related inpatient 








3.7.1.2. Adherence and persistence  
Adherence to therapy was evaluated using proportion of days covered (PDC). PDC is 
calculated by dividing the number of days that the patient had the drug(s) by the number of days 
in the particular time interval.245  
PDC= 
                    ( )         
                        
 
The numerator is not just a sum of the days’ supply; rather, it is calculated to avoid double 
counting of days.  
Calculating PDC for multiple medications 
The example provided below calculates the PDC for patients who are supposed to be 
concurrently taking two drugs. Consider 2 patients, A and B (Figure 4).246 Patient A had four 











                                               
245 Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using 
retrospective databases. Value Health 2007;10(1):3-12. 
246 Barner JC. Medication adherence: focus on secondary database analysis. International Society for 
Pharmacoeconomic and Outcomes Research (ISPOR) Student Forum Presentation. February 2010.  
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Month (30 days/month) 
  1 2 3 4 5 6 7 8 9 10 11 12 
X 360             
Y 120             
 




Month (30 days/month) 
  1 2 3 4 5 6 7 8 9 10 11 12 
X              
Y              
 
PDCB = 0/360 = 0.00 
 PDC is always a value between 0 and 1. It provides a more conservative estimate of 
adherence for patients taking multiple medications compared to the medication possession ratio 
(MPR).  
For the APP group, PDC was evaluated in two ways. In scenario 1, it was defined as the 
number of days the patient had at least two medications (for them to be considered adherent) and 
in scenario 2 it was defined as the number of days that the patient had at least one medication 
(for them to be considered adherent). This was done because there was no way of knowing what 
the patient was prescribed for the study period; we only know what claims they filled. The 
patients in the APP group could have multiple episodes of long-term (as per the definition used 
in the current study) polypharmacy during the 12-month observation period; they may not be 
prescribed polypharmacy for all 12 months. The two described scenarios provide the upper and 
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lower bounds of adherence for the patients in the APP group.  For the MT group, the PDC was 
defined as the number of days that the patient had at least one medication. 
Persistence in both the APP and MT groups was defined as the number of days on the 
antipsychotic prior to discontinuation of all medications. Discontinuation was defined as a gap in 
therapy of greater than 31 days. Patients in both groups were considered persistent on a given 
day if they had at least one medication on that day. This is because not all patients in the APP 
group started on multiple antipsychotics and it was not possible to tell from the claims data 
which patients were prescribed multiple antipsychotics for what time intervals—we only knew 
what claims were filled. Survival analysis was used to compare the time to discontinuation of the 
antipsychotic between the MT and APP groups. Survival time is the time that elapses from the 
first day of observation (index date for the antipsychotic) until the day the patient experiences the 
event of interest (discontinuation of the antipsychotic).247 This is the number of days that the 
patients were persistent with their medication. Those patients that do not experience the event of 
interest have unknown survival times and are referred to as being ‘censored.’ In this study we 
used the Kaplan-Meier Estimator to plot survival curves; however, this cannot estimate the effect 
of individual variables on the survival time after controlling for covariates.248  In order to control 





                                               
247 Allison PD, SAS Institute. Survival analysis using the SAS system: a practical guide. Cary, NC: SAS Institute; 
1995. 





Comparing adherence between the APP and MT groups 
The unadjusted value of adherence was calculated for the MT and APP groups using the 
PDC. The PDC measuring the proportion of days that patients in the APP group had two or more 
antipsychotics (Scenario 1) or at least one antipsychotic (Scenario 2), and patients in the MT 
group had at least one antipsychotic was used for the analyses. An independent group t-test was 
used to compare the unadjusted PDC between the MT and APP groups. A chi-square test was 
used to compare the proportion of adherent patients (PDC ≥ 80%) between the MT and APP 
groups. Multiple linear regression was used to compare the adjusted PDC between the two 
groups while controlling for the covariates. Logistic regression was used to compare the 
likelihood of adherence between the MT and APP groups while controlling for the covariates.  
Dependent variable: adherence to antipsychotics (measured as PDC) 
Primary independent variable: presence of APP dichotomized as yes/no  
In order to compare the unadjusted persistence between the MT and APP groups, Kaplan- 
Meier estimates were used. Cox proportional hazards regression was used to compare the time to 
discontinuation of antipsychotic medications between the MT and APP groups while controlling 
for covariates.  
Dependent variable: persistence with antipsychotics  







3.7.2. Objectives 5-8 
For Objectives 5-8, the cohorts of APP and MT patients were matched on their duration 
of exposure to antipsychotics. This was done to improve internal validity and to enable us to 
assess the association between APP and the observed outcomes. The variables provided in  
Table 7 were used as covariates for Objectives 5 to 8. 
3.7.2.1. Healthcare utilization and costs and for APP and MT groups 
Since healthcare utilization and cost data are generally not normally distributed, analysis 
using ordinary least squares (OLS) regression may not be appropriate.249 In order to compare the 
costs and healthcare utilization of the APP and MT groups, generalized linear model (GzLM) 
regression was used.250 The modified Park test was used to select the appropriate distribution. 
This test is conducted by regressing the natural log of the squared residual on the natural log of 
the predicted value of the dependent variable. The value for γ and the corresponding distribution 
to be used are provided in Table 9.       
Table 9: Modified Park test results 
Value of gamma (γ) Family of distribution to be used 
0 Normal distribution 
1 Poisson distribution 
2 Gamma distribution 
3 Wald or inverse Gaussian distribution 
 
 
     
                                               
249 Diehr P, Yanez D, Ash A, et al. Methods for analyzing health care utilization and costs. Annu Rev Public 
Health 1999;20:125-44. 
250 Deb P, Manning W, Norton E. Modeling health care costs and counts. Association for the Study of Higher 
Education, Madison Conference, 2006. 
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Healthcare utilization variables such as inpatient hospitalizations, length of stay, and 
outpatient/emergency department visits are count data and could be modeled using a Poisson 
regression.251  Poisson regression assumes that the variance is proportional to the mean. This is 
often not the case with medical utilization data; sometimes the variance is more than the mean. 
In this case, negative binomial regression can be used as it includes a random component that 
involves unobserved variance among cases. The negative binomial regression model can be used 
in the presence of over dispersion (i.e., variance greater than mean). Another issue that can arise 
with health utilization data is a preponderance of zeros since many patients may not have utilized 
any healthcare service. In this case, a zero-inflated regression model or a hurdle model can be 
used. The appropriate regression model was selected based on the mean-variance relationship 
and the number of zeros in the data. The choice between a zero-inflated models and a hurdle 
model depends on the source of the zeros.252 Sampling zeros are those that occur by chance and 
structural zeros are those that are observed due to some specific structure in the data. If the zeros 
are a combination of sampling and structural zeros, a zero-inflated model might be better suited. 
In case of hurdle models, all zeros are from one structural source and the positive data have a 
sampling origin. These regression models can examine predictive relationships with a count 
dependent variable in the absence of normality and homoscedasticity.  
GzLM regression with a gamma distribution and a log-link was used to compare the 
drug, medical, and total costs between the APP and MT groups while controlling for covariates. 
The gamma distribution assumes that the variance is proportional to the square of its mean.   
 
                                               
251 Elhai JD, Calhoun PS, Ford JD. Statistical procedures for analyzing mental health services data. Psychiatry Res 
2008;160(2):129-36. 
252 Hu MC, Pavlicova M, Nunes EV. Zero-inflated and hurdle models of count data with extra zeros: examples 





Comparing likelihood of an inpatient hospitalization between the APP and MT groups 
A chi-square test was used to compare the presence of inpatient hospitalizations between 
the APP and MT groups.  A logistic regression model was used to compare the likelihood of an 
inpatient hospitalization between the two groups after controlling for all covariates. The odds of 
having an inpatient hospitalization in the APP group compared to the MT group after controlling 
for covariates was obtained. 
Dependent variable: presence of an all-cause inpatient hospitalization dichotomized as yes/no 


















Comparing length of stay between the APP and MT groups 
A Mann-Whitney U test was used to compare the unadjusted length of stay between the 
APP and MT groups. A patient could have a zero length of hospital stay only if he was not 
hospitalized. So all the zeros came from a structural source and the positive outcomes had a 
sampling origin. Thus, a hurdle model was used for the analysis where the first part was a 
logistic regression identifying the patients with non-zero length of stay and the second part was a 
zero-truncated negative binomial regression among patients who had a non-zero length of stay.253 
The adjusted length of stay for the APP and MT groups after controlling for the covariates was 
obtained. This was done by multiplying the predicted probability of hospitalization with the 
predicted length of stay. This newly created adjusted length of stay variable was compared 
between the MT and APP groups using a Wilcoxon signed rank test.  
Dependent variable: all-cause length of stay in the inpatient settings 
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Comparing outpatient/emergency department visits between the APP and MT groups 
A paired sample t-test was used to compare the unadjusted number of 
outpatient/emergency department visits between the APP and MT groups.  A Poisson regression 
model was used to compare the adjusted number of outpatient visits between the two groups. The 
number of outpatient visits for the APP and MT groups after controlling for the covariates were 
obtained.  
Dependent variable: number of all-cause outpatient visits 


















Comparing costs between the APP and MT groups 
The unadjusted mean costs for the MT and APP groups were reported. Mean total 
healthcare costs and costs for the following categories were reported: inpatient hospitalizations, 
outpatient/emergency department visits, and prescription drug costs. Non-psychiatric and 
psychiatric-related costs were reported but separate regression models were not carried out to 
evaluate the adjusted non-psychiatric and psychiatric costs.  
In order to calculate the adjusted costs, the demographic, clinical, physician, and prior 
utilization characteristics were used as covariates in the GzLM regressions with gamma 
distributions and log-link functions. 
Dependent variables: all-cause costs (medical, drug, and total) 
Primary independent variable: presence of APP dichotomized as yes/no 
Separate regressions were carried out for all-cause medical costs, drug costs, and total 
healthcare costs. The adjusted costs of each category (medical, drug, and total) for the APP and 









3.7.3. Statistical analyses 
All data management and statistical analyses were conducted using SAS for Windows, 
Version 9.3 (SAS Institute, Cary, NC) and Stata 11 (StataCorp LP, College Station, TX, USA). 
Frequencies, histograms, and box plots were used to check for data abnormalities and normality 
assumptions. An a priori significance level of α=0.05 was used. While conducting regression 
analyses on the patients who were matched on their duration of exposure to antipsychotics, 
cluster robust standard errors were used to account for the correlation between the patients 
matched on the duration of antipsychotic exposure variable.  
Table 10 provides a list of the objectives and the corresponding statistical tests that were 
















Objective 1: Determine 
the incidence of APP —
overall and by subgroup 
and classify patients into 
the MT and APP groups  








Objective 2: Describe and 
compare the demographic, 
clinical, physician, and 
prior utilization 
characteristics of patients 
in the APP and MT groups 
Demographic: 










diagnosis (H3.5),  
Current substance 











Presence of APP Dichotomous T-tests (Mann-
Whitney U tests 
























Objective 2: Describe and 
compare the demographic, 
clinical, physician, and 
prior utilization 
characteristics of patients 
in the APP and MT groups 
Index antipsychotic 





Use of psychotropic 
therapy during 




study period (H3.13) 
 
Physician:  













Presence of APP Dichotomous T-tests (Mann-
Whitney U tests 


























Objective 2: Describe and 
compare the demographic, 
clinical, physician, and 
prior utilization 
characteristics of patients 
in the APP and MT groups 
Prior utilization: 









Presence of APP Dichotomous T-tests (Mann-
Whitney U tests 









Objective 3: Identify the 
characteristics of patients 
most likely to be 
prescribed APP 








































Objective 3: Identify the 
characteristics of patients 
most likely to be 
prescribed APP 
Presence of APP 
 













































Objective 3: Identify the 
characteristics of patients 
most likely to be 
prescribed APP 
Presence of APP 
 










Objective 4: Compare 
adjusted adherence (PDC) 
and persistence between 
MT and APP groups while 





















Objective 5: Compare 
likelihood of an all-cause 
inpatient hospitalization 
between the MT and APP 
groups while controlling 
for covariates 

























Objective 6: Compare all-
cause length of stay 
between the MT and APP 
groups while controlling 
for covariates 
All-cause length of 
stay (H6.1) 
Count Presence of APP 
(covariates)  
Dichotomous Hurdle model 
Objective 7: Compare 
number of all-cause 
outpatient/ emergency 
department visits between 
the MT and APP groups 









log link function   
Objective 8: To compare 
all-cause drug, medical 
and total (separate 
models) healthcare costs 
between the MT and APP 
groups while controlling 
for the covariates  
All-cause drug, 
medical, or total 
costs (H8.1-8.3) 
Continuous Presence of APP 
(covariates) 






3.8. Sensitivity analyses 
Due to the uncertainty associated with some assumptions and values selected for the 
study, sensitivity analyses were performed to estimate the extent to which modifications in 
operational definitions would influence the overall results. 
3.8.1. Psychiatric-related vs. all-cause costs and utilization outcomes 
In the original analyses, the operational definitions for hospitalizations, 
outpatient/emergency department visits, and costs did not differentiate between the psychiatric-
related and non-psychiatric-related measures. In order to get a better sense of the relationship 
between APP and psychiatric outcomes, the operational definitions for the outcomes was 
modified to only include resource utilization and costs associated with mental illnesses. Only 
resource utilization and costs associated with mental illnesses (ICD-9 codes 290-319) were 
considered while evaluating post-index healthcare utilization and costs to determine how 
modification in the operational definition affected the results.     
 
3.8.2. APP definition 
In this study, the following definition of APP was used: exposure to two or more 
antipsychotics for at least 60 days with no gap in polypharmacy for greater than 31 days and no 
gap in therapy for greater than 31 days. The following definition of monotherapy was used: 
exposure to no more than 1 antipsychotic with no gap in therapy for greater than 31 days. The 
overlap duration was modified to 120 days and 180 days and the gap duration was modified to 
15 days and 45 days to estimate how the change in definition influences the overall results.  




3.9. Assumptions and sample size calculations 
3.9.1. General Linear Models 
3.9.1.1. Multiple Regression 
The assumptions for multiple regression are as follows:254 
 linear relationship between independent and dependent variables; 
 normality of residuals; 
 homoscedasticity (constant variance) of errors; 
 independence of prediction errors; and 
 no multicollinearity among independent variables. 
The sample size requirement for multiple regression was checked using G*Power 
software.255 For the sample size calculation, the software requires an effect size measure, alpha 
level, required power, and the number of predictors. Assuming a small effect size (f
2
=0.02), with 




                                               
254 Multiple Regression. In: Stevens JP. Applied Multivariate Statistics for the Social Sciences 5th ed. New York, 
NY:Taylor & Francis Group, 2009.  
255 Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the 
social, behavioral, and biomedical sciences. Behav Res Methods 2007;39(2):175-91. 
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3.9.2. Generalized Linear Models 
Generalized Linear Models (GzLM) are a class of statistical models that can link the 
response to a linear combination of predictors.256 In addition to continuous dependent variables, 
these models can handle rates and proportions, binary, ordinal and multinomial variables and 
counts. A GzLM has three components257:  
Random component: specifying the conditional distribution of the response variable Yi which 
may be a member of an exponential family, such as the Gaussian (normal), binomial, Poisson, 
gamma, or inverse-Gaussian families of distributions. The use of GzLMs also extend to 
multivariate exponential families (such as the multinomial distribution), to certain non-
exponential families (such as the two-parameter negative-binomial distribution), and to some 
situations in which the distribution of Yi is not specified completely. 
Linear combination of predictors:  
ηi = α + β1Xi1 + β2Xi2 +· · ·+βkXik 
Link function: g(·); transforms the expectation of the response variable, μi ≡ E(Yi ), to the 
linear predictor. 
g(μi ) = ηi = α + β1Xi1 + β2Xi2 +· · ·+βkXik 
Some of the commonly used distributions, link functions, and their response ranges are presented 
in Table 11.258 
 
 
                                               
256 Jackman S. Generalized Linear Models. Available at: http://jackman.stanford.edu/papers/glm.pdf. Accessed 
December 7, 2012. 
257 Generalized Linear Models. In: Fox J. Applied Regression Analysis and Generalized Linear Models 2nd ed 
Chapter 15. Thousand Oaks, CA: Sage Publications, 2008.  
258 Generalized Linear Models In: Fox J. Applied Regression Analysis and Generalized Linear Models 2nd ed 




Table 11: Canonical link and response range for commonly used distribution families 
Family Canonical Link Range of Yi 
Gaussian Identity (-∞,∞) 
Binomial Logit (0,1,…ni)/ni 
Poisson Log 0,1,2,.. 
Gamma Inverse (0,∞) 
Inverse-Gaussian Inverse-square (0,∞) 
Source: Generalized Linear Models In: Fox J. Applied Regression Analysis and Generalized 
Linear Models 2
nd
 ed Chapter 15. Thousand Oaks, CA: Sage Publications, 2008. 
A general linear model (linear regression) is a special case of the generalized linear model with 
the dependent variable normally distributed and an identity link function.  
The key assumptions for Generalized Linear Models include
259
: 
 statistical independence of the observations; 
 correct specification of the link and variance functions;  
 correct scale for measurement of the explanatory variables; and 
 lack of undue influence of individual observations on the fitted model. 
3.9.2.1. Logistic regression 
Logistic regression is an example of a GzLM with a binomial distribution and a logit link 
function.  The assumptions for logistic regression are as follows:260 
 the observations are independent of one another; 
 no extraneous variables are included and no important variables are excluded; 
 the IVs (independent variables) are measured without error; and 
 the IVs are not a linear combination of each other.  
                                               
259 Breslow NE. Generalized linear models: checking assumptions and strengthening conclusions. Available at: 
http://biostat.georgiahealth.edu/~dryu/course/stat9110spring12/land16_ref.pdf. Accessed December 5, 2012. 
260 Logistic Regression Diagnostics. In: Chen X, Ender P, Mitchell M, et al. Logistic Regression with Stata. UCLA: 
Academic Technology Services, Statistical Consulting Group. Available at:  
http://www.ats.ucla.edu/stat/stata/ado/analysis/. Accessed: December 5, 2012.  
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In order to calculate the required sample size for logistic regression, the G*Power 
software was used. The odds ratios for sample size calculations were varied over a wide range 
(1.5-15.0) and the probability of the event was assumed to have a low value which translates into 
a high sample size. A two-tailed alpha level of 0.05 was used and the power was fixed at 0.80. 
Table 12 provides the different sample sizes obtained as the parameters were varied. 
 
Table 12: Sample size calculation for logistic regression 
Odds Ratio 1.5 5.0 15.0 
R-squared
a
 0.1 0.1 0.1 
Total Sample Size 4,638 201 60 
    
Odds Ratio 1.5 5.0 15.0 
R-squared
a
 0.2 0.2 0.2 
Total Sample Size 5,218 226 67 
    
Odds Ratio 1.5 5.0 15.0 
R-squared
a
 0.3 0.3 0.3 
Total Sample Size 5,963 258 77 
Y = dependent variable, X = independent variable 
Binomial distribution was assumed for the IV of interest 
Probability of event was assumed at a low value (0.04) which translates into a high sample size.  
a
 The value obtained when X1 is regressed over other independent variables or covariates in the 
regression 
 








3.9.2.2. GzLM with gamma distribution and negative binomial distribution  
Gamma and negative binomial distributions with log-link functions are examples of 
GzLMs. There is limited information in the literature regarding sample size requirements for 
GzLM with a gamma distribution and a negative binomial distribution. However, for GzLM with 
a gamma distribution, if the minimum sample size requirement for multiple regression is met, the 
study will be sufficiently powered.261      
G*Power software was used to estimate the sample size for the Poisson regression 
procedure (as it does not have the provision to estimate sample size for a negative binomial 
regression model). The baseline rate of healthcare utilization was varied from 5% to 20% and the 
sample size required to detect a difference of 10% (Exp(β1)=1.1) was estimated. The 
independent variable was assumed to have a binomial distribution with 5% of patients on APP. A 
one-sided alpha of 0.05 and a power of 0.80 was used. Table 13 provides the different sample 
sizes obtained as the parameters were varied. 
Table 13: Sample size calculation for Poisson regression 
Base rate 0.05 0.10 0.20 
R-squared
a
  0.1 0.1 0.1 
Total sample size 821 411 206 
    
Base rate 0.05 0.10 0.20 
R-squared
a
  0.2 0.2 0.2 
Total sample size 924 462 231 
    
Base rate 0.05 0.10 0.20 
R-squared
a
  0.3 0.3 0.3 
Total sample size 1,056 528 264 
The mean time of exposure was set at 365 days. The calculated sample size is to detect a 10% or 
more increase in healthcare utilization (Exp(β1)=1.1).  
                                               
261 Jin H, Zhao X. Transformation and sample size. 2009. Available at: 




 The value obtained when the independent variable was regressed over other independent 
variables or covariates in the regression 
 
Based on the sample sizes obtained in the power analyses, a minimum sample size of 1,056 
would be required for the Poisson regression analyses (used as a proxy for negative binomial 
regression analyses).  
3.9.3. Cox Proportional Hazards Regression Analysis  
The Cox proportional hazards regression is a semi-parametric model with model 
assumptions similar to those for parametric models but it makes no assumptions about the form 
or shape of the underlying hazard (h(t)). It assumes parametric form for the effect of the 




h (t/X) = h (t) exp (X1β1 + ……+ Xnβn)  
 
 h(t) is the hazard function and represents risk changes with time and it is the non-parametric 
part of the model  
 exp represents the effect of covariates  
 X1 to Xn are the predictor variables and are assumed to act addictively on log h(t/x)  
 β1 to βn are the regression coefficients  
 log h(t/x) changes linearly with the βs  
 The effect of the predictors is the same at all times t  
 
                                               
262 Allison PD, SAS Institute. Survival analysis using the SAS system: a practical guide. Cary, NC: SAS Institute; 
1995.  




Table 14 provides the sample size calculation for the Cox proportional hazards 
regression. It was carried out using the PASS 13 software. Based on the calculation (power=80% 
and alpha=0.05), a sample size of 9,192 was required for the analyses. 
Table 14: Sample size calculation for Cox proportional hazard regression 
B (Hazard ratio)
a 
0.2 0.2 0.2 
P(Overall Event Rate)
b 
0.2 0.25 0.3 
R-squared
c 
0.1 0.1 0.1 




0.2 0.2 0.2 
P(Overall Event Rate)
b 
0.2 0.25 0.3 
R-squared
c 
0.2 0.2 0.2 




0.2 0.2 0.2 
P (Overall Event Rate)
b 
0.2 0.25 0.3 
R-squared
c 
0.3 0.3 0.3 




2.0 2.0 2.0 
P(Overall Event Rate)
b 
0.2 0.25 0.3 
R-squared
c 
0.1 0.1 0.1 




2.0 2.0 2.0 
P(Overall Event Rate)
b 
0.2 0.25 0.3 
R-squared
c 
0.2 0.2 0.2 




2.0 2.0 2.0 
P (Overall Event Rate)
b 
0.2 0.25 0.3 
R-squared
c 
0.3 0.3 0.3 
Total Sample Size 9,192 7,354 6,128 
Y=dependent variable; X= independent variables (IV); α = 0.05 (one-tailed), β= 0.20 (power = 
80%) 
a 
Known as the regression coefficient defined as the predicted change in log(base e) hazards at 
one unit change in X1  when the other covariates are held constant 
b 
Denotes the proportion of subjects in which the event of interest occurs during the duration of 
the study (Based on values reported in the across studies in the literature). The modeled event 
was medication discontinuation over a 12 month follow-up period 
 
c 




This chapter provides a detailed description of the study results. The results pertaining to 
the patient selection process, patient characteristics, and the hypotheses tests are provided. 
4.1. Objectives 1-4 
Objectives 1 to 4 involved estimating the incidence of APP in the Texas Medicaid 
population, classifying patients into the MT and APP groups, describing the characteristics of the 
patients in each group, identifying characteristics associated with prescription of APP and 
comparing the medication adherence and persistence between the MT and APP groups.  
Patients newly initiated on antipsychotics were followed for one year from the index date 
and were classified into the MT and APP groups. Patients prescribed at least two antipsychotics 
for at least 60 days with no gaps in polypharmacy for more than 31 days were classified as APP 
and patients with no evidence of APP in the one year following the index antipsychotic claim 
were classified as MT. 
4.1.1. PATIENT SELECTION 
There were 58,311 patients between 18 to 63 years of age newly initiated on 
antipsychotics with claims for antipsychotics between July 1, 2006 and December 31, 2010. A 
total of 3,835 (6.6%) patients had at least one APP episode, defined as exposure to two or more 
antipsychotics for at least 60 days with no gaps in polypharmacy of greater than 31 days. Of 
these, 1,253 (2.1% of the total) were enrolled in Medicaid for the duration of the study period 
(365 days after the index date for an antipsychotic medication) and in the 180 days prior to the 
index date. A total of 54,476 (93.4%) patients did not have any APP episodes during the 365-day 
study period following the index antipsychotic claim and 21,979 (37.7% of the total) of these 
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were continuously enrolled in Medicaid in the 180-day pre-index and 365 day post-index 
periods. Figure 5 provides a flowchart showing application of the patient inclusion criteria.       



















Number of patients between 18-63 
years of age newly initiated on 
antipsychotics with at least two 
claims for an antipsychotic 
medication=58,311 
Number of patients with at least 
one APP episode of at least 60 days 
with no gaps in APP greater than 
31 days—APP group=3,835 (6.6%) 
 
Number of patients with no APP 
episodes of at least 60 days in the 





Number of patients in the APP 
group who were continuously 
enrolled in Medicaid 6 months pre-
index and 12 months post-
index=1,253 (2.1% of total) 
 
Number of patients in the MT 
group who were continuously 
enrolled in Medicaid 6 months pre-
index and 12 months post-




4.1.2. INCIDENCE OF APP, CATEGORIZING PATIENTS INTO MT AND APP GROUPS, 
CHARACTERISTICS OF PATIENTS IN MT AND APP GROUPS AND PREDICTORS OF APP 
Objective 1 was to estimate the incidence of APP in the Texas Medicaid population 
and classify patients into the MT and APP groups. The incidence of APP in the Texas 
Medicaid population continuously enrolled 6 months pre-index to 12 months post-index was 
5.4% (1,253/23,232). Table 15 provides a classification of the patients into the MT and APP 
groups. The MT patients were classified based on their index drug and the APP patients were 
classified based on the index drug combination for the longest APP episode. Hence, for the 
APP group, patients may not remain on the reported drug combination through the entire 
study period. The reported combination was the one observed at the index of the longest APP 
episode and might change to another drug combination as time progresses.  
Table 15: Classification of patients into the MT and APP groups overall and by sub 
group 
Category  Number of patients  Percentage 
Antipsychotic Monotherapy   
Typical  1,531 7.0 
Atypical  20,411 92.9 
Clozapine  37 0.2 
Total  21,979 100.1 
Antipsychotic polypharmacy   
Typical + typical  14 1.1 
Atypical + atypical  878 70.1 
Typical + atypical  347 27.7 
Typical + clozapine  4 0.3 
Atypical + clozapine  10 0.8 
Total  1,253 100 





Patients with APP had a mean ± SD of 106.6±94.2 (Median = 86, interquartile range 
[IQR] = 168) days from index of an antipsychotic drug to start of polypharmacy. The mean 
number of APP episodes per patient was 1.1±0.3 (Median = 1, IQR = 0). About 90% 
(1,126/1,253) of the patients in the APP group had only one episode of APP during the one year 
after initiation of antipsychotic therapy. In the one year following the index claim for an 
antipsychotic medication, patients in the APP group had a mean of 141.4±77.7 (Median = 118, 
IQR = 108) days on polypharmacy with antipsychotics.  
Objective 2 was to compare the characteristics of patients in the MT and APP groups. 
Table 16 provides a comparison of the characteristics of the patients in the MT and APP groups. 
A greater proportion of females had APP compared to males. African Americans, Caucasians, 
and those with race categorized as ‘other’ had a higher proportion of patients with APP 
compared to Hispanics and those with race categorized as ‘unknown.’ A greater proportion of 
patients with a schizophrenia diagnosis had APP compared to those with other diagnoses. Those 
with a substance abuse diagnosis had a greater proportion of patients using APP compared to 
those without such a diagnosis. The APP patients also had a greater number of unique mental 
illnesses but they had a lower pre-index CCI (and proportion of patients with a pre-index CCI>0) 
and pre-index CDS mean score compared to the MT patients. A greater proportion of patients 
initiated on combinations or typical antipsychotics had APP compared to those initiated on 
atypical antipsychotics. A greater proportion of those initiated on intramuscular antipsychotics 
had APP compared to those initiated on orals. Anticholinergic and psychotropic medication users 
had a greater proportion of APP patients compared to non-users of these medication classes. As 
compared to family practitioners, a greater proportion of patients with psychiatrists and ‘other’ 
prescribing physicians had APP. The APP group had a higher number of physicians prescribing 
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the antipsychotic medications. Finally, APP patients had a greater mean number of pre-index 
psychiatry-related inpatient hospitalizations (and a greater proportion of patients with a mental 
health-related pre-index hospitalization) and outpatient/emergency department visits compared to 
those with MT.  
Although it is hard to comment on the difference in the overall health status between the 
two groups, the severity of mental illnesses was higher in the APP vs. MT group as denoted by 
the higher number of mental health diagnoses during the study period and greater mental health-
related healthcare utilization during the pre-index period.
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Age (Mean, SD)   39.7 12.5  39.6 12.4  t=0.26 0.7910 
Sex Male  7,936 93.4 
(36.1) 





 Female  14,043 95.3 
(63.9) 
 696 4.7   
(55.5) 
  
Race/Ethnicity Caucasians  7,702 94.6 
(35.0) 





 African Americans  6,254 94.2 
(28.5) 
 383 5.8   
(30.6) 
  
 Hispanics  4,911 95.3 
(22.3) 
 245 4.7   
(19.6) 
  
 Others  2,,330 93.6 
(10.6) 
 160 6.4   
(12.8) 
  
 Unknown  782 97.3 
(3.6) 

































Year of initiation of index 
antipsychotic 
2006  2,765 94.7 
(12.6) 





 2007  4,550 95.2 
(20.7) 
 232 4.8   
(18.5) 
  
 2008  2,769 95.0 
(12.6) 
 146 5.0   
(11.7) 
  
 2009  5,003 94.6 
(22.7) 
 288 5.4   
(23.0) 
  
 2010  6,892 94.1 
(31.4) 
 432 5.9   
(34.5) 
  
Mental health diagnosis Schizophrenia/schizo
affective disorder 
 2,329 88.6 
(10.6) 





 Bipolar disorder  2,292 94.5 
(10.4) 
 133 5.5    
(10.6) 
  
 Depression  3,780 96.4 
(17.2) 
 142 3.6   
(11.3) 
  
 Other mental health 
diagnoses 
 7,476 94.4 
(34.0) 
 440 5.6   
(35.1) 
  
 Multiple mental 
illnesses 
 1,151 95.5 
(5.2) 
 54 4.5     
(4.3) 
  
 No mental health 
diagnoses 
 4,951 96.4 
(22.5) 
























Current substance abuse Yes  4,101 93.2 
(18.4) 





 No  17,878 94.9 
(81.3) 
 953 5.1     
(76.1) 
   
Number of unique mental 
health diagnoses (Mean, SD) 
  1.7 1.5  2.2 1.9  z=9.88 <0.0001 
CCI-pre index (Mean, SD)   0.54 1.2  0.45 1.1  z=-3.04 0.0024 
Number of patients with 
CCI-pre>0 
  5,952 95.4 
(27.1) 





CDS-pre index (Mean, SD)   3.4 2.6  2.8 2.7  z=-8.93 <0.0001 
Index antipsychotic drug
a
 Typical  1,525 91.9 
(6.9) 





 Atypical  20,448 94.8 
(93.0) 
 1,114 5.2   
(88.9) 
  
 Combination  6 54.6 
(0.03) 
 5 45.5   
(0.4) 
  




Oral  21,628 94.7 
(98.4) 





 Intramuscular  351 90.7 
(1.6) 



























Use of non-antipsychotic 
psychotropic therapy during 
study period 
Yes  17,031 94.3 
(77.5) 





 No  4,948 95.6 
(22.5) 
 227 4.4   
(18.1) 
  
Use of anticholinergic 
medications during study 
period 
Yes  1,439 84.3 
(6.5) 





 No  20,540 95.4 
(93.5) 
 985 4.6   
(78.6) 
   
Physician Characteristics 
Clinical specialty of 
prescribing physician 
Psychiatry  12,624 94.1 
(57.4) 







 3,108 95.7 
(14.1) 
 141 4.3   
(11.3) 
  
 Other  4,319 94.9 
(19.7) 
 230 5.1   
(18.4) 
  
 Unknown  1,928 95.4 
(8.8) 
 93 4.6     
(7.4) 
  
Number of physicians 
prescribing antipsychotics 
(Mean, SD) 























Urban/rural status Urban  17,253 94.5 
(78.5) 





 Rural  3,844 94.7 
(17.5) 
 214 5.3   
(17.1) 
  
 Unknown  882 96.5 
(4.0) 
 32 3.5     
(2.5) 
  
Prior utilization characteristics 
Number of mental health-
related inpatient 
hospitalizations in six-month 
pre-index period (Mean, SD) 
  0.2 0.7  0.4 1.2  z=8.89 <0.0001 
Number of patients with 
mental health-related 
inpatient hospitalizations 
during the six-month pre-
index period 
  1,933 90.0 
(8.8) 





Number of mental health-
related outpatient/emergency 
department visits in six-
month pre-index period 
(Mean, SD) 
  3.7 6.2  5.1 9.5  z=5.12 <0.0001 
Col—Column; CCI—Charlson Comorbidity Index; CDS—Chronic Disease Score 
a
 Measured at index of antipsychotic therapy 
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Objective 3 was to identify characteristics associated with prescription of APP. In order 
to identify characteristics associated with APP, a logistic regression was carried out. The overall 
model was statistically significant (Wald’s χ
2
=829.29, df=31, p<0.0001). Table 17 provides the 
regression coefficients, Wald’s Chi-square values, odds ratios, and 95% confidence intervals of 
the odds ratios for all the variables included in the model.  
While controlling for all covariates, with a one-year increase in age, patients were 1.01 
times more likely to have APP. Females were 12% less likely to have APP compared to males 
while those patients whose race was categorized as unknown were 60% less likely to have APP 
compared to Caucasians. Patients with bipolar disorder, depression, other mental health 
diagnoses, multiple mental health diagnoses, and no mental health diagnoses were 44%, 59%, 
43%, 53%, and 45%, respectively, less likely to have APP compared to those with schizophrenia 
or schizoaffective disorder. Those with current substance abuse were 22% less likely to have 
APP. A 1-unit increase in the number of unique mental illnesses increased the likelihood of APP 
1.13 times while a 1-point increase in the pre-index CDS decreased the likelihood of APP by 6%. 
Use of psychotropic drugs and anticholinergic drugs increased the likelihood of APP 1.40 and 
2.76 times, respectively. The likelihood of APP when the prescribing physician was a general 
practitioner was 17% lower than that for psychiatrists and that for those categorized as 
‘unknown’ was 37% lower than that for psychiatrists. With a 1-unit increase in the number of 
prescribers prescribing antipsychotics, the likelihood of APP increased 1.38 times while a 1-unit 
increase in the number of pre-index psychiatric-related outpatient/emergency department visits 
increased the likelihood of APP only 1.01 times.    
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Table 17: Logistic regression results to identify relationships between APP and demographic, clinical, physician, and prior 
utilization characteristics 











Age*   0.0071 7.63 1.01 1.00 1.01 0.0058 
Sex (Reference=Male)* Female -0.1268 4.03 0.88 0.78 1.00 0.0058 
Race 
(Reference= Caucasian) 
African Americans -0.0453 0.34 0.96 0.82 1.11 0.5589 
 Hispanics -0.1530 3.14 0.86 0.73 1.02 0.0765 
 Others 0.0470 0.22 1.05 0.86 1.28 0.6389 
 Unknown -0.9061 4.86 0.40 0.18 0.90 0.0272 
Clinical Characteristics 
Year of initiation of index 
antipsychotic 
(Reference=2010) 
2006 0.0138 0.02 1.01 0.83 1.24 0.8939 
 2007 -0.0415 0.21 0.96 0.80 1.15 0.6482 
 2008 0.0489 0.22 1.05 0.86 1.29 0.6371 
 2009 -0.0061 0.01 0.99 0.85 1.17 0.9403 




Bipolar disorder -0.5875 26.06 0.56 0.44 0.70 <0.0001 
 Depression -0.8977 63.55 0.41 0.33 0.51 <0.0001 
 Other mental health 
diagnoses 
-0.5676 40.20 0.57 0.48 0.68 <0.0001 
 Multiple diagnoses -0.7506 22.44 0.47 0.35 0.64 <0.0001 




Table 17: Logistic regression results to identify relationships between APP and demographic, clinical, physician, and prior 
utilization characteristics (continued) 






95% CI of odds 
ratio p-value 
Lower Upper 
Current substance abuse 
(Reference=No) 
Yes -0.2447 8.18 0.78 0.66 0.93 0.0042 
Number of unique mental 
health diagnoses (Mean, 
SD) 
 0.1248 22.91 1.13 1.08 1.19 <0.0001 
CCI-pre index (Mean, SD)  -0.0283 0.99 0.97 0.92 1.03 0.3199 





Atypical -0.1549 2.07 0.86 0.69 1.06 0.1498 





Intramuscular 0.2641 1.82 1.30 0.89 1.91 0.1777 
Use of psychotropic therapy 
during study period 
(Reference=No) 
Yes 0.3385 17.59 1.40 1.20 1.64 <0.0001 
Use of anticholinergic 
medications during study 
period 
(Reference=No) 
Yes 1.0141 155.41 2.76 2.35 3.23 <0.0001 
Physician Characteristics 
Clinical specialty of 
prescribing physician 
(Reference=Psychiatry)* 
Family practice -0.1901 3.86 0.83 0.68 1.00 0.0495 
 Other -0.0179 0.05 0.98 0.84 1.15 0.8253 




Table 17: Logistic regression results to identify relationships between APP and demographic, clinical, physician, and prior 
utilization characteristics (continued) 






95% CI of 
odds ratio p-value 
Lower Upper 
Number of physicians 
prescribing antipsychotics  
 0.3195 168.49 1.38 1.31 1.44 <0.0001 
Urban/Rural status 
(Reference=Rural) 
Urban -0.0443 0.28 0.96 0.81 1.13 0.5968 
 Unknown 0.4646 1.78 1.59 0.80 3.15 0.1825 
Prior utilization Characteristics 
Number of mental health-
related inpatient 
hospitalizations in six-
month pre-index period 
 0.0377 1.41 1.04 0.98 1.11 0.2348 
Number of mental health-
related outpatient/ 
emergency department 
visits in six-month pre-
index period*  
 0.0095 5.86 1.01 1.00 1.02 0.0155 
APP is the dependent variable in this analysis (APP=1; MT=0).  
Logistic regression was used to identify characteristics associated with prescription of APP. 
a
 Measured at index of antipsychotic therapy 
b 
Patients on initiated on combinations combined with atypical antipsychotics due to small sample size in the combinations group 
*Although the p-values were significant at an alpha level of 0.05, the 95% CI included 1.0 
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4.1.3. ADHERENCE AND PERSISTENCE FOR THE MT AND APP GROUPS 
Objective 4 consisted of comparing the medication adherence and persistence between the MT 
and APP groups. Patients in the APP group may have been prescribed multiple antipsychotics for 
varying durations during the 12-month study period (they may not have been prescribed 
polypharmacy for the entire 12-month period). Based on insurance claims data, it is not possible 
to determine the length of time for which the patients in the APP group were prescribed multiple 
antipsychotics—we only know what prescription claims were filled. Thus, adherence was 
calculated in two different ways for the APP group. In scenario 1, APP patients were considered 
adherent on a given day if they had at least two antipsychotics on that day. This gives a 
conservative estimate of the adherence for the APP group. In scenario 2, APP patients were 
considered adherent on a given day if they had at least one antipsychotic on that day. This gives 
a very liberal estimate of the adherence for the APP group. These two scenarios give the two 
extremes of the adherence levels in the APP group. In both scenarios MT patients were 
considered adherent on a given day when they had at least one antipsychotic on that day. 
Multiple regression was used to compare adjusted adherence between the two groups. 
When a patient had a PDC ≥ 80%, s/he was considered to be adherent for the duration of the 
study period. Logistic regression was used to compare the adjusted likelihood of adherence 
between the two groups. Persistence to medication (or time to medication discontinuation) was 
measured as the number of days the patients had at least one antipsychotic medication before 
discontinuation of all medications.   
Unadjusted adherence was higher in the MT group compared to the APP group (0.51 vs. 
0.39) in scenario 1 and the proportion of adherent patients (PDC ≥ 80%) was also higher in the 
MT group (21.6% vs. 6.3%). In scenario 2, the adherence (0.77 vs. 0.51) and proportion of 
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adherent patients (55.0% vs. 21.6%) was higher in the APP group compared to the MT group. 
The log rank test on the number of days persistent with an antipsychotic showed that the survival 
curves (Figure 6) differed significantly between the two groups and persistence (or time to 
medication discontinuation) was better in the APP group than in the MT group. About 25% of 
the patients in the APP group had a greater than 31 days gap in therapy prior to starting APP. 
This must be kept in mind while interpreting the results. The results are provided in Table 18. 
 













Test statistic p-value 
Scenario 1 
Adherence—PDC   0.51 (0.28) 
 [0.49 (0.52)] 
 0.39 (0.21)  
 [0.32 (0.30)] 
 t=18.83 <0.0001 
Proportion of patients 
adherent  




Adherence—PDC   0.51 (0.28) 
 [0.49 (0.52)]  
 0.77 (0.19) 
 [0.82 (0.27)] 
 t=-45.53 <0.0001 
Proportion of patients 
adherent 





  137.3 (116.2) 
 [90 (218)] 
 227.9 (118.2) 





 A log rank test was conducted to compare the two groups 
b







Figure 6: Graph of unadjusted persistence time (in days) of the MT and APP groups 
(Kaplan Meier survival estimates) 
 
 
After adjusting for other covariates, the adherence results for scenarios 1 and 2 remained 
similar to the unadjusted case. In scenario 1, after controlling for covariates, APP patients were 
83% less likely to be adherent compared to the MT patients and in scenario 2, APP patients were 
almost 4 times more likely to be adherent compared to the MT patients. The Cox proportional 
hazards regression showed that there was a significant difference in the time of medication use 
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the APP group were more persistent (51% less likely to discontinue their medication) than those 
in the MT group (Figure 7). The results are provided in Table 19.  
 










Test statistic p-value 
Scenario 1 
Adherence—PDC*  0.51 (0.09) 0.39 (0.11) z=-25.79 <0.001 
Odds of being 
adherent [PDC≥80%] 
(Reference group: 
MT) [OR (95% 
CI)]** 
0.17 (0.14-0.22) z=-14.11 <0.001 
Scenario 2 
Adherence—PDC*  0.51(0.10) 0.77 (0.11) z=33.45 <0.001 
Odds of being 
adherent [PDC≥80%] 
(Reference group: 
MT) [OR (95% 
CI)]** 





MT)  [Hazard Ratio 
(95% CI)]*** 
0.49 (0.45-0.53) z=-18.36 <0.001 
* Multiple regression; ** Logistic regression; *** Cox proportional hazards regression 
a









Figure 7: Graph of adjusted persistence time (in days) of the MT and APP groups 
 
This graph adjusts for  age, sex, race/ethnicity, year of initiation of index antipsychotic, mental 
health diagnosis, substance abuse diagnosis, number of mental health comorbidities, pre-index 
CCI, pre-index CDS, index antipsychotic drug, mode of administration of the antipsychotic, use 
of psychotropic therapy, use of anticholinergic medications, clinical specialty of prescribing 
physician, number of physicians prescribing antipsychotics, urban/rural status for prescribing 
physician, number of mental health-related inpatient hospitalizations in the pre-index period, and 
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4.2. Objectives 5-8 
Objectives 5-8 involved comparing the MT and APP groups with respect to:  the 
likelihood of an inpatient hospitalization; length of hospital stay; number of 
outpatient/emergency department visits; and medical, pharmacy and total costs. Patients newly 
initiated on antipsychotics were classified into the MT and APP groups. APP was defined as at 
least 60 days of at least two antipsychotics with no gap in polypharmacy for greater than 31 days 
and no gap in therapy for greater than 31 days. MT was defined as no evidence of APP after the 
index antipsychotic claim with no gap in therapy for greater than 31 days. The patients in the MT 
and APP groups were then matched based on duration of exposure to an antipsychotic. The 
matched cohorts were used for these analyses.  
4.2.1. PATIENT SELECTION 
There were 58,311 patients between 18-63 years of age newly initiated on antipsychotics with 
claims for antipsychotic medications between July 1, 2006 and December 31, 2010. A total of 
2,136 (3.7%) patients had at least one APP episode, defined as exposure to two or more 
antipsychotics for at least 60 days with no gaps in polypharmacy of greater than 31 days and no 
gap in therapy for greater than 31 days. Of these, 453 (0.8% of the total) were enrolled in 
Medicaid for the duration of the study period and in the 180 days prior to the index antipsychotic 
claim. A total of 6,485 (11.1%) patients did not have any APP episodes and had no gaps in 
antipsychotic therapy of greater than 31 days after the index antipsychotic claim. Of these, 3,407 
(5.8% of the total) patients were continuously enrolled in Medicaid in the 180-day pre-index 
period and the duration of the post-index study period. The prevalence of APP in the Texas 
Medicaid population among continuously eligible patients with no gap in antipsychotic therapy 
of greater than 31 days was 11.7% (453/3,860). The patients in the APP and MT groups were 
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matched to each other based on the duration of exposure to an antipsychotic medication. Post 
matching, each group had 453 patients. Figure 8 provides a flowchart showing the execution of 
the patient inclusion criteria.      







































Number of patients between 18-63 
years of age newly initiated on 
antipsychotic medications with at 
least two claims for an 
antipsychotic medication=58,311 
Number of patients with at least 
one APP episode of at least 60 days 
with no gaps in therapy greater 
than 31 days—APP group=2,136 
(3.7%) 
 
Number of patients with no APP 
episodes of at least 60 days and no 
gaps in therapy greater than 31 
days—MT group=6,485 (11.1%) 
 
Number of patients in the APP 
group who were continuously 
enrolled in Medicaid through the 
study period=453 (0.8% of total) 
 
Number of patients in the MT 
group who were continuously 
enrolled in Medicaid through the 
study period=3,407 (5.8% of total) 
 
Number of patients in the APP 
group post matching=453 (0.8% of 
total) 
Number of patients in the MT 





Table 20 provides the characteristics of patients (matched based on duration of exposure 
to an antipsychotic) in the MT and APP groups. Patients in the APP group had younger patients 
compared to the MT group. A greater proportion of patients in the APP group were males 
compared to the MT group. The two groups, APP and MT, differed with respect to the year of 
their index antipsychotic. Greater proportion of patients in the APP group had a diagnosis of 
schizophrenia or schizoaffective disorder compared to the MT group. A greater proportion of 
patients with APP had current substance abuse, used a typical antipsychotic at index, and used 
anticholinergic drugs. Patients in the APP group had a greater number of unique mental illnesses 
and higher mean pre-index CDS scores. The APP group also had greater number of prescribers 
prescribing the antipsychotics and more pre-index psychiatric-related hospitalizations and 
outpatient visits compared to the MT group. Overall, the APP group consisted of sicker patients 






Table 20: Comparison of demographic, clinical, physician, and prior utilization characteristics for the matched patients in the 











N % N % 
Demographic Characteristics 
Age (Mean, SD)*   41.8 11.8  40.0 12.3  t=2.32  0.0209 
Sex** Male  172 38.0  202 44.6  S=4.02  0.0450 
 Female  281 62.0  251 55.4   
Race** Caucasians  175 38.6  203 44.8  S=14.77  0.1408 
 African Americans  115 25.4  114 25.2   
 Hispanics  125 27.6  102 22.5   
 Others  24 5.3  31 6.8   
 Unknown  14 3.1  3 0.7   
Clinical Characteristics 
Year of initiation of index 
antipsychotic** 
2006  54 11.9  45 9.9  S=23.52  0.0090 
 2007  122 26.9  102 22.5   
 2008  77 17.0  61 13.5   
 2009  121 26.7  125 27.6   












Table 20: Comparison of demographic, clinical, physician, and prior utilization characteristics for the matched patients in the 











N % N % 
Mental health diagnosis** Schizophrenia/schizo
affective disorder 
 46 10.2  122 26.9  S=52.54  <0.0001 
 Bipolar disorder  47 10.4  43 9.5   
 Depression  76 16.9  36 8.0   
 Other mental health 
diagnoses 
 174 38.4  168 37.1   
 Multiple mental 
illnesses 
 21 4.6  15 3.3   
 No mental health 
diagnoses 
 89 14.8  69 15.2   
Current substance abuse** Yes  62 13.7  87 19.2  S=5.17  0.0230 
 No  391 86.3  366 80.8    
Number of unique mental 
health diagnoses (Mean, 
SD)* 
  1.5 1.3  2.0 1.7  t=-4.83  <0.0001 
CCI-pre index (Mean, SD)*   0.7 1.3  0.7 1.4  t=-0.31  0.7558 
Number of patients with 
CCI-pre>0** 
  149 32.9  146 32.2  S=0.05  0.8282 
CDS-pre index (Mean, SD)*   4.6 2.5  5.0 2.8  t=-2.63  0.0089 
Index antipsychotic drug
a,b,**
 Typical  26 5.7  43 9.5  S=4.31  0.0378 
 Atypical  427 94.3  410 90.5   




Oral  441 97.3  433 95.6  S=2.13  0.1441 




Table 20: Comparison of demographic, clinical, physician, and prior utilization characteristics for the matched patients in the 











N % N % 
Use of psychotropic therapy 
during study period** 
Yes  358 79.0  377 83.2  S=2.46  0.1171 
 No  95 21.0  76 16.8   
Use of anticholinergic 
medications during study 
period** 
Yes  52 11.5  133 29.4  S=43.45  <0.0001 
 No  401 88.5  320 70.6    
Physician Characteristics 
Clinical specialty of 
prescribing physician** 
Psychiatry  256 56.5  267 58.9  S=5.40  0.4933 
 General/Family 
practice 
 67 14.8  53 11.7   
 Other  104 23.0  96 21.2   
 Unknown  26 5.7  37 8.2   
Number of physicians 
prescribing antipsychotics 
(Mean, SD)* 
  1.6 0.9  2.1 1.3  t=-5.66  <0.0001 
Urban/rural status** Urban  353 77.9  368 81.2  S=8.35  0.0393 
 Rural  83 18.3  80 17.7   







Table 20: Comparison of demographic, clinical, physician, and prior utilization characteristics for the matched patients in the 











N % N % 
Prior utilization characteristics 
Number of mental health-
related inpatient 
hospitalizations in six-month 
pre-index period (Mean, 
SD)*** 
  0.05 0.2  0.2 0.6  S=791  <0.0001 
Number of patients with 
mental health-related 
inpatient hospitalizations 
during the six-month pre-
index period** 
  64  
 
14.3  104 23.0 S=11.42 0.0007 
Number of mental health-
related outpatient visits in 
six-month pre-index period 
(Mean, SD)*** 
  4.8 7.9  7.5 11.4 S=11488  <0.0001 
a
 Measured at index of antipsychotic therapy 
b 
Patients on initiated on combinations combined with atypical antipsychotics due to small sample size in the combinations group 
* Paired sample t-tests; ** McNemar’s tests; *** Wilcoxon sign rank tests
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4.2.2. HEALTH CARE UTILIZATION FOR MT AND APP GROUPS 
Objectives 5-7 involved comparing the likelihood of an inpatient hospitalization, hospital 
length of stay, and the number of outpatient and emergency department visits between the MT 
and APP groups. Table 21 provides a comparison of the unadjusted healthcare utilization 
between the MT and APP groups. A significantly greater proportion of APP patients had been 
hospitalized during the study period compared to MT patients (23.0% vs. 14.1%). The APP 
group had a significantly greater mean number of inpatient hospitalizations (0.5 [1.1] vs. 0.2 
[0.8]), days of hospital stay (5.0 [12.2] vs. 2.4 [7.4]), and outpatient visits (46.1 [43.0] vs. 35.9 
[37.4]) compared to the MT group.  
 




























 0.2 (0.8) 
 [0 (0)] 
 0.5 (1.1) 
 [0 (0)]  
 S=1819.5   0.0002 




 1.2 (4.5) 
 [0 (0)] 
 2.6 (8.7) 
 [0 (0)] 
 S=1982.5  0.0001 
Outpatient visits
c
  35.9 (37.4) 
 [26 (36)] 
 46.1 (43.0) 
 [35 (52)] 




 Wilcoxon sign rank test; 
c






In the regression models used to compare the adjusted healthcare utilization between the 
MT and APP groups, all demographic, clinical, physician, and prior utilization characteristics 
were used as covariates. Comparison of the adjusted likelihood of an inpatient hospitalization 
between the MT and APP groups was done using logistic regression; the odds between the two 
groups did not vary significantly (Odds ratio=1.47, 95% CI: 0.97-2.25, z=1.80, p=0.072). The 
adjusted mean length of hospital stay (in days) was higher for the APP group compared to the 
MT group (2.6 [4.7] vs. 1.2 [1.9]; p<0.001). This comparison was done using a hurdle model. In 
order to compare the adjusted number of outpatient/emergency department visits between the 
APP and MT groups, a GzLM regression with a Poisson distribution and a log link function 
(Modified Park’s coefficient 1.3) was used; the adjusted number of outpatient/ emergency 
department visits between the two groups did not vary significantly (Table 22).   
 
Table 22: Results of regression models for the comparison of adjusted all-cause 
healthcare utilization between the MT and APP groups 
Health care utilization 
category 
Odds Ratio [OR] (95% CI of 
OR) (N=453) 
Test statistic p-value 




MT) [OR (95% CI)]
a
 
1.47 (0.97-2.25)   z=1.80 0.072 










Test statistic p-value 




1.2                   
(1.9) 
2.6                      
(4.7) 





35.9            
(20.7) 
46.1            
(30.0) 
 z=1.38 0.167 
SD: Standard Deviation 
a
 Logistic regression; 
b
 Hurdle model;  
c
 GzLM regression with Poisson distribution and a log-link function 
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4.2.3. COSTS FOR MT AND APP GROUPS 
Objective 8 involved comparing the pharmacy, medical and total costs between the 
MT and APP groups. The regression models that compared the adjusted costs between the 
two groups used all demographic, clinical, physician, and prior utilization characteristics as 
covariates. Table 23 provides the unadjusted costs for the MT and APP groups. Costs are 
categorized by type of healthcare utilization—medical costs, which includes costs associated 
with inpatient hospitalizations and outpatient/emergency department visits; and drug costs. In 
addition, costs are also categorized by whether they are psychiatric related or non-psychiatric 
related. The costs for the APP group were statistically significantly higher for all categories 







Table 23: Comparison of unadjusted costs (in USD) between the MT and APP groups 
















Test statistic p-value 
Medical Costs 


















































































* All comparisons were conducted using Wilcoxon signed rank tests 
a
 Total medical costs = inpatient costs + outpatient costs  
b 
Total costs = medical costs + drug costs; 
c
 Total costs = psychiatric costs + non-psychiatric costs
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In the regression analyses used to compare the adjusted costs between the MT and APP 
groups, demographic, clinical, physician, and prior utilization characteristics were controlled. 
GzLM regression was used to estimate the costs (medical, drug, and total costs as per objective 
8) after adjusting for the covariates. In order to identify the appropriate family to be used for the 
GzLM regression, a Modified Park’s test was used. The Modified Park’s tests produced gamma 
coefficients (γ) of 1.6, 1.6, and 2.1 for medical, drug, and total costs, respectively. A γ coefficient 
of 2 denotes that a gamma distribution would be most appropriate for the regression analysis 
(Table 9 provides the γ coefficient values for other commonly used distributions). Thus, GzLM 
with a gamma distribution and a log link function was used to estimate the adjusted drug, 
medical, and total costs for the APP and MT groups. Results are provided in Table 24. The 
adjusted medical costs (mean [SD] $10,040.47 [$11,984.24] vs. $6,242.64 [$6,055.36]), drug 
costs ($14,909.13 [$5,103.79] vs. $9,579.34 [$2,826.93]), and total costs ($24,426.28 
[$12,289.23] vs. $15,503.87 [$6,806.68]) were significantly higher in the APP group compared 
to the MT group.  
 
Table 24: Results of the regression models for comparison of adjusted all-cause costs (in 










Test statistic p-value 




 z=1.99 0.047 




 z=10.88 <0.001 




 z=8.21 <0.001 




4.3. Sensitivity Analysis 
1. All cause costs vs. psychiatric-related costs  
In the base case healthcare utilization and cost calculations, we used all-cause outcomes 
and costs. This is because the effect of APP is not well known; non-mental health-related 
healthcare utilization and cost outcomes could also be affected in addition to the mental health-
related outcomes—such as, increased use of antipsychotics may lead to increase in 
cardiometabolic diseases such as diabetes which could lead to increased health resource 
utilization and outcomes. In addition, high antipsychotic medication use could also cause 
extrapyramidal symptoms leading to increased healthcare utilization and costs. As a sensitivity 
analysis, we included psychiatric-related utilization and costs instead of the all-cause ones in 
order to get a sense of the relationship between the psychiatric-related outcomes and APP. The 
results of the sensitivity analyses associated with the all-cause vs. psychiatric-related utilization 




Table 25: Comparison of healthcare utilization and cost (in USD) outcomes between the MT and APP groups for all-cause 
outcomes and psychiatric-related outcomes  
Category 

























Health care utilization 
Odds of having an 
inpatient hospitalization 
(Reference Group: MT) 
[OR (95% CI)] 
1.47 (0.97-2.25) z=1.80 0.072 2.20 (1.10-4.41) z=2.22 0.026 
Length of hospital stay
a
 1.2                   
(1.9) 
2.6                      
(4.7) 







35.9            
(20.7) 
46.1            
(30.0) 
z=1.38 0.167 10.0    
(12.2) 
18.3       
(23.6) 
z=2.18 0.029 
Costs (in USA) 
Medical costs
b
































 In the length of hospital stay model for psychiatric-related outcomes, mode of administration (oral vs. intramuscular) was not 
included as a covariate as it caused model convergence issues 
b 
In the medical costs model for psychiatric-related outcomes, the variable denoting the specific diagnosis of the patient was not 
included as it caused model convergence issues
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When only psychiatric-related outcomes were included, APP patients were twice as likely 
as MT patients to have an inpatient hospitalization (OR=2.20, 95% CI=1.10-4.41, z=2.22, 
p=0.026) and the adjusted length of stay was significantly higher for the APP vs. the MT group 
(1.9 [13.2] vs. 0.3 [1.3], p<0.001). The number of outpatient visits was significantly higher in the 
APP group compared to the MT group (18.3 [23.6] vs. 10.0 [12.2], z=2.18, p=0.029).  
The adjusted psychiatric-related medical cost ($8,290.86 [$35,051.37] vs. $2,511.00 
[$15,313.80])), drug costs ($9,353.19 [$1,892.04] vs. $4,577.12 [$839.0]) and total costs 
($12,440.25 [$5,466.31] vs. $5,705.42 [$2,192.48]) were significantly higher in the APP group 




2. Varying the definition of APP 
a) Varying the overlap period 
In the base case, APP was defined as exposure to two or more antipsychotics for at least 
60 days with no gap in polypharmacy of greater than 31 days and no gap in therapy of more than 
31 days. The overlap period was increased to 120 days and 180 days to determine how that 
would affect the prevalence and outcomes associated with APP. When the overlap period was 
increased to 120 days, there were 590 patients in the APP group and these were used for the 
incidence and adherence analyses. A total of 271 patients did not have any gaps in polypharmacy 
for greater than 31 days and no gap in therapy for greater than 31 days and could be matched to 
MT patients (on duration of exposure to an antipsychotic); thus, this set was used for healthcare 
utilization and cost outcomes analysis. When the overlap period was further increased to 180 
days, there were 316 patients in the APP group who were used for the incidence and adherence 
analyses. A total of 221 patients had no gap in polypharmacy for greater than 31 days and no gap 
in therapy for greater than 31 days and could be matched to the MT patients (on duration of 
exposure to an antipsychotic). This set was used for the healthcare utilization and cost outcomes 
analysis. Table 26 provides the results for these sensitivity analyses. 
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Table 26: Comparison of healthcare utilization and cost (in USD) outcomes when APP was defined as at least 60 days (base 
case), 120 days, and 180 days of  antipsychotic medication overlap  




























Incidence, adherence, and persistence 
 N=21,979 N=1,253  N=22,642 N=590  N=22,916 N=316  









0.51    
(0.10) 




0.52     
(0.10) 












0.51    
(0.10) 




0.52     
(0.10) 




Scenario 1: Odds 
of being adherent 
[PDC≥80%] 
(Reference 
Group: MT) [OR 
(95% CI)] 
0.17 (0.14-0.22) z=-14.11; 
<0.001 
0.38 (0.29-0.49) z=-7.38; 
<0.001 
0.77 (0.58-1.03) z=-1.78; 
0.075 
Scenario 2: Odds 
of being adherent 
[PDC≥80%] 
(Reference 
Group: MT) [OR 
(95% CI)] 
3.90 (3.44-4.42) z=21.20; 
<0.001 
6.92 (5.72-8.39) z=19.78; 
<0.001 






(95% CI)]  












Table 26: Comparison of healthcare utilization and cost (in USD) outcomes when APP was defined as at least 60 days (base 
case), 120 days, and 180 days of  antipsychotic medication overlap (continued) 




























Health care utilization 
 N=453 per group N=271 per group N=221 per group 





[OR (95% CI)] 
1.47 (0.97-2.25) z=1.80 
0.072 
1.36 (0.78-2.35) z=1.09; 
0.276 
1.44 (0.77-2.72) z=1.13; 
0.257 
Length of 
hospital stay  
1.2                   
(1.9) 










0.9      
(1.2) 







35.9            
(20.7) 




37.3    
(19.3) 
43.0    
(30.8) 
z=-0.23   
0.814 







Costs (in USD) 


























































MT: Antipsychotic monotherapy; APP: Antipsychotic polypharmacy 
a 
In the APP group, 19% of the patients had a 31 days gap in therapy prior to start of APP 
b 
In the APP group, 10% of the patients had a 31 days gap in therapy prior to start of APP
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When 120-day and 180-day overlap periods were used to define APP, the incidence of 
APP changed to 2.5% and 1.4%, respectively. With respect to adherence, as the overlap period 
was increased (from 60 to 120 and 180 days), the adherence in the APP group increased and was 
higher than the MT group in scenarios 1 and 2. Patients with a PDC≥80% were considered to be 
adherent. For the 120-day overlap period, the odds of MT patients being adherent were higher 
than APP patients for scenario 1 and the opposite was true for scenario 2. For the 180-day 
overlap period (scenario 1) the odds of being adherent were not significantly different between 
the MT and APP groups. For scenario 2 (with a 180-day overlap period), the results were similar 
to the base case; adherence and odds of being adherent were higher in the APP group compared 
to the MT group. The duration of medication use prior to discontinuation (persistence) varied 
between the MT and APP groups in both sensitivity analyses cases and number of days of 
medication use prior to discontinuation (persistence) was higher in the APP group. Figure 9 
provides the graphs showing the adjusted persistence for the MT and APP groups.   
The odds of a hospitalization did not differ significantly between the MT and APP groups 
for the 120 and 180 days overlap period. The adjusted length of hospital stay was higher in the 
APP group compared to the MT group in both sensitivity analyses cases. Like the base care 
scenario, drug costs and total costs were higher in the APP group compared to the MT group for 
both sensitivity analysis cases, when the overlap period was increased to 120 days and 180 days. 
The difference in medical costs between the APP and MT groups was not statistically significant 







Figure 9: Graphs for adjusted persistence (in days) for the sensitivity analyses of days of 
overlap in therapy 
 
(a) Overlap period = 120 days 
 
 
This graph adjusts for age, sex, race/ethnicity, year of initiation of index antipsychotic, mental 
health diagnosis, substance abuse diagnosis, number of mental health comorbidities, pre-index 
CCI, pre-index CDS, index antipsychotic drug, mode of administration of the antipsychotic, use 
of psychotropic therapy, use of anticholinergic medications, clinical specialty of prescribing 
physician, number of physicians prescribing antipsychotics, urban/rural status for prescribing 
physician, number of mental health-related inpatient hospitalizations in the pre-index period, and 
































0 100 200 30
0 
400 
Persistence (in days) 



















(b) Overlap period = 180 days 
This graph adjusts for age, sex, race/ethnicity, year of initiation of index antipsychotic, 
mental health diagnosis, substance abuse diagnosis, number of mental health 
comorbidities, pre-index CCI, pre-index CDS, index antipsychotic drug, mode of 
administration of the antipsychotic, use of psychotropic therapy, use of anticholinergic 
medications, clinical specialty of prescribing physician, number of physicians prescribing 
antipsychotics, urban/rural status for prescribing physician, number of mental health-
related inpatient hospitalizations in the pre-index period, and number of mental health-





















0 100 200 300 400 
Persistence (in days) 



















b) Varying the gap in therapy 
In the base case, APP was defined as two or more antipsychotics for at least 60 days with 
no gap in polypharmacy for greater than 31days. As a sensitivity analysis, the gap was varied to 
15 days and 45 days. When a gap period of 15 days was used, 1,076 patients were classified as 
APP. They were used for the incidence and adherence analyses. Of these, 174 patients had no 
gaps in polypharmacy of greater than 15 days and no gap in therapy of greater than 15 days and 
could be matched to patients in the MT group (on duration of exposure to an antipsychotic). 
They were used for the healthcare utilization and cost analyses. When 45 days was used as the 
gap period, 1,369 patients were classified as APP and were used for the incidence and adherence 
analyses. Of these, 601 patients had no gaps in any polypharmacy for greater than 45 days and 
no gap in therapy of greater than 45 days and could be matched to MT patients (on duration of 
exposure to an antipsychotic); these patients were used for the healthcare utilization and cost 
outcomes. Table 27 provides the results of the sensitivity analyses.      
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Table 27: Comparison of healthcare utilization and cost (in USD) outcomes with gap in therapy defined as at least 31 days, 
15 days, and 45 days   




























Incidence, adherence, and persistence 
 N=21,979 N=1,253  N=22,156 N=1,076  N=21,863 N=1,369  









0.51    
(0.10) 
0.42   
(0.11) 
















0.51    
(0.10) 




0.51   
(0.09) 




Scenario 1: Odds 
of being adherent 
[PDC≥80%] 
(Reference group: 
MT) [OR (95% 
CI)] 
0.17 (0.14-0.22) z=-14.11; 
<0.001 
0.20 (0.16-0.26) z=-12.84; 
<0.001 
0.16 (0.12-0.20) z=-14.92; 
<0.001 
Scenario 2: Odds 
of being adherent 
[PDC≥80%] 
(Reference group: 
MT) [OR (95% 
CI)] 
3.90 (3.44-4.42) z=21.20; 
<0.001 
4.37 (3.81-5.00) z=21.33; 
<0.001 





Ratio (95% CI)]  













Table 27: Comparison of healthcare utilization and cost (in USD) outcomes with gap in therapy defined as at least 31 days, 
15 days, and 45 days (continued) 




























Health care utilization 
 N=453 per group N=174 per group N=601 per group 





[OR (95% CI)]  
1.47 (0.97-2.25) z=1.80 
0.072 
1.48 (0.71-3.08) z=1.04; 
0.299 
1.91 (1.32-2.76) z=3.44; 
0.001 
Length of hospital 
stay  
 
1.2                   
(1.9) 




1.0        
(1.5) 




0.9      
(1.2) 







35.9            
(20.7) 




37.1    
(22.8) 




35.7    
(21.8) 




Costs (in USD) 






















































MT: Antipsychotic monotherapy; APP: Antipsychotic polypharmacy 
a 
In the APP group, 24% of the patients had a 31 days gap in therapy prior to start of APP 
b 
In the APP group, 25% of the patients had a 31 days gap in therapy prior to start of APP
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When the gap period was changed to 15 days and 45 days, the incidence of APP changed 
to 4.6% and 5.9%, respectively. With respect to adherence, varying the gap period produced 
results similar to those in the base case for both scenarios 1 and 2; adherence was higher and the 
odds of being adherent were higher in the MT group compared to the APP group in scenario1 
and the opposite was true for scenario 2.  The duration of medication use prior to discontinuation 
(persistence) varied between the MT and APP groups in both sensitivity analyses cases and time 
to medication discontinuation (persistence) was higher in the APP group. Figure 10 provides the 
graphs showing the adjusted persistence for the MT and APP groups.    
When the gap in therapy was increased to 45 days, patients in the APP group were almost 
twice as likely (OR: 1.91 [95% CI: 1.32-2.76]) to have an inpatient hospitalization compared to 
the MT group. This difference was not statistically significant for the 15 days gap scenario. The 
adjusted length of hospital stay was higher in the APP group compared to the MT group when 
the gap in therapy was varied to 15 days and 45 days. The number of outpatient/emergency 
department visits did not differ significantly between the MT and APP groups in both sensitivity 
analyses cases. The APP patients had higher medical, drug, and total costs compared to the MT 
group when the gap in therapy was 45 days. When the gap in therapy was reduced to 15 days, the 
pharmacy and total costs were higher in the APP group compared to the MT group. There was no 
difference in the medical costs between the two groups when the gap period was reduced to 15 











Figure 10: Graphs for adjusted persistence (in days) for the sensitivity analyses of  
 gap in therapy  
(a) Gap in therapy = 15 days 
 
This graph adjusts for age, sex, race/ethnicity, year of initiation of index antipsychotic, mental 
health diagnosis, substance abuse diagnosis, number of mental health comorbidities, pre-index 
CCI, pre-index CDS, index antipsychotic drug, mode of administration of the antipsychotic, use 
of psychotropic therapy, use of anticholinergic medications, clinical specialty of prescribing 
physician, number of physicians prescribing antipsychotics, urban/rural status for prescribing 
physician, number of mental health-related inpatient hospitalizations in the pre-index period, and 
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(b) Gap in therapy = 45 days 
 
 
This graph adjusts for age, sex, race/ethnicity, year of initiation of index antipsychotic, mental 
health diagnosis, substance abuse diagnosis, number of mental health comorbidities, pre-index 
CCI, pre-index CDS, index antipsychotic drug, mode of administration of the antipsychotic, use 
of psychotropic therapy, use of anticholinergic medications, clinical specialty of prescribing 
physician, number of physicians prescribing antipsychotics, urban/rural status for prescribing 
physician, number of mental health-related inpatient hospitalizations in the pre-index period, and 
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In all the analyses conducted for this study, mean values have been provided for the 
healthcare utilization and cost outcomes for the MT and APP groups. In order to better assess the 
difference in outcomes and costs between the MT and APP groups, Table 28 provides the 
difference between the APP and MT groups for both utilization and costs. The difference (APP-
MT) is provided for the base case as well as the five sensitivity analyses cases. As can be noted 
from the table, the magnitude of utilization and cost outcomes were higher for the APP group 
compared to the MT group. The likelihood of an inpatient hospitalization was represented as an 
odds ratio and hence no difference is provided.   
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 adjusted for age, sex, race/ethnicity, year of initiation of index antipsychotic, mental health diagnosis, substance abuse diagnosis, 
number of mental health comorbidities, pre-index CCI, pre-index CDS, index antipsychotic drug, mode of administration of the 
antipsychotic, use of psychotropic therapy, use of anticholinergic medications, clinical specialty of prescribing physician, number of 
physicians prescribing antipsychotics, urban/rural status for prescribing physician, number of mental health-related inpatient 
hospitalizations in the pre-index period, and number of mental health-related outpatient and emergency department visits in the pre-
index period 








Table 29: Results of hypotheses tests 
Objectives/Hypotheses Result 
Objective 1: Determine the incidence of APP —overall and by subgroup and classify patients into the MT and APP 
groups  
No hypothesis 
Objective 2: Describe and compare the demographic, clinical, physician, and prior utilization characteristics of 
patients in the APP and MT groups 
No hypothesis  
Objective 3: Identify the characteristics of patients most likely to be prescribed APP 
H3.1: Younger patients are more likely to be on APP compared to older patients after controlling for other 
demographic, clinical, physician, and prior utilization characteristics. 
Rejected 
H3.2: Male patients are more likely to be on APP compared to female patients after controlling for other 
demographic, clinical, physician, and prior utilization characteristics. 
Failed to reject 
H3.3: Caucasian patients are more likely to be on APP compared to the other ethnicities after controlling 
for other demographic, clinical, physician, and prior utilization characteristics. 
Rejected 
H3.4: Patients with an index antipsychotic claim in 2010 are more likely to be on APP compared to those 
with an index claim in other years after controlling for other demographic, clinical, physician, and 
prior utilization characteristics.  
Rejected 
H3.5: Patients with a schizophrenia/schizoaffective disorder diagnosis are more likely to be on APP 
compared to those with other mental health diagnoses after controlling for other demographic, 
clinical, physician, and prior utilization characteristics. 
Failed to reject 
H3.6: Patients without a substance abuse diagnosis are more likely to be on APP compared to those with 
such a diagnosis after controlling for other demographic, clinical, physician, and prior utilization 
characteristics. 
Failed to reject 
H3.7: The likelihood of APP increases with each additional comorbidity experienced by patients after 
controlling for other demographic, clinical, physician, and prior utilization characteristics. 
Failed to reject 
H3.8: Patients with a lower pre-index period CCI score are more likely to be on APP compared to those 








Table 29: Results of hypotheses tests (continued) 
Objectives/Hypotheses Result 
H3.9: Patients with a lower pre-index period CDS score are more likely to be on APP compared to those 
with a higher score after controlling for other demographic, clinical, physician, and prior utilization 
characteristics. 
Failed to reject 
H3.10: Patients initiated on typical antipsychotics are more likely to be on APP compared to those initiated 
on atypical antipsychotics after controlling for other demographic, clinical, physician, and prior 
utilization characteristics. 
Rejected   
H3.11: Patients initiated on oral antipsychotics are more likely to be on APP compared to those initiated on 
intramuscular antipsychotics after controlling for other demographic, clinical, physician, and prior 
utilization characteristics.  
Rejected 
H3.12: Patients with non-antipsychotic psychotropic drug use in addition to antipsychotic use are more 
likely to be on APP compared to those without it after controlling for other demographic, clinical, 
physician, and prior utilization characteristics.  
Failed to reject 
H3.13: Patients with anticholinergic drug use in addition to antipsychotic use are more likely to be on APP 
compared to those without it after controlling for other demographic, clinical, physician, and prior 
utilization characteristics. 
Failed to reject 
H3.14: Physician specialty is not associated with the likelihood of being on APP after controlling for other 
demographic, clinical, physician, and prior utilization characteristics. 
Rejected   
H3.15: Patients with multiple physicians prescribing antipsychotics are more likely to be on APP compared 
to those with a single physician prescribing antipsychotics after controlling for other demographic, 
clinical, physician, and prior utilization characteristics. 
Failed to reject 
H3.16: Patients whose prescribers are from rural areas are more likely to be prescribed APP compared to those 
whose physicians are from urban areas after controlling for other demographic, clinical, physician, 
and prior utilization characteristics. 
Rejected  
H3.17: Patients with a greater number of prior mental health-related hospitalizations are more likely to be 
on APP compared to those with fewer prior mental health-related hospitalizations after controlling 
for other demographic, clinical, physician, and prior utilization characteristics. 
Rejected  
H3.18: Patients with a greater number of prior mental health-related outpatient visits are more likely to be 
on APP compared to those with fewer prior mental health-related outpatient visits after controlling 
for other demographic, clinical, physician, and prior utilization characteristics. 
Failed to reject 
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Table 29: Results of hypotheses tests (continued) 
Objectives/Hypotheses Result 
Objective 4: Compare adjusted adherence (PDC) and persistence between MT and APP groups while controlling for covariates 
H4.1: The adjusted adherence (PDC) is lower for the APP group compared to the MT group after 
controlling for covariates. 
Scenario 1: Failed to reject 
Scenario 2: Rejected 
H4.2: The odds of being adherent are lower for the APP group compared to the MT group after 
controlling for covariates.  
Scenario 1: Failed to reject 
Scenario 2: Rejected 
H4.3: The adjusted persistence (days of medication use prior to discontinuation) is lower for the APP 
group compared to the MT group after controlling for covariates. 
Rejected 
Objective 5: Compare likelihood of an all-cause inpatient hospitalization between the MT and APP groups while controlling for covariates 
H5.1: The likelihood of an all-cause inpatient hospitalization in the post-index period is higher for the 
APP group compared to the MT group after controlling for covariates. 
Rejected 
Objective 6: Compare all-cause length of stay between the MT and APP groups while controlling for covariates 
H6.1: The adjusted all-cause length of stay in an inpatient facility during the post-index period is higher 
for the APP group compared to the MT group after controlling for covariates.    
Failed to reject 
Objective 7: Compare number of all-cause outpatient visits between the MT and APP groups while controlling for covariates  
H7.1: The adjusted number of all-cause outpatient and emergency department visits is higher for the 
APP group compared to the MT group after controlling for covariates. 
Rejected 
Objective 8: To compare all-cause drug, medical and total (separate models) healthcare costs between the MT and APP groups while controlling for 
the covariates  
H8.1: The adjusted all-cause medical costs are higher for the APP group compared to the MT group after 
controlling for the covariates. 
Failed to reject 
H8.2: The adjusted all-cause drug costs are higher for the APP group compared to the MT group after 
controlling for the covariates. 
Failed to reject 
H8.3: The adjusted all-cause total costs are higher for the APP group compared to the MT group after 
controlling for the covariates.  
Failed to reject 
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5. Discussion and Conclusions 
5.1. Chapter overview 
This chapter provides a detailed discussion of the study. It begins with reviewing the 
study purpose. The study results are then discussed with possible explanations and are compared 
and contrasted with previous studies. The chapter ends with the study implications, limitations, 
and potential future research. 
  
5.2. Review of study purpose 
This study aimed at estimating the incidence of APP, identifying its predictors, and 
comparing healthcare utilization and costs for the MT and APP groups in the Texas Medicaid 
population. There is very limited evidence regarding the safety and efficacy of APP from 
controlled clinical trials and none of the established clinical guidelines advocate its use. Previous 
studies have evaluated the prevalence and outcomes associated with APP in other state Medicaid 
programs such as California, Georgia,
264





However, no such study has been conducted in Texas. It is especially important to 
study APP in the Texas Medicaid population due to the large number of patients with mental 
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  and the increase in use of antipsychotic medications and the associated 
costs in the Texas Medicaid program during the past decade.
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5.3. Objectives 1-4 
5.3.1. Patient selection 
The first four objectives involved estimating the incidence of APP, describing the 
characteristics of patients in the MT and APP groups, identifying predictors of APP, and 
comparing medication adherence and persistence between the MT and APP groups. For the first 
four objectives, external validity was considered to be of greater value compared to internal 
validity. Hence, patients newly initiated on antipsychotic medications were identified and 
followed for one year from their index antipsychotic claim. Patients with exposure to two or 
more antipsychotics for at least 60 days with no gap in polypharmacy of more than 31 days were 
classified as APP patients and those with no evidence of APP for one year after the index 
antipsychotic claim were classified as MT patients. Incidence, descriptive sample statistics (for 
APP and MT patients), predictor relationships, and medication adherence and persistence were 










5.3.2. Incidence of APP 
In this study, the incidence of APP was estimated at 5.4%. The definition of APP was use 
of at least two or more antipsychotics for at least 60 days with no gaps in APP for more than 31 
days. Several studies have estimated the prevalence of APP in different practice settings. This 
discussion will focus on studies that used retrospective databases, particularly state Medicaid 
databases, and APP definitions similar to ours. There was only one study that looked at the 
incidence of APP (Morratto et al.—they evaluated prevalence of APP among patients newly 
initiated on antipsychotics which is similar to an incidence estimate); hence, the study results 
have been compared to studies that estimated prevalence of APP using insurance claims data and 
definitions of APP similar to the one used in the current study.  
Moratto et al. estimated the prevalence of APP among newly initiated antipsychotic users 
(which is similar to an incidence estimate) from the Medicaid program of five states (California, 
Nebraska, Oregon, Utah and Wyoming) between 1998 and 2003.
270
 Their estimate of APP was 
6.4%. Polypharmacy was defined as the initiation of multiple antipsychotics or at least 60 
consecutive days of concomitant antipsychotic medication overlapping the index medication. 
This estimate is quite similar to our estimate of 5.4%.  
Ganguly et al. reported an estimated APP prevalence of 23% among Medicaid-eligible 
patients with schizophrenia from California and Georgia.
271
 The definition of APP use was 
concomitant use of two or more antipsychotics for at least 61 days without a break period of 31 
days or more. Using data from the FFS population of Florida’s Medicaid program from 2002 to 
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2006, Constantine et al. estimated the prevalence of APP at 21%.
272
 APP was defined as the use 
of two or more antipsychotics for 60 consecutive days with no gap exceeding 15 days. Again, the 
current study measured incidence, not prevalence. Our APP incidence estimate (5.4%) would be 
expected to be lower than prevalence estimates. The current study estimated occurrence of APP 
in patients newly initiated on antipsychotics while the other studies estimated its occurrence in 
continuing antipsychotic users. In addition, the studies also differed on the specific patient 
inclusion criteria and the definitions of APP used.  
Kreyenbuhl et al. used VA patients with schizophrenia and schizoaffective disorder 
during 2000 and estimated the prevalence at 9.5%.
273
 APP was defined as receipt of two or more 
antipsychotics concomitantly for at least 90 consecutive days during the study period. This study 
evaluated APP (defined as 90 days of overlap) among prevalent antipsychotic users—we looked 
at 60-day, 120-day, and 180-day overlap periods to estimate the incidence of APP; our estimates 
were 5.4%, 2.5%, and 1.4%, respectively. The difference is the estimates are likely due to 
differences in definitions of APP, differences in patient selection (prevalent vs. incident 
antipsychotic users), as well as the difference in the patient population (VA patients vs. Texas 
Medicaid beneficiaries). The VA prevalence estimate is lower than that observed in other studies 
since the VA study consisted only of patients with schizophrenia/schizoaffective disorder 
patients. Furthermore, there may be differences in utilization criteria, such as prior authorization 
requirements, in the VA system as compared to the Medicaid systems.   
This discussion is focused only on four studies as these used data sets and APP 
definitions most similar to the ones used in the current study.   
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5.3.3. Patient characteristics in the MT and APP groups 
In the unadjusted unmatched analyses, we found that a greater proportion of females had 
APP as compared to males. This trend was also observed in other studies.
274,275,276,277
 A greater 
proportion of Caucasian patients had APP compared to patients from other racial/ethnic 
backgrounds and this was also observed in the study by Kreyenbuhl et al.
278
  
Patients with schizophrenia had a greater proportion of APP users as compared to 
patients with other mental illnesses and this was also observed by Morrato et al.
279
 Patients with 
substance abuse and those with a greater number of mental health illnesses had a greater 
proportion of APP users; Morrato et al. observed a similar trend in their study. The pre-index 
CCI and CDS were higher in the MT group compared to the APP group. A greater proportion of 
patients with CCI≥1 in the MT group was also observed by Kreyenbuhl et al.
280
 APP was greater 
among those initiating on typical antipsychotics which was also observed by Morrato et al. (they 
observed the highest proportion of APP users among those initiated on clozapine but we did not 
have a separate group of clozapine users due to the low sample size). Those initiated on 
intramuscular antipsychotics had greater proportion of APP users compared to those initiated on 
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orals; this was also observed by Ganguly et al.
281
 A greater proportion of patients prescribed APP 
had concurrent use of non-antipsychotic psychotropic and anticholinergic medication compared 
to those in the MT group.  
In this study, we attempted to identify certain physician characteristics associated with 
APP. It was observed that patients with psychiatrists as their prescribers were more likely to have 
APP compared to patients with prescribers from other physician specialties. This is surprising as 
there are multiple guidelines discouraging the concurrent use of multiple antipsychotics and the 
clinical literature showing its benefits to be limited. Another potential explanation for this 
observation is that psychiatrists may be more experienced and hence more likely to prescribe 
multiple antipsychotic medications. Patients with multiple prescribers had more APP which 
might be due to lack of coordination between the prescribers. Urban/rural location of prescriber 
was also found to be significantly associated with APP but this was likely due to the low 
proportion of APP among those prescribers whose urban/rural status was classified as ‘unknown’ 
rather than a difference in the proportion of APP users between the ‘urban’ and ‘rural’ groups. 
Identifying prescriber characteristics in the APP group is critical as in most cases the decision to 
use multiple antipsychotics is that of the prescriber rather than the patient. More information on 
the characteristics of physicians likely to prescribe APP would help in efforts to understand the 
reason for the prescribed APP.  
This study found  greater  mental health-related healthcare utilization events (inpatient 
hospitalizations and outpatient/ emergency department visits) in patients with APP compared to 
the MT group; this was also observed by Ganguly et al. and Kreyenbuhl et al.
282,283
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Although, it is difficult to comment on the overall health status between the two groups, 
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5.3.4. Predictors of APP 
In order to identify the independent association of the demographic, clinical, physician, 
and prior utilization characteristics with APP, a logistic regression model was used. This study 
found that APP increased with an increase in age after controlling for other covariates. This was 
contrary to the findings observed by Morrato et al.
284
 and Kreyenbuhl et al.
285
 Females were 12% 
(adjusted OR=0.88; 95% CI: 0.78-1.00) less likely than males to have APP; this was observed by 
Ganguly et al.286, Morrato et al., Constantine et al.
287
, and Kreyenbuhl et al.  
The adjusted odds of APP were higher for patients with schizophrenia compared to other 
mental illnesses—Morrato et al. made a similar observation in their study. Patients with ongoing 
substance abuse were 7% less likely to have APP. Also similar to Morrato et al., we found that 
the adjusted odds of APP increased with an increase in the number of mental health illnesses 
during the study period. Patients with a  lower CDS, non-antipsychotic psychotropic medication 
use during the study period, and anticholinergic medication use during the study period were 
associated with increased adjusted odds of APP. Patients prescribed APP were more likely to use 
anticholinergic medications possibly due to the association of  antipsychotics with 
extrapyramidal symptoms (EPS).
288
   
As observed in the unadjusted analysis, the adjusted logistic regression model showed 
that psychiatrists were more likely than family practitioners and prescribers with the specialty 
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categorized as ‘unknown’ to prescribe APP—this is surprising, especially in light of the 
widespread literature discouraging the use of APP. Another potential explanation could be the 
patients in the APP group are more severely ill and hence go to psychiatrists; due to the severe 
illness they are prescribed APP. Psychiatrists also could have more experience and hence are 
able to determine who APP should be prescribed to. Also similar to the unadjusted analysis, with 
an increase of one unit in the number of prescribers prescribing antipsychotics, patients were 
1.38 (95% CI: 1.31-1.44) times more likely to have APP. Understanding characteristics of 
physicians likely to prescribe APP is an important step and a promising area for future research.   
After adjusting for other covariates, the number of mental health-related inpatient 
hospitalizations was not significantly associated with APP. However, the number of mental 
health-related outpatient/emergency department visits was significantly associated with APP—
with a one unit increase in the number of mental health-related outpatient or emergency 
department visits, the odds of APP increased by 1.03 (95% CI: 1.00-1.02). This is similar to the 
observation made by Ganguly et al. in their study.    











5.3.5. Adherence and persistence for the MT and APP groups 
In the current study, we measured medication adherence using PDC;  two different 
definitions of adherence were used for the APP group—scenario1 and 2. In scenario 1, a patient 
in the APP group was considered adherent on a given day only if he had at least two 
antipsychotics on that day. In scenario 2, an APP patient was considered adherent on a given day 
if he had at least one antipsychotic on that day. These two methods give the possible range of 
adherence for the APP group. It was not possible to determine what the patient was prescribed 
based on the claims data available to us. We only had information on the prescriptions that were 
filled. The patients in the APP group could have one or more episodes of long term 
polypharmacy during the 12-month study period. Hence, we used these two extreme methods to 
calculate adherence.   
Several studies have evaluated adherence to antipsychotic medications. This discussion is 
focused on  studies that have compared adherence in patients with antipsychotic monotherapy 
and polypharmacy.  We found three studies that compared medication adherence between the 
MT and APP groups—one was a randomized trial
289
,  the other was a retrospective database 
analysis using data from the Hungarian National Health Insurance Fund's database290 and the 
third one was a retrospective database analysis using multistate Medicaid data.
291
   
In a six-month randomized trial, Essock et al. assigned people on APP to either remain on 
APP or switch to MT. Patients assigned to the group switching to MT had a higher all-cause 
discontinuation rate compared to those on APP. At month six, 86% of those in the APP group 
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were still using both medications while 68% in the MT group were using the medication 
assigned to them. We compared discontinuation of all medication therapy between the MT and 
APP groups and found that patients in the APP group were 51% less likely to discontinue their  
antipsychotic therapy compared to the MT group (after controlling for covariates). Thus, similar 
to Essock et al., the current study found that patients in the APP group were more persistent. 
However, we considered a patient in the APP group to be persistent if s/he had at least one 
antipsychotic on a given day (as not all patients started on multiple antipsychotics and it was not 
possible to determine the length of time for which the APP group patients were prescribed 
multiple antipsychotics; we only had information on the claims they filled). The definition of 
persistence used in the current study is one of the reasons for the higher persistence in the APP 
group. In addition, between 10%-25% (depending on definition of APP used) of the patients had 
a greater than 31-day gap in therapy prior to their APP start date. This must be kept in mind 
while interpreting the results.      
Katona et al. started with patients prescribed antipsychotic monotherapy and classified 
them into monotherapy if they continued using one drug and polypharmacy if they used two 
antipsychotics. They found that the all-cause discontinuation was higher among polypharmacy 
users for second generation antipsychotics (both oral and depot). For first generation 
antipsychotics, there was no difference between the monotherapy and polypharmacy groups for 
oral antipsychotic users but the results showed an advantage in the polypharmacy group for the 
depot users. Our results on time of medication use prior to discontinuation were similar to what 
was observed among depot first generation antipsychotic medication users in the study by 
Katona et al. The observed difference between the current study results and the results on 
atypical antipsychotics observed by Katona et al. is likely because they followed the patients in 
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the polypharmacy group for one year after they started using two antipsychotics while the current 
study followed patients for a year from the time they started using an antipsychotic, i.e. they may 
have had one or more polypharmacy episodes during the one year study period.   
In the study that used multistate Medicaid data, Morrato et al. measured adherence to the 
index antipsychotic in the MT and APP groups and found that adherence (measured as MPR) 
was higher in the APP group compared to the MT group. Their method of measurement most 
resembles our scenario 2 (described above) and we made a similar observation that the adherence 
(measured as PDC) was higher in the APP vs. MT group.  
Despite previous studies showing poor medication adherence when patients use multiple 
drugs, the current study (and other studies in the literature) found the contrary. This is likely due 
to the method  used to define an adherent patient in the APP group in the current study. In 
scenario 1 (described above), the adherence was higher in the MT vs. APP group. Since it is not 
possible to determine exactly what the patient was prescribed using insurance claims data, we 
had to use conservative and liberal definitions for adherent patients in the APP group;  the liberal 
definition showed better adherence among patients with APP. Thus, the observed results are due 
to the definitions  used because of unavailability of information on what was prescribed to the 









The first four objectives provide an estimate of the incidence of APP; comparison of 
characteristics of the MT and APP cohorts; identify potential predictors of polypharmacy and 
carry out a comparative analysis of medication adherence and persistence in the two groups 
using varying definitions for ‘adherent’ patients in the APP cohort. 
The incidence of APP was estimated at 5.4% in the Texas Medicaid population. Several 
demographic, clinical, physician, and prior utilization characteristics differed between the MT 
and APP groups in both the unadjusted and adjusted (logistic regression) analyses. The 
comparative analysis for adherence between the MT and APP groups varied depending on the 
definition used for an ‘adherent’ patient in the APP group.  
 These analyses provide useful information, especially regarding the Texas Medicaid 
system, due to the increasing costs associated with antipsychotics in recent years. 
292
 The 
predictors of APP would help providers and payers identify patients likely to be prescribed APP 
early on during the course of their illness. The high-risk patients can then be carefully monitored 
to determine if they are appropriate candidates for polytherapy with antipsychotics. If so, they 




                                               
292 Medicaid Analytic eXtract (MAX) Rx Table Listing. Available at: http://www.cms.gov/Research-Statistics-
Data-and-Systems/Computer-Data-and-Systems/MedicaidDataSourcesGenInfo/Medicaid-Analytic-eXtract-MAX-





5.4. Objectives 5-8  
5.4.1. Patient selection  
Objectives 5-8 involved comparing the likelihood of an inpatient hospitalization, length 
of hospital stay, number of outpatient and emergency department visits, and the medical, drug, 
and total costs between the MT and APP groups. For these objectives, internal validity was 
deemed to be more important than external validity. Hence, only patients with no gaps in 
antipsychotic therapy for greater than 31 days were included. This would increase the possibility 
of making the association between MT/APP and the outcomes as this sample would largely 
consist of patients adherent to their antipsychotic therapy.  Prior studies have shown that non-
adherence to antipsychotic therapy is associated with poor clinical and economic outcomes; only 
including patients with no gaps in antipsychotic therapy for more than 31 days will help exclude 
those patients who might experience increased healthcare utilization and/or costs due to lack of 
therapy rather than type of medication therapy i.e. MT vs. APP. In order to ensure that patients in 
the MT and APP groups had comparable exposure to antipsychotic therapy, the two groups were 
matched based on their exposure to antipsychotics and the outcomes for both groups were 
assessed during the one-year period after the APP index date (pseudo index date for MT group) 
(more explanation provided in section 3.4.4). This group of patients, matched on the length of 
exposure to an antipsychotic, was used for the comparative analysis—assessing the likelihood of 
an inpatient visit, length of hospital stay, number of outpatient/emergency department visits, and 
costs (medical, pharmacy, and total costs) between the MT and APP groups.   
Demographic, clinical, physician, and prior utilization characteristics of the MT and APP 
patients matched on duration of antipsychotic exposure were compared. They differed on several 
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characteristics since they were only matched on one variable. Hence, in all regression procedures 
for the comparative analyses, all measured covariates were controlled for.   
Due to the structure of the data for the current study, we could not differentiate between 
emergency department, professional, and outpatient visits; all of these visits were combined into 
a single category. This might have implications for the utilization and costs as emergency 
department visits typically are less frequent and more expensive compared to outpatient and 



















5.4.2. Healthcare utilization for patients in the MT and APP groups 
There is limited research that evaluates healthcare utilization in patients with APP. Few 
studies have evaluated healthcare utilization in patients with schizophrenia and other mental 
illnesses. This discussion focuses on studies that have addressed healthcare utilization in patients 
with APP.  
Using San Diego County Medicaid beneficiaries with schizophrenia, Gilmer et al. 
estimated the prevalence of APP and the proportion of patients hospitalized between 1999 and 
2004.
293
 The proportion of APP increased from 3.3% in 1999 to 13.7% in 2004 and the 
proportion of patients hospitalized over the same period increased from 7.2% to 9.0%. In the 
current study, we found that the likelihood of an all-cause inpatient hospitalization did not differ 
significantly between the APP and MT groups. However, the length of hospital stay was longer 
in the APP group compared to the MT group.   
Chen et al. studied the effect of adjunctive mood stabilizers on antipsychotic utilization 
patterns and health resource utilization for Medicaid enrollees with schizophrenia.
294
 The authors 
found that the use of emergency room services, long-term facilities, and inpatient care did not 
differ significantly between propensity score-matched patients with schizophrenia who did and 
did not use adjunctive mood stabilizers. Although the use of adjunctive mood stabilizers was not 
considered in the current study, we made a similar observation that the MT and APP groups did 
not vary significantly in the likelihood of an all-cause inpatient hospitalization and number of all-
cause outpatient/emergency department visits.  
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Due to the limited research of healthcare utilization in patients with APP, we have only 
compared our study results to the two studies. Unfortunately, only one looked at patients with 
multiple antipsychotics (although its study design was different from the current study—no 
comparator group of MT patients). The other one (Chen et al.) compared patients with 
schizophrenia who did and did not have adjunctive mood stabilizer therapy. This should be noted 


















5.4.3. Healthcare costs in patients with MT and APP 
Several studies have looked at costs associated with antipsychotic users; this discussion 
focuses on studies that have evaluated costs in patients using multiple antipsychotics. Care has 
been taken to ensure that the current study results are compared to studies using similar datasets.   
In the current study, we found that the medical costs were higher in the APP group 
compared to the MT group. Valuck et al. found that compared to patients on MT, patients on 
APP had higher costs ranging from $71-$211 depending on the state Medicaid program.
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Loosbrock et al. also found that the institutional costs (hospital inpatient, hospital outpatient, 
psychiatric day/night facility, nursing facility, and emergency room costs) were higher for the 
APP vs. MT group.296  
The pharmacy costs in the APP group were higher than those in the MT group in this 
study. Stahl et al. found that patients with short- and long-term polypharmacy had greater 
pharmacy costs than those with monotherapy, with those on long-term polypharmacy costing 
almost three times as much as monotherapy patients.
297
 A similar observation was made by 
Gilmer et al. who noted an increase in pharmacy costs from 1999 to 2004 as the prevalence of 
APP increased.
298
 Valuck et al. also observed greater pharmacy costs in the APP vs. MT 
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 However, Loosbrock et al. found that medication costs did not differ significantly 
between the MT and APP groups.
300
  
The total  costs (sum of medical and pharmacy costs) in the current study were higher in 
the APP group compared to the MT group. This was also observed by Loosbrock et al. In 
patients with APP, the increased pharmacy costs were not offset by decreased medical costs (in 
fact, medical costs were higher in the APP group) which caused the total costs to be higher in the 
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Objectives 5 to 8 carried out a comparative analysis and observed the likelihood of an 
inpatient hospitalization, length of hospital stay, number of outpatient/emergency department 
visits and the costs (medical pharmacy and total) between the MT and APP groups.  
The length of hospital stay was longer for the APP vs. MT group. Likelihood of an 
inpatient visit and the number of outpatient visits did not differ significantly between the two 
groups. With respect to costs, the medical, drug, and total costs were higher for the APP vs. MT 
group. 
Although several covariates were  controlled for in the regression models for the 
comparative analyses and  patients were matched based on their duration of exposure to 
antipsychotics, there is still a possibility of selection bias during the formation of the MT and 
APP groups—patients in the APP group may be sicker at onset compared to the MT group on 
factors we were not able to account for. This must be noted while interpreting the results of this 
study. However, the comparative analysis portion of this study does provide valuable 
information to the extent it highlights the magnitude of extra healthcare utilization events and 
costs and among potentially comparable patients in the APP vs. MT groups after controlling for 






5.5. Sensitivity analyses 
Several sensitivity analyses were conducted surrounding the outcomes (all-cause vs. 
psychiatric-related) and the definition of APP—both the overlap period (60 days vs. 120 days 
and 180 days) and gap period (31 days vs. 15 days and 45 days) were varied.  
The definition of APP used affected the incidence. As the overlap period was increased, 
the incidence decreased; as the gap in therapy period was decreased, the incidence decreased. In 
the case of psychiatric-related outcomes, the cost outcomes were in the same direction as the 
base case (greater in the APP vs. MT group). Contrary to the base case, the likelihood of an 
inpatient hospitalization and number of outpatient and emergency department visits were 
significantly higher in the APP vs. MT group in some sensitivity analyses cases. The outcome 
with respect to hospital length of stay was higher in the APP vs. MT group which was also 
observed in the base case.  
A detailed description of how the results changed as the definition of APP was changed 
has been provided in the Results chapter (section 4.3), but overall they remained quite similar to 
the base case which indicates that the results are robust with respect to the outcomes assessed 











The current study estimated the incidence of APP in the Texas Medicaid population, 
described patient characteristics in the MT and APP groups, identified predictors of APP, and 
compared healthcare utilization and costs between the MT and APP groups. The incidence of 
long-term APP was estimated at 5.4%.  The results of this study have implications for several 
stakeholders in the healthcare delivery system. 
First, it affects patients. Using multiple antipsychotics increases the possibility of side 
effects and adverse drug reactions; the current study found greater healthcare utilization in terms 
of hospital length of stay in patients with APP compared to MT. The extent to which APP has a 
favorable or negative impact on outcomes, in turn, also affects the families of the patients using 
antipsychotic medications.  
Next, these results affect providers. Awareness of characteristics of patients likely to be 
prescribed APP could be useful to providers as it helps them identify potential APP patients early 
during the course of treatment; the early identification may give the providers time to determine 
the appropriateness of APP for the particular patients. 
These results provide important information to policy makers with respect to the 
prevalence of long-term APP despite limited clinical evidence supporting its use. This might 
highlight the need for intervention programs to provide information to clinicians about the 
benefits and harms of APP and also help assess the appropriateness of the APP prescribed by 
them. This is especially important in light of the high financial burden imposed by co-
prescription of multiple antipsychotics.      
Finally, the results of this study have important implications for the payers—Texas 
Medicaid in our case, which was also the perspective of the study. This study highlights the 
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incidence  of APP in the Texas Medicaid population and also highlights the economic burden of 
this practice. This is very important information for Texas Medicaid as they spend a large 
amount of their limited resources on antipsychotics—an expensive drug class. In fact, from 2001 
to 2008, antipsychotics have consistently topped the list of the top 10 drug classes for pharmacy 
benefit use for non-dual-eligible Texas Medicaid beneficiaries in terms of total Medicaid 
prescription drug spending.
301
 The results of this study could help Texas Medicaid assess the 
need and target physician population for intervention programs to determine the appropriateness 
of the prescribed APP and help in the development of programs to potentially control this 
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In the formation of the APP group, there is a possibility of potential selection bias—
sicker patients might potentially get selected into the APP group i.e. the APP group might have 
sicker patients at baseline. However, in order to avoid this potential bias, patients in the MT and 
APP groups were matched based on their duration of antipsychotic exposure and the regression 
analyses controlled for several measures indicating disease severity such as pre-index CCI, pre-
index CDS, number of mental health diagnoses during study period, concurrent non-
antipsychotic psychotropic drug and anticholinergic drug utilization, and prior mental health-
related healthcare utilization. However, there may be other variables which we were not able to 
control. This must be noted while interpreting the study results. 
Due to the use of insurance claims data, it was not possible to determine whether the 
prescribed polypharmacy was appropriate or not. However, our intention was not to classify the 
APP as appropriate or not but rather bring forth its incidence, predictors, and the economic 
burden imposed by it.  
Although we tried to identify several demographic, clinical, physician, and prior 
utilization characteristics associated with APP, there are several clinical characteristics that are 
not captured in the claims data. Several direct disease measures such as Positive and Negative 
Syndrome Scale (PANSS) which might be important predictors of APP were not captured. Also, 
certain other demographic characteristics such as education level, marital status, and others were 
not captured in the current study. We had very limited data on physician characteristics. The 
decision to prescribe multiple antipsychotics to patients is generally made by the prescriber and 
not by the patient. Hence, physician characteristics are likely to be important predictors of APP.  
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Since we did not have information on what the patients were prescribed, in order to 
calculate adherence in the APP group, we used two different definitions—one very conservative 
and one very liberal representing the two extremes of adherence in the APP group. These varied 
definitions produced varying results on the adherence measures between the MT and APP 
groups. In calculating medication persistence, 10%-25% (depending on the definition of APP 
used) of the patients had a greater than 31 days gap in therapy prior to their APP start date.   
Finally, this study has limited generalizability beyond the Texas Medicaid population. 
Caution must be exercised while generalizing these findings to other state Medicaid programs or 
to other insurance settings as patient characteristics, and clinical and financial practices vary 

































5.8. Future Research 
Although the results of this study address important gaps in the literature, future studies 
can be conducted to improve generalizability of the results and add to the existing knowledge 
base. Studies should be conducted using varied patient populations, including patients insured 
privately and those insured using Medicare, in order to generalize the results to a broader patient 
population.  
An important next step is to observe clinical and patient reported outcomes in actual 
practice in patients on MT and APP to better understand the effect of using multiple 
antipsychotics on patients. These studies could be conducted using electronic medical records 
(EMR) data. They might be limited to a smaller population due to the difficulty in obtaining 
detailed clinical data for a large number of patients, but they would provide essential 
information.  
Several patient-level characteristics such as demographic, clinical, and prior healthcare 
utilization variables were included in the logistic regression analysis to identify predictors of 
APP. However, there may still be several other factors that we were not able to include due to the 
structure of our data which might be important predictors. Socio-demographic characteristics 
such as family support, education level, employment status and others might also be important 
factors associated with APP. We included a few physician characteristics in our analyses such as 
physician specialty, number of physicians prescribing the antipsychotic medications, and 
urban/rural status—however, there might be several other physician-level characteristics which 
may determine whether a patient will be prescribed APP or not. Future research could look into 
identifying characteristics of physicians likely to prescribe APP; this might aid our understanding 
of the reasons they prescribe APP despite limited evidence demonstrating its benefit and several 
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clinical guidelines discouraging its use. Understanding the reasons for APP would better equip us 
to plan interventions against APP that is not appropriate. Intervention designed to provide peer-
based reviews to clinicians about their prescribing habits could also help determine whether the 























The incidence of APP in the Texas Medicaid population was estimated at 5.4%.  Several 
demographic, clinical, physician, and prior utilization characteristics were identified that 
predicted the incidence of APP. In general, patients prescribed APP cost more (in terms of drug 
costs) than those with MT but did not have significantly lower healthcare utilization and/or and  
medical costs. Sensitivity analyses varying the definition of APP were conducted and the results 
were by and large similar to the base case. There is a possibility of bias where more severely ill 
patients might get selected into the APP group—in order to avoid this, various measures of 
disease severity including number of mental illnesses during study period, concurrent non-
antipsychotic psychotropic and anticholinergic drug use, pre-index CCI and CDS and prior 
mental health utilization were controlled during the regression procedures and patients in the MT 
and APP groups were matched based on their duration of exposure to antipsychotics. However, 
the potential for selection bias still exists and this must be noted while interpreting the results of 
the study.  
This study provides information on the characteristics of patients most likely to be 
prescribed APP. It also provides information on the burden of APP in terms of health resource 
utilization and costs. The results of this study could encourage providers to carefully consider 
effectiveness and economic factors while prescribing APP to patients. Payers could use this 
information to design interventions to control APP which might help control the increasing 
healthcare costs. 
Although the incidence of APP in the Texas Medicaid population was low, utilization and 
cost outcomes remain high. This may be a subject of interest to Medicaid. However, it must be 
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noted that the high utilization and cost outcomes could be associated with a number of known 
and unknown factors, not just APP.  
Long-term APP raises concern as antipsychotics are fairly expensive drugs and state 
Medicaid agencies are allocating their limited resources to this expensive treatment which has 
very scarce effectiveness data supporting its use. More research is needed to examine the risks 
and benefits associated with APP due to its costly nature. More effectiveness research on APP is 
needed to help provide prescription guidance to clinicians for patients who do not respond well 
to treatment with a single antipsychotic.  
   





The appendix provides tables with the regression coefficients for all the models carried out for the base case scenario. For the 
sensitivity analyses, similar models were used but the full tables are not provided in the appendix. 
Table 30: Results of regression analysis comparing adherence in the MT and APP groups (Scenario 1) 
Characteristics Coef. 
Robust 
Std. Err. Z P>z [95% Conf. Interval] 
              
APP -0.1774 0.0069 -25.79 0.000 -0.1908 -0.1639 
Age 0.0017 0.0002 11.55 0.000 0.0015 0.0020 
Male 0.0227 0.0038 6.04 0.000 0.0154 0.0301 
              
Race/ethnicity             
African American 0.0017 0.0002 11.55 0.000 0.0015 0.0020 
Other 0.0227 0.0038 6.04 0.000 0.0154 0.0301 
Unknown 0.0017 0.0002 11.55 0.000 0.0015 0.0020 
Caucasian  0.0227 0.0038 6.04 0.000 0.0154 0.0301 
              
Year of initiation of index antipsychotic 
medication             
2007 -0.0173 0.0062 -2.81 0.005 -0.0294 -0.0052 
2008 0.0009 0.0070 0.13 0.900 -0.0128 0.0146 
2009 0.0091 0.0063 1.45 0.148 0.0032 0.0213 
2010 0.0165 0.0060 2.75 0.006 0.0047 0.0282 




Table 30: Results of regression analysis comparing adherence in the MT and APP groups (Scenario 1) (continued) 
Characteristics Coef. 
Robust 
Std. Err. Z P>z [95% Conf. Interval] 
Diagnosis             
Depression -0.0084 0.0067 -1.26 0.209 -0.0216 0.0047 
No mental illness -0.0544 0.0072 -7.59 0.000 -0.0684 -0.0403 
Other -0.0126 0.0061 -2.06 0.039 -0.0245 -0.0006 
Schizophrenia 0.0344 0.0074 4.66 0.000 0.0199 0.0488 
Multiple mental illnesses -0.0400 0.0090 -4.44 0.000 -0.0576 -0.0223 
              
Current substance abuse -0.0559 0.0051 -10.94 0.000 -0.0660 -0.0459 
Number of unique mental illnesses 0.0040 0.0017 2.33 0.020 0.0006 0.0075 
Pre-index Charlson Comorbidity Index -0.0047 0.0015 -3.13 0.002 -0.0077 -0.0018 
Pre-index Chronic Disease Score 0.0027 0.0007 3.74 0.000 0.0013 0.0042 
              
Index antipsychotic drug             
Combination 0.1332 0.0755 1.76 0.078 -0.0148 0.2811 
Typical  -0.0752 0.0070 -10.77 0.000 -0.0889 -0.0615 
              
Injectable antipsychotic 0.0155 0.0150 1.04 0.299 -0.0138 0.0449 
Psychotropic medication 0.0689 0.0044 15.56 0.000 0.0602 0.0775 
Anticholinergic medication 0.1417 0.0063 22.44 0.000 0.1293 0.1540 
              
Physician specialty              
Psychiatrist 0.0113 0.0054 2.12 0.034 0.0008 0.0218 
Other 0.0057 0.0063 0.91 0.363 -0.0066 0.0181 
Unknown -0.0309 0.0075 -4.12 0.000 -0.0455 -0.0162 




Table 30: Results of regression analysis comparing adherence in the MT and APP groups (Scenario 1) (continued) 
Characteristics Coef. 
Robust 
Std. Err. Z P>z [95% Conf. Interval] 
Number of physicians prescribing the 
antipsychotic  0.0499 0.0016 30.41 0.000 0.0467 0.0531 
  
      Urban/rural status 
      Unknown -0.0229 0.0255 -0.90 0.368 -0.0729 0.02670 
Urban -0.0318 0.0049 -6.49 0.000 -0.0414 -0.0222 
  
      Pre-index psychiatric-related inpatient 
hospitalizations -0.0286 0.0024 -12.08 0.000 -0.0332 -0.0239 
Pre-index psychiatric-related outpatient visits  0.0012 0.0003 3.91 0.000 0.0006 0.0018 
Constant 0.3031 0.0125 24.16 0.000 0.2785 0.3277 
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Table 31: Results of regression analysis comparing adherence in the MT and APP groups (Scenario 2) 
Characteristics Coef. 
Robust 
Std. Err. Z P>z [95% Conf. Interval] 
              
APP 0.2053 0.0061 33.45 0.000 0.1933 0.2174 
Age 0.0018 0.0002 11.68 0.000 0.0015 0.0021 
Male 0.0206 0.0037 5.50 0.000 0.0133 0.0279 
  
      Race/ethnicity 
      African American -0.0318 0.0049 -6.54 0.000 -0.0414 -0.0223 
Other 0.0283 0.0065 4.37 0.000 0.0156 0.0409 
Unknown -0.0100 0.0273 -0.37 0.715 -0.0636 0.0436 
Caucasian  0.0442 0.0049 9.06 0.000 0.0346 0.0537 
  
      Year of initiation of index antipsychotic 
medication 
      2007 -0.0178 0.0061 -2.90 0.004 -0.0298 -0.0058 
2008 -0.0008 0.0069 -0.11 0.910 -0.0144 0.0128 
2009 0.0072 0.0062 1.16 0.247 -0.0050 0.0194 
2010 0.0148 0.0059 2.50 0.013 0.0032 0.0265 
  
      Diagnosis 
      Depression -0.0100 0.0067 -1.49 0.135 -0.0231 0.0031 
No mental illness -0.0554 0.0071 -7.78 0.000 -0.0694 -0.0414 
Other -0.0134 0.0061 -2.21 0.027 -0.0253 -0.0015 
Schizophrenia 0.0302 0.0073 4.14 0.000 0.0159 0.0445 
Multiple mental illnesses -0.0410 0.0090 -4.58 0.000 -0.0586 -0.0235 
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Std. Err. Z P>z [95% Conf. Interval] 
Current substance abuse -0.0589 0.0051 -11.60 0.000 -0.0689 -0.0489 
Number of unique mental illnesses 0.0052 0.0017 3.04 0.002 0.0019 0.0086 
Pre-index Charlson Comorbidity Index -0.0048 0.0015 -3.18 0.001 -0.0077 -0.0018 
Pre-index Chronic Disease Score 0.0032 0.0007 4.43 0.000 0.0018 0.0046 
  
      Index antipsychotic drug 
      Combination 0.0698 0.0718 0.97 0.331 -0.0709 0.2106 
Typical  -0.0724 0.0070 -10.41 0.000 -0.0860 -0.0588 
  
      Injectable antipsychotic 0.0212 0.0150 1.41 0.158 -0.0083 0.0506 
Psychotropic medication 0.0710 0.0044 16.11 0.000 0.0624 0.0796 
Anticholinergic medication 0.1353 0.0062 21.87 0.000 0.1232 0.1474 
  
      Physician specialty  
      Psychiatrist 0.0096 0.0053 1.79 0.073 -0.0009 0.0200 
Other 0.0054 0.0063 0.85 0.394 -0.0070 0.0177 
Unknown -0.0323 0.0075 -4.33 0.000 -0.0469 -0.0177 
  
      Number of physicians prescribing the 
antipsychotic  
0.0518 0.0016 32.27 0.000 0.0487 0.0550 
  
      Urban/rural status 
      Unknown -0.0209 0.0253 -0.83 0.409 -0.0706 0.0288 
Urban -0.0346 0.0049 -7.08 0.000 -0.0442 -0.0250 
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Std. Err. Z P>z [95% Conf. Interval] 
Pre-index psychiatric-related inpatient 
hospitalizations 
-0.0279 0.0023 -12.07 0.000 -0.0324 -0.0233 
Pre-index psychiatric-related outpatient visits  0.0012 0.0003 4.23 0.000 0.0007 0.0018 















Std. Err. z P>z [95% Conf. Interval] 
              
APP 0.17 0.02 -14.11 0.000 0.14 0.22 
Age 1.01 0.00 9.05 0.000 1.01 1.02 
Male 1.24 0.04 6.03 0.000 1.16 1.33 
              
Race/ethnicity             
African American 0.79 0.04 -4.50 0.000 0.71 0.88 
Other 1.26 0.08 3.75 0.000 1.12 1.43 
Unknown 1.09 0.27 0.34 0.731 0.67 1.78 
Caucasian  1.52 0.07 8.98 0.000 1.39 1.67 
              
Year of initiation of index antipsychotic 
medication             
2007 1.00 0.06 0.06 0.949 0.89 1.13 
2008 1.12 0.08 1.59 0.111 0.98 1.28 
2009 1.21 0.08 3.08 0.002 1.07 1.37 
2010 1.28 0.08 4.12 0.000 1.14 1.44 
  
      Diagnosis 
      Depression 1.03 0.07 0.44 0.656 0.91 1.17 
No mental illness 0.81 0.06 -2.92 0.004 0.71 0.93 
Other 1.07 0.06 1.12 0.263 0.95 1.20 
Schizophrenia 1.45 0.10 5.20 0.000 1.26 1.67 
Multiple mental illnesses 0.80 0.08 -2.33 0.020 0.67 0.97 
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Std. Err. z P>z [95% Conf. Interval] 
Current substance abuse 0.61 0.03 -9.48 0.000 0.55 0.67 
Number of unique mental illnesses 1.04 0.02 2.55 0.011 1.01 1.08 
Pre-index Charlson Comorbidity Index 0.97 0.01 -2.40 0.016 0.94 0.99 
Pre-index Chronic Disease Score 1.03 0.01 4.83 0.000 1.02 1.05 
  
      Index antipsychotic drug 
      Combination 4.73 2.59 2.84 0.005 1.62 13.85 
Typical  0.62 0.05 -6.22 0.000 0.53 0.72 
  
      Injectable antipsychotic 1.05 0.15 0.33 0.741 0.79 1.38 
Psychotropic medication 1.26 0.06 5.34 0.000 1.16 1.38 
Anticholinergic medication 2.28 0.14 13.34 0.000 2.02 2.57 
  
      Physician specialty  
      Psychiatrist 0.93 0.05 -1.45 0.146 0.84 1.03 
Other 1.01 0.06 0.26 0.796 0.91 1.14 
Unknown 0.76 0.06 -3.65 0.000 0.66 0.88 
  
      Number of physicians prescribing the 
antipsychotic  
1.18 0.02 9.31 0.000 1.14 1.22 
  
      Urban/rural status 
      Unknown 1.01 0.24 0.05 0.961 0.64 1.59 










Std. Err. z P>z [95% Conf. Interval] 
Pre-index psychiatric-related inpatient 
hospitalizations 
0.78 0.03 -7.60 0.000 0.73 0.83 











Err. z P>z [95% Conf. Interval] 
              
APP 3.90 0.25 21.20 0.000 3.44 4.42 
Age 1.01 0.00 9.53 0.000 1.01 1.02 
Male 1.22 0.04 5.58 0.000 1.13 1.30 
  
      Race/ethnicity 
      African American 0.77 0.04 -5.28 0.000 0.69 0.85 
Other 1.26 0.08 3.80 0.000 1.12 1.42 
Unknown 1.15 0.29 0.55 0.583 0.70 1.88 
Caucasian  1.50 0.07 9.00 0.000 1.37 1.64 
  
      Year of initiation of index antipsychotic 
medication 
      2007 1.00 0.06 0.02 0.980 0.89 1.13 
2008 1.09 0.07 1.27 0.205 0.95 1.24 
2009 1.20 0.07 2.97 0.003 1.06 1.34 

















Err. z P>z [95% Conf. Interval] 
Diagnosis 
      Depression 1.02 0.06 0.39 0.698 0.91 1.16 
No mental illness 0.81 0.06 -3.03 0.002 0.71 0.93 
Other 1.07 0.06 1.19 0.234 0.96 1.20 
Schizophrenia 1.41 0.10 4.94 0.000 1.23 1.62 
Multiple mental illnesses 0.83 0.07 -2.06 0.039 0.70 0.99 
  
      Current substance abuse 0.59 0.03 -10.16 0.000 0.54 0.66 
Number of unique mental illnesses 1.05 0.02 2.96 0.003 1.02 1.08 
Pre-index Charlson Comorbidity Index 0.97 0.01 -2.47 0.013 0.94 0.99 
Pre-index Chronic Disease Score 1.03 0.01 5.07 0.000 1.02 1.05 
  
      Index antipsychotic drug 
      Combination 5.68 3.29 3.00 0.003 1.83 17.70 
Typical  0.66 0.05 -5.70 0.000 0.58 0.76 
  
      Injectable antipsychotic 1.10 0.15 0.69 0.487 0.84 1.43 
Psychotropic medication 1.26 0.05 5.50 0.000 1.16 1.37 















Err. z P>z [95% Conf. Interval] 
Physician specialty  
      Psychiatrist 0.92 0.04 -1.78 0.076 0.83 1.01 
Other 1.01 0.06 0.24 0.807 0.91 1.13 
Unknown 0.75 0.05 -4.04 0.000 0.65 0.86 
  
      Number of physicians prescribing the 
antipsychotic  
1.17 0.02 9.55 0.000 1.14 1.21 
  
      Urban/rural status 
      Unknown 0.92 0.21 -0.36 0.717 0.58 1.45 
Urban 0.85 0.04 -3.78 0.000 0.78 0.92 
  
      Pre-index psychiatric-related inpatient 
hospitalizations 
0.81 0.02 -7.33 0.000 0.77 0.86 










Ratio Std. Err. z P>z [95% Conf. Interval] 
              
APP 0.49 0.02 -18.36 0.000 0.45 0.53 
Age 0.99 0.00 -8.57 0.000 0.99 1.00 
Male 0.93 0.01 -4.67 0.000 0.90 0.96 
  
      Race/ethnicity 
      African American 1.14 0.02 6.36 0.000 1.10 1.19 
Other 0.92 0.03 -3.02 0.003 0.87 0.97 
Unknown 0.95 0.11 -0.48 0.633 0.75 1.19 
Caucasian  0.83 0.02 -8.84 0.000 0.80 0.87 
  
      Year of initiation of index antipsychotic 
medication 
      2007 1.03 0.03 1.15 0.249 0.98 1.08 
2008 1.00 0.03 -0.11 0.913 0.94 1.06 
2009 0.92 0.02 -3.03 0.002 0.88 0.97 











Table 34: Results of Cox proportional hazards regression analysis comparing medication persistence between the MT and 
APP groups (continued) 
Characteristics 
Haz. 
Ratio Std. Err. z P>z [95% Conf. Interval] 
Diagnosis 
      Depression 1.01 0.03 0.41 0.681 0.96 1.07 
No mental illness 1.13 0.03 3.85 0.000 1.06 1.20 
Other 0.99 0.03 -0.27 0.784 0.94 1.05 
Schizophrenia 0.87 0.03 -4.3 0.000 0.81 0.93 
Multiple mental illnesses 1.10 0.04 2.36 0.018 1.02 1.19 
  
      Current substance abuse 1.26 0.03 10.33 0.000 1.20 1.31 
Number of unique mental illnesses 0.98 0.01 -2.05 0.041 0.97 1.00 
Pre-index Charlson Comorbidity Index 1.02 0.01 3.1 0.002 1.01 1.03 
Pre-index Chronic Disease Score 0.98 0.00 -5.39 0.000 0.98 0.99 
  
      Index antipsychotic drug 
      Combination 0.60 0.27 -1.15 0.250 0.25 1.44 
Typical  1.38 0.04 10.67 0.000 1.30 1.46 
  
      Injectable antipsychotic 1.01 0.06 0.13 0.900 0.89 1.14 
Psychotropic medication 0.85 0.02 -8.6 0.000 0.82 0.89 
Anticholinergic medication 0.62 0.02 -14.79 0.000 0.59 0.66 
  
      Physician specialty  
      Psychiatrist 1.02 0.02 1.08 0.279 0.98 1.07 
Other 0.99 0.03 -0.32 0.746 0.94 1.04 
Unknown 1.19 0.04 5.33 0.000 1.11 1.26 
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Table 34: Results of Cox proportional hazards regression analysis comparing medication persistence between the MT and 
APP groups (continued) 
Characteristics 
Haz. 
Ratio Std. Err. z P>z [95% Conf. Interval] 
Number of physicians prescribing the 
antipsychotic  0.91 0.01 -11.58 0.000 0.90 0.93 
  
      Urban/rural status 
      Unknown 1.00 0.11 0.04 0.965 0.81 1.25 
Urban 1.06 0.02 2.89 0.004 1.02 1.10 
  
      Pre-index psychiatric-related inpatient 
hospitalizations 1.10 0.01 9.56 0.000 1.08 1.12 


















Std. Err. z P>z [95% Conf. Interval] 
              
APP 1.47 0.32 1.80 0.072 0.97 2.25 
Age 1.02 0.01 2.23 0.026 1.00 1.04 
Male 0.71 0.14 -1.68 0.093 0.48 1.06 
  
      Race/ethnicity 
      African American 0.76 0.22 -0.95 0.344 0.42 1.35 
Other 1.10 0.53 0.19 0.847 0.42 2.85 
Unknown
a
 294175.90 331859.20 11.16 0.000 32238.02 2684391.00 
Caucasian  0.96 0.23 -0.15 0.878 0.60 1.54 
  
      Year of initiation of index antipsychotic 
medication 
      2007 0.44 0.16 -2.32 0.021 0.22 0.88 
2008 0.83 0.31 -0.50 0.614 0.40 1.72 
2009 0.55 0.19 -1.71 0.087 0.27 1.09 
2010 0.65 0.24 -1.18 0.237 0.32 1.32 
  
      Diagnosis 
      Depression 3.23 1.49 2.54 0.011 1.31 7.98 
No mental illness 1.71 0.92 1.00 0.316 0.60 4.92 
Other 2.23 0.92 1.94 0.052 0.99 5.00 
Schizophrenia 3.10 1.32 2.66 0.008 1.35 7.15 
Multiple mental illnesses 1.25 0.79 0.35 0.724 0.36 4.30 
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Std. Err. z P>z [95% Conf. Interval] 
Current substance abuse 1.61 0.41 1.85 0.064 0.97 2.67 
Number of unique mental illnesses 1.48 0.13 4.51 0.000 1.25 1.76 
Pre-index Charlson Comorbidity Index 1.04 0.07 0.62 0.536 0.91 1.19 
Pre-index Chronic Disease Score 1.12 0.04 2.94 0.003 1.04 1.21 
  
      Index antipsychotic drug 
      Combination 0.00 0.00 -17.87 0.000 0.00 0.00 
Typical  0.71 0.31 -0.78 0.436 0.30 1.68 
  
      Injectable antipsychotic 2.08 1.19 1.28 0.202 0.68 6.38 
Psychotropic medication 1.93 0.53 2.40 0.016 1.13 3.30 
Anticholinergic medication 0.84 0.22 -0.67 0.505 0.50 1.41 
  
      Physician specialty  
      Psychiatrist 1.12 0.36 0.35 0.730 0.59 2.11 
Other 1.80 0.64 1.65 0.098 0.90 3.60 
Unknown 0.63 0.31 -0.94 0.345 0.24 1.66 
  
      Number of physicians prescribing the 
antipsychotic  
1.17 0.10 1.81 0.071 0.99 1.39 
  
      Urban/rural status 
      Unknown 0.00 0.00 -22.88 0.000 0.00 0.00 










Std. Err. z P>z [95% Conf. Interval] 
  
     Pre-index psychiatric-related inpatient 
hospitalizations 
1.21 0.20 1.14 0.255 0.87 1.69 
Pre-index psychiatric-related outpatient visits  0.98 0.01 -1.72 0.086 0.95 1.00 
a 
















Std. Err. z P>z [95% Conf. Interval] 
              
APP -0.39 0.22 -1.80 0.072 -0.81 0.03 
Age -0.02 0.01 -2.23 0.026 -0.04 0.00 
Male 0.34 0.20 1.68 0.093 -0.06 0.74 
        
Race/ethnicity       
African American 0.28 0.30 0.95 0.344 -0.30 0.86 
Other -0.09 0.49 -0.19 0.847 -1.05 0.86 
Unknown -12.59 1.13 -11.16 0.000 -14.80 -10.38 
Caucasian  0.04 0.24 0.15 0.878 -0.43 0.51 
        
Year of initiation of index antipsychotic 
medication 
      
2007 0.82 0.35 2.32 0.021 0.13 1.51 
2008 0.19 0.37 0.50 0.614 -0.54 0.92 
2009 0.60 0.35 1.71 0.087 -0.09 1.29 









Table 36: Results of the regression analysis (hurdle model) comparing the hospital length of stay between the MT and APP 
groups 
Logistic regression (continued) 
Characteristics Coef. 
Robust 
Std. Err. z P>z [95% Conf. Interval] 
Diagnosis       
Depression -1.17 0.46 -2.54 0.011 -2.08 -0.27 
No mental illness -0.54 0.54 -1.00 0.316 -1.59 0.51 
Other -0.80 0.41 -1.94 0.052 -1.61 0.01 
Schizophrenia -1.13 0.43 -2.66 0.008 -1.97 -0.30 
Multiple mental illnesses -0.22 0.63 -0.35 0.724 -1.46 1.01 
        
Current substance abuse -0.48 0.26 -1.85 0.064 -0.98 0.03 
Number of unique mental illnesses -0.39 0.09 -4.51 0.000 -0.56 -0.22 
Pre-index Charlson Comorbidity Index -0.04 0.07 -0.62 0.536 -0.17 0.09 
Pre-index Chronic Disease Score -0.12 0.04 -2.94 0.003 -0.19 -0.04 
        
Index antipsychotic drug       
Combination 13.24 0.74 17.87 0.000 11.78 14.69 
Typical  0.34 0.44 0.78 0.436 -0.52 1.21 
        
Injectable antipsychotic -0.73 0.57 -1.28 0.202 -1.85 0.39 
Psychotropic medication -0.66 0.27 -2.40 0.016 -1.19 -0.12 







Table 36: Results of the regression analysis (hurdle model) comparing the hospital length of stay between the MT and APP 
groups 
Logistic regression (continued) 
Characteristics Coef. 
Robust 
Std. Err. z P>z [95% Conf. Interval] 
Physician specialty        
Psychiatrist -0.11 0.32 -0.35 0.730 -0.75 0.52 
Other -0.59 0.35 -1.65 0.098 -1.28 0.11 
Unknown 0.47 0.50 0.94 0.345 -0.50 1.44 
        
Number of physicians prescribing the 
antipsychotic  
-0.16 0.09 -1.81 0.071 -0.33 0.01 
        
Urban/rural status       
Unknown 13.82 0.60 22.88 0.000 12.64 15.01 
Urban 0.45 0.23 1.99 0.047 0.01 0.90 
        
Pre-index psychiatric-related inpatient 
hospitalizations 
-0.19 0.17 -1.14 0.255 -0.52 0.14 
Pre-index psychiatric-related outpatient visits  0.02 0.01 1.72 0.086 0.00 0.05 







Table 36: Results of the regression analysis (hurdle model) comparing the hospital length of stay between the MT and APP 
groups 
Zero truncated negative binomial regression 
Characteristics Coef. 
Robust 
Std. Err. z P>z [95% Conf. Interval] 
              
APP -0.2277 0.1777 -1.28 0.200 -0.5759 0.1206 
Age 0.0052 0.0060 0.86 0.389 -0.0066 0.0169 
Male 0.2979 0.1513 1.97 0.049 0.0014 0.5945 
  
      Race/ethnicity 
      African American 0.1698 0.2158 0.79 0.432 -0.2533 0.5928 
Other -0.6825 0.3479 -1.96 0.050 -1.3643 -0.0006 
Unknown -0.3297 0.4428 -0.74 0.456 -1.1975 0.5380 
Caucasian  0.2024 0.1887 1.07 0.283 -0.1674 0.5722 
  
      Year of initiation of index antipsychotic 
medication 
      2007 -0.4838 0.3256 -1.49 0.137 -1.1219 0.1543 
2008 -0.3725 0.2834 -1.31 0.189 -0.9280 0.1829 
2009 -0.2716 0.3040 -0.89 0.372 -0.8675 0.3242 
2010 -0.2672 0.2938 -0.91 0.363 -0.8431 0.3087 
  
      Diagnosis 
      Depression -0.0231 0.3427 -0.07 0.946 -0.6949 0.6486 
No mental illness 0.6756 0.3683 1.83 0.067 -0.0464 1.3975 
Other 0.8303 0.3380 2.46 0.014 0.1679 1.4927 
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Table 36: Results of the regression analysis (hurdle model) comparing the hospital length of stay between the MT and APP 
groups 
Zero truncated negative binomial regression (continued) 
Characteristics Coef. 
Robust 
Std. Err. z P>z [95% Conf. Interval] 
Schizophrenia 1.1723 0.3443 3.40 0.001 0.4974 1.8471 
Multiple mental illnesses 0.7203 0.4153 1.73 0.083 -0.0937 1.5343 
Current substance abuse -0.6568 0.1764 -3.72 0.000 -1.0026 -0.3111 
Number of unique mental illnesses 0.0663 0.0522 1.27 0.204 -0.0360 0.1687 
Pre-index Charlson Comorbidity Index 0.0157 0.0531 0.30 0.767 -0.0883 0.1197 
Pre-index Chronic Disease Score 0.0596 0.0274 2.18 0.029 0.0060 0.1133 
Typical antipsychotics 0.5240 0.3403 1.54 0.124 -0.1429 1.1910 
Injectable antipsychotic -0.5755 0.2634 -2.18 0.029 -1.0917 -0.0592 
Psychotropic medication 0.3989 0.2530 1.58 0.115 -0.0970 0.8947 
Anticholinergic medication 0.0956 0.2763 0.35 0.729 -0.4459 0.6371 
  
      Physician specialty  
      Psychiatrist 0.0213 0.2558 0.08 0.933 -0.4799 0.5226 
Other -0.1415 0.2679 -0.53 0.597 -0.6667 0.3836 
Unknown -0.6057 0.3805 -1.59 0.111 -1.3515 0.1401 
  
      Number of physicians prescribing the 
antipsychotic  
0.1671 0.0510 3.27 0.001 0.0670 0.2671 
  
      Urban/rural status 
      Unknown (omitted) 
     Urban 0.3437 0.1813 1.90 0.058 -0.0117 0.6991 
243 
 
Table 36: Results of the regression analysis (hurdle model) comparing the hospital length of stay between the MT and APP 
groups 
Zero truncated negative binomial regression (continued) 
Characteristics Coef. 
Robust 
Std. Err. z P>z [95% Conf. Interval] 
Pre-index psychiatric-related inpatient 
hospitalizations 
0.2027 0.0780 2.60 0.009 0.0498 0.3556 
Pre-index psychiatric-related outpatient visits  0.0210 0.0100 2.11 0.035 0.0014 0.0405 
Constant  -0.2121 0.6591 -0.32 0.748 -1.5039 1.0796 
  
  
    /lnalpha -0.4360 0.2188 
 
-0.865 -0.0072 
   
  
























Std. Err. z P>z [95% Conf. Interval] 
              
APP 0.0748 0.0541 1.38 0.167 -0.0312 0.1808 
Age 0.0084 0.0024 3.49 0.000 0.0037 0.0132 
Male -0.0613 0.0549 -1.12 0.264 -0.1689 0.0462 
  
      Race/ethnicity 
      African American -0.0767 0.0854 -0.90 0.369 -0.2441 0.0907 
Other -0.0146 0.1193 -0.12 0.902 -0.2485 0.2192 
Unknown -0.7806 0.2558 -3.05 0.002 -1.2821 -0.2792 
Caucasian  -0.0786 0.0740 -1.06 0.288 -0.2237 0.0665 
  
      Year of initiation of index antipsychotic 
medication 
      2007 0.0358 0.1180 0.30 0.762 -0.1955 0.2670 
2008 0.1363 0.1211 1.13 0.260 -0.1010 0.3737 
2009 0.0410 0.1069 0.38 0.701 -0.1685 0.2504 
2010 0.0535 0.1152 0.46 0.643 -0.1724 0.2793 
  
      Diagnosis 
      Depression 0.2046 0.0956 2.14 0.032 0.0171 0.3920 
No mental illness -0.3972 0.1422 -2.79 0.005 -0.6759 -0.1185 
Other 0.2656 0.0748 3.55 0.000 0.1190 0.4122 
Schizophrenia 0.3178 0.0874 3.64 0.000 0.1466 0.4891 
Multiple mental illnesses -0.1884 0.1412 -1.33 0.182 -0.4652 0.0884 
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Std. Err. z P>z [95% Conf. Interval] 
Current substance abuse 0.0256 0.0672 0.38 0.703 -0.1062 0.1574 
Number of unique mental illnesses 0.0798 0.0165 4.84 0.000 0.0475 0.1121 
Pre-index Charlson Comorbidity Index 0.1150 0.0190 6.05 0.000 0.0778 0.1523 
Pre-index Chronic Disease Score 0.0445 0.0124 3.59 0.000 0.0202 0.0689 
  
      Index antipsychotic drug 
      Combination -0.0348 0.2827 -0.12 0.902 -0.5889 0.5193 
Typical  -0.1876 0.0982 -1.91 0.056 -0.3801 0.0050 
  
      Injectable antipsychotic -0.0071 0.1208 -0.06 0.953 -0.2438 0.2296 
Psychotropic medication 0.1437 0.0749 1.92 0.055 -0.0032 0.2905 
Anticholinergic medication -0.0221 0.0825 -0.27 0.789 -0.1839 0.1397 
  
      Physician specialty  
      Psychiatrist 0.0200 0.1047 0.19 0.849 -0.1852 0.2252 
Other 0.0614 0.1077 0.57 0.569 -0.1497 0.2725 
Unknown 0.1063 0.1508 0.70 0.481 -0.1893 0.4019 
  
      Number of physicians prescribing the 
antipsychotic  
0.0445 0.0205 2.17 0.030 0.0042 0.0847 
  
      Urban/rural status 
      Unknown 0.0352 0.1626 0.22 0.829 -0.2836 0.3539 








Std. Err. z P>z [95% Conf. Interval] 
Pre-index psychiatric-related inpatient 
hospitalizations 
-0.0422 0.0531 -0.79 0.427 -0.1463 0.0619 
Pre-index psychiatric-related outpatient visits  0.0180 0.0021 8.44 0.000 0.0138 0.0222 





Table 38: Results of regression (gamma regression with log link) analysis comparing the medical costs between the MT and 
APP groups 
Characteristics  Coef. 
Robust 
Std. Err. z P>z [95% Conf. Interval] 
              
APP 0.1741 0.0876 1.99 0.047 0.0024 0.3458 
Age 0.0121 0.0039 3.13 0.002 0.0045 0.0196 
Male -0.1048 0.0814 -1.29 0.198 -0.2643 0.0546 
  
      Race/ethnicity 
      African American -0.2481 0.1220 -2.03 0.042 -0.4873 -0.0089 
Other -0.2623 0.1827 -1.44 0.151 -0.6205 0.0959 
Unknown -0.8863 0.4850 -1.83 0.068 -1.8369 0.0643 
Caucasian  -0.2366 0.1110 -2.13 0.033 -0.4541 -0.0190 
  
      Year of initiation of index antipsychotic 
medication 
      2007 -0.3186 0.1785 -1.78 0.074 -0.6684 0.0313 
2008 0.0550 0.1872 0.29 0.769 -0.3119 0.4218 
2009 -0.0195 0.1806 -0.11 0.914 -0.3735 0.3345 
2010 -0.0179 0.1876 -0.10 0.924 -0.3856 0.3498 
  
      Diagnosis 
      Depression 0.2453 0.1520 1.61 0.107 -0.0526 0.5432 
No mental illness -0.0959 0.1829 -0.52 0.600 -0.4544 0.2627 
Other 0.4633 0.1230 3.77 0.000 0.2223 0.7043 
Schizophrenia 0.4893 0.1464 3.34 0.001 0.2025 0.7762 
Multiple mental illnesses -0.1681 0.2219 -0.76 0.449 -0.6030 0.2668 
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Table 38: Results of regression (gamma regression with log link) analysis comparing the medical costs between the MT and 
APP groups (continued) 
Characteristics  Coef. 
Robust 
Std. Err. z P>z [95% Conf. Interval] 
Current substance abuse 0.0994 0.1101 0.90 0.366 -0.1163 0.3152 
Number of unique mental illnesses 0.1578 0.0381 4.14 0.000 0.0832 0.2325 
Pre-index Charlson Comorbidity Index 0.1739 0.0379 4.59 0.000 0.0996 0.2481 
Pre-index Chronic Disease Score 0.0850 0.0191 4.45 0.000 0.0476 0.1225 
  
      Index antipsychotic drug 
      Combination -1.2261 0.3455 -3.55 0.000 -1.9032 -0.5489 
Typical  -0.1175 0.2175 -0.54 0.589 -0.5437 0.3087 
  
      Injectable antipsychotic -0.2132 0.2271 -0.94 0.348 -0.6582 0.2318 
Psychotropic medication 0.2891 0.1137 2.54 0.011 0.0663 0.5118 
Anticholinergic medication 0.1024 0.1293 0.79 0.428 -0.1510 0.3557 
  
      Physician specialty  
      Psychiatrist 0.0308 0.1495 0.21 0.837 -0.2623 0.3239 
Other 0.2018 0.1693 1.19 0.233 -0.1301 0.5337 
Unknown 0.1455 0.2376 0.61 0.540 -0.3203 0.6112 
  
      Number of physicians prescribing the 
antipsychotic  
0.0109 0.0388 0.28 0.779 -0.0652 0.0870 
  
      Urban/rural status 
      Unknown -0.3340 0.3664 -0.91 0.362 -1.0522 0.3842 




Table 38: Results of regression (gamma regression with log link) analysis comparing the medical costs between the MT and 
APP groups (continued) 
Characteristics  Coef. 
Robust 
Std. Err. z P>z [95% Conf. Interval] 
Pre-index psychiatric-related inpatient 
hospitalizations 
0.0176 0.0928 0.19 0.850 -0.1642 0.1994 
Pre-index psychiatric-related outpatient visits  0.0151 0.0037 4.11 0.000 0.0079 0.0222 











Table 39: Results of regression (gamma regression with log link) analysis comparing the drug costs between the MT and 
APP groups 
Characteristics  Coef. 
Robust 
Std. Err. z P>z [95% Conf. Interval] 
              
APP 0.4599 0.0423 10.88 0.000 0.3770 0.5428 
Age 0.0030 0.0018 1.65 0.100 -0.0006 0.0065 
Male 0.0498 0.0386 1.29 0.197 -0.0259 0.1255 
  
      Race/ethnicity 
      African American -0.2036 0.0580 -3.51 0.000 -0.3173 -0.0900 
Other -0.1553 0.0927 -1.68 0.094 -0.3370 0.0264 
Unknown -0.0032 0.3152 -0.01 0.992 -0.6210 0.6146 
Caucasian  -0.0160 0.0519 -0.31 0.757 -0.1177 0.0857 
  
      Year of initiation of index antipsychotic 
medication 
      2007 0.0082 0.0606 0.14 0.893 -0.1106 0.1270 
2008 0.1730 0.0782 2.21 0.027 0.0197 0.3263 
2009 -0.0097 0.0673 -0.14 0.885 -0.1416 0.1221 
2010 -0.0026 0.0699 -0.04 0.971 -0.1396 0.1345 
  
      Diagnosis 
      Depression 0.0251 0.0911 0.28 0.783 -0.1535 0.2036 
No mental illness -0.0192 0.0908 -0.21 0.833 -0.1971 0.1588 
Other -0.0315 0.0809 -0.39 0.697 -0.1901 0.1271 
Schizophrenia -0.0147 0.0837 -0.18 0.861 -0.1788 0.1494 
Multiple mental illnesses -0.0911 0.1172 -0.78 0.437 -0.3207 0.1386 
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Table 39: Results of regression (gamma regression with log link) analysis comparing the drug costs between the MT and 
APP groups (continued) 
Characteristics  Coef. 
Robust 
Std. Err. z P>z [95% Conf. Interval] 
Current substance abuse -0.0134 0.0624 -0.21 0.830 -0.1357 0.1089 
Number of unique mental illnesses -0.0183 0.0155 -1.18 0.240 -0.0487 0.0122 
Pre-index Charlson Comorbidity Index 0.0731 0.0180 4.05 0.000 0.0377 0.1084 
Pre-index Chronic Disease Score 0.0526 0.0081 6.54 0.000 0.0369 0.0684 
  
      Index antipsychotic drug 
      Combination -0.5227 0.0917 -5.70 0.000 -0.7024 -0.3430 
Typical  -0.4027 0.0757 -5.32 0.000 -0.5511 -0.2544 
  
      Injectable antipsychotic 0.0383 0.1060 0.36 0.718 -0.1695 0.2460 
Psychotropic medication 0.1294 0.0521 2.48 0.013 0.0273 0.2315 
Anticholinergic medication -0.1844 0.0577 -3.20 0.001 -0.2975 -0.0713 
  
      Physician specialty  
      Psychiatrist 0.0695 0.0578 1.20 0.229 -0.0437 0.1828 
Other 0.1503 0.0654 2.30 0.022 0.0221 0.2785 
Unknown 0.0993 0.1119 0.89 0.375 -0.1199 0.3186 
  
      Number of physicians prescribing the 
antipsychotic  
0.0092 0.0169 0.54 0.588 -0.0240 0.0424 
  
      Urban/rural status 
      Unknown -0.0474 0.2673 -0.18 0.859 -0.5713 0.4765 




Table 39: Results of regression (gamma regression with log link) analysis comparing the drug costs between the MT and 
APP groups (continued) 
Characteristics  Coef. 
Robust 
Std. Err. z P>z [95% Conf. Interval] 
Pre-index psychiatric-related inpatient 
hospitalizations 
-0.0036 0.0331 -0.11 0.913 -0.0684 0.0612 
Pre-index psychiatric-related outpatient visits  0.0034 0.0022 1.56 0.120 -0.0009 0.0077 








Std. Err. z P>z [95% Conf. Interval] 
              
APP 0.3664 0.0447 8.21 0.000 0.2789 0.4540 
Age 0.0051 0.0018 2.90 0.004 0.0017 0.0086 
Male -0.0114 0.0400 -0.29 0.775 -0.0898 0.0669 
  
      Race/ethnicity 
      African American -0.2303 0.0577 -3.99 0.000 -0.3434 -0.1171 
Other -0.1891 0.0902 -2.10 0.036 -0.3659 -0.0122 
Unknown -0.1471 0.2963 -0.50 0.620 -0.7277 0.4336 
Caucasian  -0.0761 0.0525 -1.45 0.147 -0.1789 0.0267 
  
      Year of initiation of index antipsychotic 
medication 
      2007 -0.0471 0.0705 -0.67 0.504 -0.1853 0.0911 
2008 0.1813 0.0803 2.26 0.024 0.0240 0.3387 
2009 0.0278 0.0748 0.37 0.711 -0.1188 0.1744 
2010 0.0431 0.0772 0.56 0.577 -0.1083 0.1944 
  
      Diagnosis 
      Depression 0.1010 0.0794 1.27 0.203 -0.0546 0.2566 
No mental illness 0.0362 0.0840 0.43 0.667 -0.1285 0.2008 
Other 0.1462 0.0685 2.13 0.033 0.0119 0.2805 
Schizophrenia 0.1647 0.0726 2.27 0.023 0.0224 0.3071 
Multiple mental illnesses -0.1423 0.1022 -1.39 0.164 -0.3426 0.0581 
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Table 40: Results of regression (gamma regression with log link) analysis comparing the total costs between the MT and 
APP groups (continued) 
Characteristics Coef. 
Robust 
Std. Err. z P>z [95% Conf. Interval] 
Current substance abuse 0.0439 0.0596 0.74 0.461 -0.0729 0.1607 
Number of unique mental illnesses 0.0451 0.0190 2.37 0.018 0.0079 0.0824 
Pre-index Charlson Comorbidity Index 0.1067 0.0172 6.22 0.000 0.0730 0.1403 
Pre-index Chronic Disease Score 0.0634 0.0090 7.04 0.000 0.0458 0.0810 
  
      Index antipsychotic drug 
      Combination -0.7741 0.0878 -8.82 0.000 -0.9461 -0.6021 
Typical  -0.3052 0.0886 -3.44 0.001 -0.4789 -0.1316 
  
      Injectable antipsychotic -0.0149 0.1024 -0.15 0.885 -0.2155 0.1858 
Psychotropic medication 0.1887 0.0511 3.70 0.000 0.0886 0.2888 
Anticholinergic medication -0.0799 0.0652 -1.22 0.221 -0.2077 0.0480 
  
      Physician specialty  
      Psychiatrist 0.0494 0.0688 0.72 0.472 -0.0854 0.1842 
Other 0.1441 0.0742 1.94 0.052 -0.0014 0.2896 
Unknown 0.0906 0.1188 0.76 0.446 -0.1422 0.3234 
  
      Number of physicians prescribing the 
antipsychotic  
0.0197 0.0183 1.07 0.283 -0.0163 0.0556 
  
      Urban/rural status 
      Unknown -0.2009 0.2509 -0.80 0.423 -0.6927 0.2908 




Table 40: Results of regression (gamma regression with log link) analysis comparing the total costs between the MT and 
APP groups (continued) 
Characteristics Coef. 
Robust 
Std. Err. z P>z [95% Conf. Interval] 
Pre-index psychiatric-related inpatient 
hospitalizations 
0.0291 0.0424 0.68 0.494 -0.0541 0.1123 
Pre-index psychiatric-related outpatient visits  0.0068 0.0021 3.23 0.001 0.0027 0.0110 
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